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ABSTRACT

SECRETION OF MALARIA TRANSMISSION-BLOCKING
PROTEINS FROM PARATRANSGENIC BACTERIA

By
Nicholas James Bongio
May 2015

Dissertation supervised by Dr. David Lampe
Malaria is a debilitating and deadly disease that afflicts over 200 million people
and kills over 600 thousand each year. Due to quickly evolving drug resistance and lack
of an affordable vaccine, novel interventions are needed to fight the Plasmodium
parasites that cause malaria. Targeting Plasmodium inside their mosquito hosts is one
approach that could complement other preventative and medicinal interventions by
reducing the ability of the mosquitoes to transmit the disease to humans. The research
presented here uses paratransgenesis, the genetic modification of symbiotic bacteria
within the mosquito midgut, to provide antimalarial protein to the mosquito and to
interfere with the life cycle of Plasmodium within the insect host.
This research has produced three new antimalarial paratransgenic tools. The first
tool is a set of new antimalarial effector proteins that were constructed by converting
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anti-Plasmodium mouse antibodies into single-chain variable fragment (scFv) versions
for expression by bacteria. These antibodies bind to Plasmodium surface proteins and
interfere with critical steps in the parasite life cycle. The second tool is a modified
bacterial species, Pantoea agglomerans, which was engineered to secrete diverse
antimalarial proteins via the hemolysin secretion pathway. Modified P. agglomerans
were fed to mosquitoes and were capable of inhibiting the invasion of Plasmodium within
the midgut. The third tool is another modified bacterial species, Asaia sp. SF2.1. Native
Type II secretion signals were discovered that enable the creation of paratransgenic
strains of these bacteria. Modified strains of Asaia sp. SF2.1 were also demonstrated to
interfere with the invasion of Plasmodium within the mosquito.
These tools have laid the groundwork for the future use of paratransgenic bacteria
to combat malaria in the wild. Asaia sp. SF2.1 bacteria, in particular, are capable of
spreading throughout mosquito populations, so they provide their own drive mechanism
to establish themselves within the mosquito vectors of malaria. While further
modifications will be required to make these bacteria ready for field use, the findings of
this research provide proof of concept that the bacteria are suitable for eventual use in
malaria transmission-blocking interventions.
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Chapter 1
The problem of human malaria
MALARIA: THE DISEASE
In 2012, there were approximately 207 million cases of human malaria, and the
disease was estimated to have caused 627,000 deaths worldwide, the majority of these
deaths being among children under 5 years old in sub-Saharan Africa (WHO 2013).
Currently, there are 104 countries and territories where malaria is considered endemic,
meaning that 3.4 billion people are at risk of becoming infected with malaria every day
(WHO 2013).
Malaria is one of the deadliest infectious diseases on earth, and accordingly, a
great deal of research focuses on its prevention and treatment. The two main areas of
research to combat the virulent Plasmodium parasite, which causes malaria, have
concentrated on the synthesis of antimalarial drugs to target the parasite in the human
host, and on the manufacture of insecticides to eliminate or to reduce the mosquito vector
populations (Karunamoorthi 2014, Ansari 2013). Despite decades of research providing
new drugs and interventions, malaria is still a large problem in many developing nations
across the world. This is due to the fact that Plasmodium rapidly evolves resistance to
new drugs, and the drugs themselves are expensive to produce and distribute in the
quantities necessary to cure the millions of cases that occur every year (Poirot 2013,
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Sibley 2014). Reaching infected individuals in impoverished nations is extraordinarily
difficult.
The malaria parasite has been coevolving with humans throughout history (Cox
2010), and was described as early as the year 2700 BC, when the symptoms of malaria
were described in the “Nei Ching,” a medical text edited by Emperor Huang Ti of China.
The malaria parasite was identified in humans as long ago as 1323 BC in ancient Egypt,
and Plasmodium was identified by molecular means in the autopsy of King
Tutankhamun, and was hypothesized to be one cause of his death (Timmann 2010).
Malaria was given its current name by the contraction of the Italian words mala aria
meaning “bad air,” because prior to the discovery of the mosquito vector, it was believed
that breathing foul vapors from swamps caused the disease. In 1880, the malaria parasite
was discovered by Alphonse Laveran (Cox 2010), and in 1897, the function of the
mosquito vector in transmission was identified in avian malaria by Ronald Ross (Ross
1898).
Due to centuries of parasite-host coevolution, Plasmodium has become adept at
avoiding the human immune system. Within the human blood stream, for instance, the
parasite undergoes antigenic shifting which allows it to evade detection by the host's
adaptive immune system. A prime example of antigenic shifting is the Plasmodium
falciparum erythrocyte membrane protein 1. This protein is encoded by 60 unique var
genes, each of which produces a different protein that is displayed on the surface of host
erythrocytes. Through a developmentally-regulated process, the parasite randomly selects

2

one of these proteins to display upon invasion of a cell, so the host's immune system will
not recognize the new antigen presented (Chen 1998).
Not only has Plasmodium adapted to evade the human immune system, but also
the human population has experienced genetic changes which impart resistance against
the parasite (Kwiatkowski 2005, Allison 2009). Many human genetic mutations have
been identified that provide resistance against infection, including alterations in
membrane proteins of red blood cells, alterations in enzymes of red blood cells, and
mutations in the hemoglobin genes responsible for oxygen transport (Williams 2006,
Lopez 2010). For example, sickle cell disease is a result of a hemoglobin gene mutation
which interferes with Plasmodium within infected erythrocytes (Beutler 1955, Bunn
2013). Though the sickle cell phenotype has a protective effect against Plasmodium, it
also has a serious health cost for the host and can cause fatal organ failure (Powars 1990).
Such adaptations provide important perspective on the evolutionary cost of malaria on
humans; the cost is so great that we have evolved resistance mechanisms to the disease,
many of which are deleterious mutations on their own (Lopez 2010).

ANTIMALARIAL EFFORTS
Since malaria has plagued mankind throughout history, many interventions have
been attempted to curb the devastation it causes. The first medicines used to treat malaria
were derived from plants. These medicines include quinine, which is naturally found in
the bark of trees in the Cinchona genus, and artemisinin, which is produced by Artemisia
annua or sweet wormwood. Modern science has allowed us to produce artemisinin
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artificially by expressing the gene in yeast, and variants of these medicines have also
been synthesized in laboratories (Dhingra 1999). There is a constant need for new
medicines since the parasite has been steadily evolving resistance to each new drug used
(Enayati 2009). Typically, these drugs are used in combination in an attempt to curtail the
development of resistant strains and still quickly eliminate infections (Fairhurst 2012).
Vaccines against malaria have demonstrated some effectiveness (Seder 2013);
however, these require attenuated sporozoite stage parasites, and production of the
necessary large quantities of the sporozoites is time and cost prohibitive. Probably the
most effective interventions to prevent transmission of the disease have been in vector
control, including bed nets, window screens, and insecticides that either physically
separate people from the mosquito or eliminate the vector population. These simple
treatments can lead to a great reduction in transmission of malaria, but supplying them to
millions of individuals in impoverished nations is difficult to orchestrate and can be
expensive (Sabot 2010).

THE BIOLOGY AND LIFE CYCLE OF PLASMODIUM
There are five species of Plasmodium that cause human malaria. These are
Plasmodium falciparum, P. malariae, P. vivax, P. knowlesi, and P. ovale. Among these
species, P. falciparum is the most deadly. Plasmodium are protozoan parasites in the
phylum Apicomplexa. Apicomplexans have a plastid organelle called an apicoplast, which
is believed to have evolved from the endosymbiosis of algae. The apicoplast is important
for the production of a large number of proteins for Plasmodium, and it is involved in the
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invasion of host cells (Kalanon 2010). Apicomplexans use two structures to invade host
tissues: (1) an apical complex, which is cone-shaped structure composed of spirallyarranged microtubules, and (2) the rhoptry, which is a secretory complex for invasionrelated enzymes and proteases. Plasmodium use these structures at many points in its life
cycle to invade diverse tissues of each host it infects.
Plasmodium have a complex life cycle requiring both an Anopheles mosquito and
a human host (Ghosh 2000) (Figure 1.1). The parasite enters into the bloodstream of the
human host when an infected female mosquito injects saliva while taking a blood meal.
The saliva contains the sporozoite form of Plasmodium, which travel through the blood
stream into the liver where they invade Kuppfer cells. In the case of P. vivax, P.
malariae, and P. ovale, it is common for some of the infected cells to go into a dormant
state called the hypnozoite, or “sleeping parasite,” and to delay the transformation into
blood stage parasites for months or years. The sporozoite-infected cell then forms a
schizont, which is a rapidly growing and dividing cell that produces tens of thousands of
blood-stage merozoites. The schizont bursts open to release the merozoites into the blood
stream. Merozoites infect red blood cells where they reproduce asexually, bursting open
and releasing more merozoites every 1-3 days, perpetuating the cycle. This cyclical
invasion and rupturing of red blood cells is what causes most of the disease symptoms of
malaria, such as anemia and fever. The periodicity of these cycles of asexual
reproduction and fever are synchronized and have a specific frequency for the different
species of Plasmodium that can be tertian, occurring every two days, or quartan,
occurring every three days (Garcia 2001). A small percentage of the trophozoites, or
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newly infected red blood cells, will produce male or female gametes instead of producing
merozoites. These infected cells remain dormant while in the blood stream. They can
then be taken up by an uninfected Anopheles mosquito during a blood meal.
Once ingested in a blood meal, Plasmodium-infected red blood cells burst open
and the released gametes undergo sexual reproduction in the mosquito midgut (Figure
1.1 part C). Their activity is triggered by the change in pH, the decrease in temperature,
and the exposure to xanthurenic acid produced by the mosquito (Billker 1998). Within 24
hours, the male and female gametes fuse to form a zygote which transforms into an
ookinete, a motile form of Plasmodium. The ookinete actively invades and passes
through the midgut epithelium of the mosquito. On the outer surface of the midgut and
under the basement membrane, the ookinete forms an oocyst in which it divides to
produce thousands of sporozoites. These oocysts burst open when mature, releasing their
sporozoites into the hemolymph of the mosquito, which can travel to and invade the
salivary glands, ready to be injected into the next human host.
Fertilization within the mosquito host and subsequent invasion of the mosquito
midgut present the greatest bottlenecks to Plasmodium transmission (Su 2007). This
critical life stage has, therefore, been targeted for transmission-blocking experiments in
attempts to stop the development of the parasite before the anopheline host is infected.
Fertilization is complex and requires multiple protein interactions between male and
female gametocytes. Blocking the proteins involved with neutralizing antibodies can
prevent successful fertilization, hence arresting development. For example, antibodies
that bind to Pfs48/45, a protein on the surface of the female macrogametocyte required
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for interaction with the male gametocyte, and Pfs230, a large protein on the surface of
male gametocytes involved in the formation of exflagellation centers necessary for
fertilization, have been shown to interfere with the life cycle of P. falciparum
(Outchkourov 2008, Eksi 2006).
Other proteins can be targeted to block ookinete invasion. These include the
Plasmodium and Anopheles proteins that the parasite uses to attach to and to penetrate the
midgut epithelial cells. One of these proteins is Pfs25, a P. falciparum surface protein
that is necessary for parasite binding to the midgut epithelium. Antibodies have been
produced that will block invasion of mosquito tissues by interfering with the function of
Pfs25 (Saxena 2007) and have been used for transmission-blocking interventions by
masking the Pfs25-binding domains necessary for invasion. Similarly, the SM1 peptide
blocks the anopheline receptor of the enolase binding protein of ookinetes and the use of
the lectin, Jacalin, that binds to anopheline aminopeptidase N, yet another target of
ookinete binding (Ghosh 2001, Dinglasan 2007). A final example of a target is
Plasmodium chitinase, an enzyme which is necessary for degrading the peritrophic matrix
of the mosquito to allow the ookinete to reach the midgut epithelium and invade (Tsai
2001).

TRANSMISSION-BLOCKING EFFECTOR PROTEINS
Passage through the peritrophic matrix and midgut epithelium is one of the major
bottlenecks in the life cycle of the parasite, making it a prospective target for
transmission-blocking therapies. In field-caught anopheline malaria vectors, there are
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typically only between 0 - 5 oocysts per midgut (Gouagna 1998). An intervention at this
life stage of Plasmodium development targets the parasite when it is especially
vulnerable, and previous antimalarial techniques have not yet exploited this avenue.
Antibodies have been used in the treatment of multiple diseases and have proven
effective in providing immunity in some cases of malaria. Furthermore, multiple
antibodies have been shown to be capable of blocking transmission through the midgut
(Barr 1991, Outchkourov 2008, Quakyi 1987). These antibodies have been expressed
from hybridoma cell lines and subsequently fed to mosquitoes mixed into an infective
blood meal to demonstrate their activity artificially (Barr 1991, Roeffen 1995, Roeffen
2001). An anti-chitinase single-chain antibody (scFv) has also been demonstrated to
block transmission (Li 2005). Plasmodium chitinase is an important factor for the parasite
to make its way through the midgut peritrophic matrix. A different scFv was generated
which targets Pbs21, a surface protein on ookinetes of Plasmodium berghei, a rodent
malaria that has been widely used for transmission-blocking experiments in the lab
(Yoshida 1999). This scFv expressed by a baculovirus expression system blocked 93% of
oocyst development in the mosquito (Yoshida 1999).
Proteinase inhibitors have been demonstrated to prevent transmission by
disrupting various parts of the parasite's reproductive cycle in the midgut (Rupp 2008).
There are multiple protease inhibitors that can be used to block transmission, because the
parasite requires different proteinases to break through the mosquito's defenses. For
example, ankyrin, a 10 amino acid peptide, has been shown to prevent exit of the parasite
from erythrocytes by blocking the protease function of Falcipain-2 (Dhawan 2003). It
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should be relatively simple to secrete this small peptide from bacteria; however, the
fitness cost associated with the protease inhibitors may be significant for the mosquito
host. Such inhibition could interfere with blood meal digestion, and without a blood meal,
female mosquitoes would be unable to produce eggs and to propagate the species.
Various antimicrobial peptides from arthropods have also been demonstrated to
have anti-Plasmodium properties. Gomesin is an antimicrobial peptide isolated from the
spider Acanthoscurria gomesiana (Silva 2000). It has displayed the ability to inhibit
exflagellation and ookinete formation (Moreira 2007). Scorpine is a potent antimalarial
and antibacterial agent from Pandinus imperator scorpion venom that causes membrane
disruption and cell lysis across a range of microbial species (Corzo 2001, Conde 2000). If
either of these proteins can be expressed from bacteria in the mosquito midgut, then it
would provide a powerful inhibitory effect on both gametes and ookinetes. The scorpine
protein is rather small, too, at only 8,350 Da, and this should be easy to produce
heterologously, if a suitable host bacterium which is itself resistant to the antibacterial
mechanism can be found. It has been expressed from transgenic strains of the fungus
Metarhizium anisopliae and been demonstrated to disrupt Plasmodium development in
vivo (Fang 2011).
The goal of using effectors to block transmission in the mosquito midgut is to
prevent the parasite from ever reaching the human host. After all, malaria is a disease of
poverty, primarily affecting the poorest regions in the world where the population has
limited access to health care or preventative measures (Sabot 2010). Transmissionblocking effectors are a cheap and renewable source of disease prevention and can lessen
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the heavy medical and financial burden caused by the production and delivery of
conventional medicines and vaccines.

THE MOSQUITO VECTORS OF HUMAN MALARIA
Globally, the Plasmodium parasites that cause human malaria are vectored by
over 100 species of anopheline mosquitoes, with 30 to 40 of these species effecting the
bulk of transmission (Raghavendra 2011). These mosquitoes live on all continents except
Antarctica and have been known historically to transmit malaria worldwide. Although the
disease has been eliminated in many regions of the world including North America, most
of Europe, Australia, and northern Asia, the vector mosquitoes still inhabit these places
and the reintroduction of malaria remains a threat (Cohen 2012). Female anopheline
mosquitoes spread the Plasmodium parasite during blood meals which are essential for
their reproductive cycle. When taking the blood meal, an infected female mosquito can
inject sporozoites into an uninfected human host; while an uninfected female mosquito
can itself become infected by taking a blood meal from a human with a blood-stage
infection.
A female Anopheles mosquito requires a blood meal from a mammalian host in
order to produce eggs. Upwards of 200 eggs per female are laid in fresh water, and the
eggs undergo four life stages: egg, larva, pupa, and adult. The egg, larva, and pupa stages
are all aquatic, and ambient temperature determines the speed of progression from egg to
adult, which can be anywhere from 5 to 14 days. It takes 10 to 18 days after the female
mosquito feeds on an infected human for sporozoites to develop and to reach the salivary
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glands. After this time, the mosquito can take a blood meal from another human host and
inject sporozoites to continue the cycle of infection. These growth and survival
requirements for malaria transmission are important determinants in the prevalence of
malaria in a given geographic region. During a drought, malaria transmission can
decrease drastically in an area which typically has hyperendemic malaria transmission, as
was observed in Southern Zambia between 2004 and 2005 (Kent 2007).
The anopheline host is not immune to the effects of malaria infection.
Plasmodium can decrease host life expectancy depending on both the intensity of
infection as well as on the age of the mosquito when it becomes infected (Dawes 2009).
Anopheles mosquitoes have evolved resistance mechanisms against the malaria parasite
to lessen this burden. The mosquito can produce an immune response that can be
modulated by the midgut microbiome and that can interfere with Plasmodium
development (Cirimotich 2011). Anopheline mosquitoes also have a natural immune
response that causes melanization of oocysts. Melanization occurs when the mosquito's
immune system encapsulates foreign objects in order to isolate and to destroy them.
Despite these adaptations to combat infection, anopheline mosquitoes remain viable
vectors for Plasmodium.

MOSQUITO MICROBIOTA
Anopheline mosquitoes have a diverse community of microbes inhabiting their
midguts (Rani 2009, Wang 2011). The bacteria of the midgut have been shown to change
from the larva life stage to the adult, presumably by the shedding of the meconium, or
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lining of the midgut, during the transformation (Moll 2001). During the larval stage of
life, the mosquito microbiota consist largely of photosynthetic Cyanobacteria (Wang
2011). The shedding of the meconium after emergence partially sterilizes the midgut of
the larva. The midgut will be repopulated with new species when the adult mosquito
feeds on plant nectar that contains bacteria. The reestablished population of the adult
mosquito midgut is very different and consists primarily of Proteobacteria and
Bacteroidetes

with

the

predominant

taxa

being

Enterobacteriaceae

and

Flavobacteriaceae (Wang 2011). Pantoea agglomerans (previously known as
Enterobacter agglomerans), a Gram-negative, γ-proteobacterium, is a particular midgut
symbiont of interest (Gavini 1989). Pantoea agglomerans is a common bacterium found
in the midgut of Anopheles and Aedes mosquitoes, and it is easily cultured and
manipulated in the lab (Moro 2013, Straif 1998).
Other important anopheline midgut symbionts include the Asaia sp. bacteria.
Asaia are Gram-negative, α-proteobacteria which been isolated from flower nectar
(Yamada 2000, Chouaia 2010).

Asaia represent a large proportion of the midgut

bacterial population, in some isolates encompassing 60% of all bacteria as identified by
454 sequencing (Boissiere 2012). Asaia has been identified in all species of Anopheles
mosquitoes, and it seems to be an integral part of the host's midgut microbiome and
necessary for the health of the mosquito host (Mitraka 2013). In addition, Asaia
contribute to overall health during larval development (Mitraka 2013). Asaia bacteria
within the midgut of anopheline mosquito larvae increase the transcription of certain host
genes that allow the larvae to develop more rapidly (Mitraka 2013). These aspects of
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Asaia's microbial ecology make this bacterium a prime candidate for paratransgenesis
(Favia 2007, Damiani 2010).

TRANSGENESIS AND PARATRANSGENESIS
Previous transmission-blocking approaches in mosquitoes have used direct
transgenesis of the anopheline mosquito host of Plasmodium to make the insect produce
antimalarial proteins (Ito 2002). Ito et al. used the piggyBac transposon system to insert
the gene encoding the SM1 peptide that inhibits P. berghei invasion of the midgut
epithelium. This gene was inserted under control of the Anopheles gambiae
carboxypeptidase promoter, which is highly activated by a blood meal in the mosquito
(Ito 2002). The results found by Ito et al. showed that transgenic mosquitoes produced in
this way would have greatly enhanced resistance to infection by P. berghei malaria. A
study of the fitness of transgenic mosquitoes expressing antimalarial effector genes
determined that lab-reared transgenic mosquitoes that were fed infected blood had a
fitness advantage over wild type mosquitoes fed the same infected blood (Marrelli 2006).
Marrelli et al. concluded that the fitness advantage perceived in the lab setting would not
translate to the field due to the much lower infection rate of wild mosquitoes (Taye
2006). Some other mechanism would be required to cause a transgene to spread through
the wild mosquito population and become established permanently.
Gene drive mechanisms have been proposed that can cause a gene to be selected
for in a population; these mechanisms use naturally occurring selfish genetic elements
that can increase in frequency within a population (Sinkins 2006). Transposons could be
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used to drive genes through mosquito populations and deliver the genes necessary to
make the population refractory to infection; Arensburger et al. identified an active
transposon called Herves in Anopheles gambiae, the primary vector of P. falciparum that
could be used to drive antimalarial genes into a population (Arensburger 2005). An
approach such as this would not harm the mosquito population but make them less
suitable hosts for Plasmodium. Another mechanism that forces a gene to increase in
frequency is underdominance; mosquitoes that contain a set of genes on different
chromosomes that each encode a toxin gene and a trans-acting repressor for the toxin
gene on the opposite chromosome would necessitate that offspring have a copy of each to
survive, or they will produce the toxin and die. Any gene can be inserted into a construct
such as this, and it will be selected for along with it (Davis 2001). This setup will allow
the transgenic mosquitoes to mate with one another and produce homozygous offspring,
but if they mate with wild mosquitoes, the offspring will die therefore increasing the
transgenic genotype over time. A caveat to this approach is necessity of an antibiotic
resistance gene, which would likely never gain approval for release in the wild.
Some other mechanisms seek to decrease the population of the vector mosquito
by delivering dominant lethal genes into the population by a technique called the release
of insects carrying a dominant lethal (RIDL); an example of this is the dominant
flightless female gene which is only expressed in female mosquitoes (Marinotti 2013).
Males with the flightless gene are not affected, therefore they can be raised and released
into the wild to mate, and any female offspring they produce will be flightless and die
causing a population crash (Marinotti 2013). The generation of transgenic mosquitoes for
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malaria control is time intensive, and replacing the natural population of vector
mosquitoes in the wild has an additional obstacle associated with it, driving the gene into
multiple populations. Malaria is not transmitted by a single mosquito species, and there
are over 100 species that can carry Plasmodium (Raghavendra 2011). Even within a
single vector species, there can be distinct sexually-isolated molecular types that do not
interbreed, as is the case with the Anopheles gambiae molecular forms (Favia 1997). For
these reasons, transgenic mosquitoes would be extremely difficult to utilize in field
applications and to guarantee that all modes of transmission have been targeted.
A simpler, alternative approach to generating transgenic mosquitoes would be to
produce paratransgenic bacteria, which are capable both of inhabiting the midgut of
diverse mosquito species and of rapidly spreading among wild mosquito populations
(Wang 2013). Paratransgenesis is the modification of symbiotic microorganisms residing
within a host in order to alter that host's phenotype (Durvasula 2008). A ubiquitous
anopheline midgut symbiont would present a single target for modification and be much
easier to utilize than the numerous species of mosquito hosts (Wang 2013). Furthermore,
if this paratransgenic bacterial strain expressed a protein that targets all five malariacausing Plasmodium species, then that single paratransgenic strain could be utilized
worldwide against any species of Plasmodium and in any anopheline vector.
Paratransgenesis has previously been used to combat human diseases. The first
demonstration of this technique was the use of paratransgenic Rhodococcus rhodnii in the
triatomine bug, Rhodnius prolixus, to combat Chagas disease (Durvasula 1997). R.
rhodnii were modified to secrete Cecropin A, an antimicrobial peptide that is lethal to
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Trypanosoma cruzi, the parasite that causes Chagas disease (Hurwitz 2011). Durvasula et
al. reported reduction or elimination of T. cruzi in R. prolixus bugs that had been
inoculated with the paratransgenic bacteria. They further identified a mechanism to
spread bacteria to R. prolixus in the wild by allowing the insect to ingest the bacteria
mixed in with artificial feces, simulating their natural route of coprophagous symbiote
acquisition (Durvasula 1997).
Five other notable studies have also used paratransgenesis to fight disease. One
study worked to combat African sleeping sickness by utilizing the tsetse fly symbiont,
Sodalis glossinidius. S. glossinidius was modified to secrete nanobodies which target the
variant surface glycoprotein of Trypanosoma bruci, the cause of African sleeping
sickness, by using the pelB secretion signal (De Vooght 2012). A second study targeted
HIV by using modified Lactobacillus jensenii to secrete functional human CD4
glycoprotein, which inhibits HIV entry into host T-cells (Chang 2003). A third study
targeted malaria by engineering modified Pantoea agglomerans to secrete the
antimalarial peptide SM1, the anti-Pbs21 single chain antibody, and the PLA2 enzyme
into the midgut of the Anopheles host of Plasmodium. This was accomplished via two
secretion pathways, by using the pelB leader peptide and the hemolysin secretion system
(Bisi 2011). Two additional studies also targeted malaria: an Anopheles densonucleovirus
was discovered and modified to produce green fluorescent protein within the Anopheles
host to demonstrate its potential for delivery of antimalarial effectors (Ren 2008); and the
fungus Metarhizium anisopliae, a natural pathogen of mosquitoes, was modified to
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produce the antimalarial peptide SM1 and the antimicrobial scorpine and proved capable
of reducing sporozoite counts by 98% (Fang 2012).
These previous studies have been proofs of concept of using paratransgenic
organisms to reduce disease transmission. In order to create strains of paratransgenic
bacteria that can be applied in the real world, however, certain hurdles must be overcome
to ensure the organism is suitable for release. A paratransgenic organism intended to
combat malaria must be prevalent across anopheline species and must have a suitable
microbial ecology that allows it to remain in the mosquito population for the long term.
One such species, Asaia sp. SF2.1, has already been isolated (Favia 2007). This Gramnegative, acetic acid bacterium is associated with many tissues of the mosquito body; it
can be found inhabiting the reproductive organs, the salivary glands, and the midgut
(Favia 2007). All three of these organs are important for paratransgenic malaria
intervention. Asaia sp. SF2.1 has also been demonstrated to be transmitted from female
mosquitoes to their progeny by a process termed "egg smearing," in which the mother
paints bacteria on the surface of eggs, and the bacteria passed on survive until adulthood
(Favia 2007, Damiani 2008). These bacteria can also be passed from male to female
during copulation since they inhabit the reproductive organs of the mosquito host
(Damiani 2008).

PROTEIN SECRETION FROM GRAM-NEGATIVE BACTERIA
A challenge of creating paratransgenic bacteria is the identification of a protein
secretion system, which will allow the bacteria to deliver effector proteins into the
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mosquito midgut environment. Effectors must be secreted in order to make contact with
Plasmodium and interfere with its development. One way to accomplish this is by fusing
an effector protein to a signal sequence that directs it for export through a preexisting
secretion system of the host bacteria.
Gram-negative bacteria possess diverse protein transport systems which have
evolved to move proteins across two lipid membranes and through the protective
peptidoglycan layer surrounding their cells. Protein production by the ribosome takes
place in the cytosol of the bacterial cell. Proteins that are needed in the periplasm, that are
inserted into either membrane, that are part of the protective peptidoglycan layer, or that
are exported from the cell must be translocated through either one or two cell membranes
depending on their localization. There are currently nine recognized secretion systems
that have been identified in Gram-negative bacteria to accomplish this; however, the
Type I and Type II secretion pathways are the most useful for the secretion of
heterologous proteins (Mergulhao 2005).
Type I secretion involves the export of folded proteins directly from the cytosol to
the environment. This is accomplished by a secretory complex consisting of three
proteins that form a channel linking the outer and inner membranes of the cell, allowing
proteins to pass through the channel without stopping in the periplasm. These proteins
include an ABC protein within the inner membrane, which facilitates protein recognition
and initiates transport, a membrane fusion protein that spans the inner and outer
membrane, providing a channel for direct secretion, and an outer membrane protein that
allows passage of the translocated protein through the outer membrane (Kudva 2013).
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The first identified Type I secretion system was the hemolysin secretion system of
E. coli. This system is used by some pathogenic E. coli strains to secrete the alphahemolysin toxin, a 107 kDa protein. This protein inserts into the membrane of a host cell,
causing membrane disruption and cell lysis. The hemolysin secretion complex consists of
three proteins, HemolysinB (HlyB), HemolysinD (HlyD), and TolC, which mediate the
export of the HemolysinA (HlyA) toxin (Figure 1.2). The HlyB protein forms the inner
membrane pore which recognizes and initiates secretion of HlyA. The C-terminal portion
of the HlyA protein interacts with HlyB to direct it for secretion (Zhang 1993). HlyB is
part of the family of ATP-binding cassette (ABC) transporters, and it couples ATP
hydrolysis with protein export. HlyD is the membrane fusion protein in the hemolysin
secretion apparatus; it forms a trimer that connects HlyB in the inner membrane to TolC
in the outer membrane to facilitate direct transfer of the secreted protein (Gentschev
2002). The TolC protein also forms a trimer to produce the outer membrane pore through
which directed HlyA exits the cell. TolC is a general pore complex found across a wide
range of Gram-negative bacteria, and it is not specific to this secretion complex (Wiener
2000).
The hemolysin secretion system has previously been adapted for the secretion of
heterologous proteins. It has been used in E. coli to secrete scFv antibodies and to allow
the formation of disulphide bonds during transport through the periplasm (Fernandez
2001). Part of the HlyA gene encoding the C-terminal domain that directs secretion was
fused to an scFv gene to create a fusion protein, and the scFv proteins exported by the
Type I hemolysin system were found to form disulphide bonds while traversing the
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periplasm (Fernandez 2001). This is useful for the secretion of effector scFvs, since these
proteins require disulphide bridges between cysteine residues to maintain protein
conformation and function (Schouten 2002). Hemolysin secretion has been utilized to
secrete active scFv and other effector proteins that inhibit Plasmodium, as well. The
phospholipase A2 enzyme and an anti-Pbs21 scFv, both antimalarial effectors, were
successfully secreted in Pantoea agglomerans via fusion to the HlyA C-terminal domain
(Bisi 2011). More recent experiments have demonstrated the activity of these effectors
and others as secreted by P. agglomerans in vivo against P. berghei and P. falciparum
within the midgut of Anopheles mosquitoes (Wang 2012). Interestingly, the HlyA
secretion system has also been used on an industrial scale for the production and
extracellular accumulation of molecules such as polyhydroxyalkanoates, which are nonproteinaceous polymers (Rahman 2013). These results demonstrate the flexiblity of the
secretion system for its potential use with a wide range of effector molecules.
In contrast to Type I secretion, Type II secretion pathways do not directly export
proteins through a channel between membranes. These secretion pathways use specific
translocases within the inner membrane to move proteins into the periplasm before they
are exported by a separate mechanism. Two inner membrane transporters handle the
majority of membrane traffic in Gram-negative bacteria (Figure 1.2): (1) the general
secretory (Sec) translocon, which secretes the majority of exported proteins and cytosolic
membrane-inserted proteins (Natale 2008), and (2) the twin-arginine translocation (Tat)
channel, which transports specific proteins that are incompatible with the Sec pathway,
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such as assembled protein complexes and individual proteins that require folding to take
place in the cytosol (Lee 2006).
Type II secretion by the Sec-dependent pathway is a common mechanism found
in all bacteria and is coupled with ATP hydrolysis. This secretion pathway is also
essential, unlike the TolC-dependant pathway which can be disrupted without causing
lethality (Forestal 2006). The Sec translocon transports proteins across the cytosolic
membrane in the general secretion pathway and is responsible for the majority of protein
secretion in bacteria. The translocon is composed of secYEG heterotetramers which form
a transmembrane hydrophilic pore that regulates and facilitates protein transport (Saier
2006). Proteins are directed to this pore complex by leader sequences that consist of a
positively charged N-terminal domain, a hydrophobic middle region, and a polar Cterminal domain followed by a signal peptidase cleavage site. There are many variations
of the signal peptide, and those that are very hydrophobic are recognized by the signal
recognition particle (SRP) protein to be directed to the Sec pore complex (Zhou 2014).
The Type II PelB leader sequence from the pectate lyase gene of Erwinia
carotovora, a Gram-negative plant pathogen, has been demonstrated to be able to direct
secretion of heterologous proteins by a Sec-dependent pathway in E. coli and P.
agglomerans (Bisi 2011). The PelB leader has also been used successfully with scFv
antibody secretion, and it is the leader used in the Tomlinson I + J human scFv library for
the selection of scFvs binding to antigens in a selective screen (Winter 1994). This leader
peptide has great potential for use in targeted interventions due to the possibility of using
specific antigen binding scFvs against pathogens.
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Type II Tat-dependent protein secretion requires a complex of three proteins in
the inner membrane: TatA, TatB, and TatC which function together to recognize and
transport proteins with specific N-terminal signal sequences. These signal sequences are
similar to those recognized by the Sec pathway, with a positively charged N-terminal
domain, a hydrophobic middle domain, and a polar C-terminal domain; however, they
have a much longer N-terminal domain which contains a pair of conserved arginine
residues, thus giving the system its name. Proteins secreted by this pathway are fully
folded in the cytosol before passage through the Tat translocon. Protein transport via the
Tat pathway does not require ATP hydrolysis, but rather it is driven by the proton motive
force (Saier 2006). The Tat secretion pathway has been used for the large scale
production of recombinant proteins, as demonstrated by the use of the TorA signal
peptide and TatAdAc system of Bacillus subtilis in E. coli to secrete GFP into culture
medium (Albiniak 2013) and the use of the B. subtilis TatAyAc to secrete methyl
parathion hydrolase directed by the YwbN signal peptide (Liu 2014).
The research described here focused both on discovering protein secretion signals
for use in Asaia sp. bacteria and on using these secretion signals to transport antimalarial
effectors outside the cell for direct delivery into the mosquito midgut.
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Figure 1.1. The Plasmodium life cycle. The Plasmodium life cycle is complex, and
requires two hosts, both a human and a mosquito. When a human is bitten by an infected
mosquito seeking a blood meal, it injects sporozoites into the blood stream which invade
liver cells (Part A). Within the liver cells, the sporozites divide and produce blood-stage
parasites called merozoites. These are released into the bloodstream, where they invade
red blood cells and continue to reproduce asexually (Part B). These cells burst open
releasing more mereozoites and perpetuating the cycle. A small fraction of these
asexually reproducing cells instead make gametes that remain dormant until a new
mosquito takes them up in a blood meal (Part C). Male and female gametocytes from the
ingested blood meal fertilize within the midgut and develop into an invasive ookinete that
is capable of penetrating the midgut epithelium of the host.
(public domain Figure provided by CDC – DPDx/ Alexander J. da Silva, PhD, Melanie
Moser)

23

Figure 1.2. Secretion systems of Gram-negative bacteria. Type I secretion systems,
such as the hemolysin secretion pathway, transport folded proteins through both
membranes without stopping in the periplasm. The hemolysin secretion system
recognizes the C-terminal domain of hemolysin A to direct proteins for export. Type II
secretion systems translocate unfolded (Sec) or folded (Tat) proteins into the periplasm,
after which they are exported fully from the cell. Type II secretion systems export
proteins that are recognized by short N-terminal peptide leader sequences that are cleaved
off in the periplasm prior to the protein exiting the cell.
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Chapter 2
Production of single-chain variable fragment antibodies and
secretion from bacteria

ABSTRACT
To date, at least 30 antimalarial effector peptides and proteins have been
discovered or produced that interfere with the transmission of malaria. Such effector
proteins are capable of interfering with the development of the Plasmodium parasite
within the mosquito host. For example, three single-chain antibodies produced by
hybridoma cell lines are known to bind Plasmodium falciparum gamete or ookinete
surface proteins and to cause a disruption of fertilization or invasion of host tissues within
the mosquito midgut (Barr 1991, Roeffen 1995, 2001). In this study, antibody variable
regions from these three hybridoma lines were converted into single-chain antibody
(scFv) format that can be expressed from bacteria (Fernandez 2000).
These three scFv proteins are designed to bind to P. falciparum surface proteins
Pfs25, Pfs48/45, and Pfs230 (Barr 1991, Roeffen 1995, 2001). As described in this work,
scFv genes were cloned in-frame with various secretion signals from Escherichia coli,
Gluconobacter oxydans, and Gluconacetobacter diazotrophicus, and expression plasmids
with these gene constructs were transformed into Pantoea agglomerans and Asaia SF2.1.
The bacteria expressing these secretion constructs displayed unhealthy phenotypes and
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had growth defects. Therefore, the scFv effector genes require a novel secretion system to
allow export of the proteins from the bacteria without causing these growth defects.

BACKGROUND
Previously, most experiments involving P. falciparum transmission-blocking
proteins have observed transmission-blocking effects by feeding purified protein to
mosquitoes along with an infective blood meal (Barr 1991, Roeffen 1995, 2001). While
this technique has led to the identification of many useful midgut transmission-blocking
molecules, no method has been devised to adequately deliver the protein to wild
mosquitoes in the field.
Alternatively, transgenic mosquitoes expressing antimalarial proteins can be
produced to inhibit P. falciparum invasion (Riehle 2007). This technique, however,
imposes a large metabolic load on the mosquito, and replacement of the natural mosquito
population with these transgenic mosquitoes cannot be easily achieved. Gene drive
mechanisms have been proposed to spread the transmission-blocking genes into wild
populations (Huang 2007, Akbari 2013); but this approach may require an extended
period of time, and the parasite would likely evolve resistance to the effector molecule,
therefore necessitating that the entire process be repeated using a new drive mechanism.
Genetic manipulation of the mosquito itself may get more complicated over time, since
new transmission blocking genes must be incorporated into the genome.
Effectors capable of being secreted from bacteria can be designed which will both
remain in the mosquito without direct intervention and continue to inhibit the parasite
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from generation to generation. Rather than feeding an effector molecule to mosquitoes in
the lab or creating transgenic mosquitoes that produce the effector, bacteria will be fed to
mosquitoes in the wild and persist in the population, thus providing an unlimited supply
of the transmission-blocking effector. In addition to the ease of deploying such bacteria,
they could also be genetically modified to contain different effector proteins and be rereleased if the parasite ever evolves resistance to the current strain. The experiments in
this chapter demonstrate the cloning of anti-Plasmodium falciparum single-chain
antibodies and their attempted expression from bacterial vectors, as well as their
subsequent secretion utilizing a number of cloned secretion signals.

Anti-Plasmodium falciparum antibodies
P. falciparum proteins Pfs25, Pfs48/45, and Pfs230 exist on the surface of
gametocytes and ookinetes and are necessary for transmission through the midgut
epithelium of the mosquito host (Rener 1983). These surface proteins are necessary for
the parasite to either bring the male and female gametocytes together or to invade the
midgut epithelium. Antibodies or other effector proteins which prevent the function of
these surface proteins can inhibit the different stages of host reproduction or invasion.
Mouse-derived monoclonal antibodies have been proven to block transmission
when produced by hybridoma cells and directly fed to mosquitoes with an infective blood
meal (Barr 1991, Roeffen 1995, 2001). The three hybridoma lines that produce these
antibodies are MRA-315, MRA-316, and MRA-878 from the MR4 Malaria Research
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Center (www.mr4.org). These antibodies target Plasmodium proteins Pfs25, Pfs48/45,
and Pfs230, respectively (Barr 1991, Rener 1983, Quakyi 1987).
Previous use of these monoclonal antibodies has demonstrated inhibition via
purified antibody protein fed to mosquitoes in infective blood meals (Barr 1991, Saxena
2007, Eksi 2006). All of these antibodies target specific proteins that are only expressed
or displayed on the surface of the gamete, zygote, or ookinete stages of the Plasmodium
life cycle. Since these proteins are not exposed to the human immune system, they do not
normally produce an immune response in the host. Injection of these proteins as a
vaccine, however, can produce transmission-blocking immunity in a person (Carter
2001). A person vaccinated in this way produces IgG antibodies against the Plasmodium
surface proteins, and these antibodies are able to bind to the parasite only after they are
taken up during a mosquito blood meal. This immunity prevents Plasmodium from
infecting mosquitoes that feed on the vaccinated individual.
Among transmission-blocking candidates, Pfs25 is the most widely utilized due to
its small size, which makes it easier to express heterologously for vaccine production.
Monoclonal antibodies against this protein have long been known to block transmission
of P. falciparum (Barr 1991). Pfs25 is a 25 kDa protein expressed at the surface of zygote
and ookinete forms of P. falciparum as they develop in the host mosquito's midgut (Barr
1991). Pfs25 plays an important role in attachment of the parasite to the mosquito; it
interacts with the midgut basement membrane to attach the parasite to the surface. This
binding is an essential step in the transformation from ookinete to oocyst (Saxena 2007).
This protein has been expressed in a variety of organisms for use in transmission-
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blocking vaccines and in the production of monoclonal antibodies, including the yeast
Pichia pastoris and eukaryotic green microalgae Chlamydomonas reinhardtii (Barr 1991,
Gregory 2012).
Pfs48/45 is a protein expressed on the surface of female macrogametes, and it
plays an important role in parasite fertilization (Outchkourov 2008). The MRA316
hybridoma line produces monoclonal antibodies against this surface protein which are
known to inhibit P. falciparum transmission in vivo by preventing fertilization and zygote
formation (Rener 1983).
Pfs230 is a protein expressed at the surface of the male gametocyte, and it
mediates the binding of the exflagellating male gamete to human red blood cells. The
function of this binding is to create an exflagellation center, a cluster consisting of
parasite gametes and host erythrocytes which is needed for proper fertilization and
ookinete formation (Eksi 2006). Transmission-blocking activity of monoclonal antibodies
against specific domains of this 230kDa protein have been shown (Quakyi 1987).
Unfortunately, the whole protein is too large to express in bacteria, and only fragments of
it have been produced and used separately for use in immunizations. Active monoclonal
antibodies against the Pfs230 antibody are produced by the MRA878 hybridoma line
(Quakyi 1987).

Prokaryotic expression of scFv antibodies
Hybridoma lines that produce monoclonal antibodies of a know function can be
powerful tools in the lab and in medicine. The IgG proteins that are produced by the cell
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line can be purified and used as molecular detection tools or as treatment for specific
disease such as non-Hodgkin lymphoma which can be treated with Rituximab, a
monoclonal antibody that targets B-cells for destruction (Maloney 1997). For large-scale
production of antibodies, useful IgG proteins can be converted into a single-chain
variable fragment (scFv) format that is suitable for expression in bacteria and that can be
cheaply produced (Bayly 2002). The basic scFv format antibody retains only the antigenbinding variable regions from the heavy and light chain proteins of the IgG complex
which have been recombined into a single protein as shown in Figure 2.1 B. The scFv
protein is capable of being secreted from bacteria (Better 1988). Given that there are
antimalarial antibodies that can block transmission of Plasmodium, this technique could
be used to make paratransgenic bacteria that produce scFv proteins engineered from those
antibodies and that could secrete the proteins directly into the mosquito midgut.

Selecting suitable bacteria for paratransgenesis
Effector secretion constructs were produced in expression vectors capable of
replicating in E. coli, Pantoea agglomerans, and Asaia bogorensis. E. coli was selected
because it is an easy-to-use host strain, which is useful for manipulation of plasmids and
for laboratory testing of expression effectiveness P. agglomerans and A. bogorensis are
both good candidates for paratransgenic approaches to malaria control, as both commonly
inhabit the mosquito midgut (Lindh 2005, Favia 2007). The Gram-negative, αproteobacteria A. bogorensis is a particularly good candidate for transmission blocking,
as it transfers vertically from mother to progeny, so it would produce a longer-lasting
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effect in the mosquito population (Favia 2008). Asaia was detected in Anopheles
stephensi salivary glands, which is rather unusual; most microbes that compose an
organism's microbiome inhabit the digestive tract. It may be possible to take advantage of
this fact and to secrete proteins in the salivary glands which may prevent passage of P.
falciparum sporozoites into the salivary glands or interfere with invasion of the human
host.
Transformation of An. stephensi mosquitoes with transgenic Asaia has already
been shown to work by Favia et al., by feeding a GFP-expressing strain of Asaia to An.
stephensi (Favia 2007). Fluorescent bacteria were detected in a large portion of fed
mosquitoes, and bacteria were stably detected throughout the mosquitoes lifespan (Favia
2007).

Molecular tools for bacterial protein expression
The origin of replication of plasmid pBBR1, originally from a cryptic Bordetella
bronchiseptica plasmid, has been demonstrated to replicate in a wide range of Gramnegative bacteria (Kovach 1995). pBBR1MCS-2, a plasmid containing this replication
origin, was created as a cloning platform for the expression of genes in these diverse
bacteria (Kovach 1995). Previously, similar plasmids with the pBBR1 replication origin
have been modified for the cloning and expression of fluorescent proteins in Asaia sp.
bacteria (Favia 2007). The pBBR1MCS-2 plasmid contains a kanamycin selective
marker, the neomycin phosphotransferase II gene (nptII). This is very useful because
kanamycin is one of the few antibiotics that Asaia is known to be susceptible to. This
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plasmid contains the lacZ alpha gene with a multiple cloning site (MCS) for blue-white
screening. This was modified to contain an MCS compatible with the genes that have
been inserted and to allow the promoter to be easily changed. The lac promoter is not
known to function in Asaia, but the nptII promoter does function. This is a constitutive
promoter that has been demonstrated to have a high level of protein expression in
transformed Asaia (Favia 2007). The expression of heterologous proteins can have a high
fitness cost to bacteria with a constitutive promoter. Therefore, it may be necessary to
change this promoter to an inducible promoter that is controllable in Asaia, or to a weaker
constitutive promoter if the bacteria cannot survive.

Combining scFv effectors
The activity of an scFv effector gene can be amplified by combining two scFv
binding domains in one protein (Figure 2.1 D). The resulting fusion protein, or diabody,
is produced from heavy and light chain immunoglobulins with a short, inflexible linker
peptide between the two. These proteins do not fold to join the two antigen-binding
domains together, as in a standard scFv; instead, the heavy and light chains dimerize and
form one protein complex with two binding sites. The result is that the two antigenbinding domains end up facing directly opposite from one another. A diabody has the
advantage of increasing the avidity of the protein for its antigen (Fernandez 2004).
Some antibodies, such as MRA-316 and MRA-315, act by binding and
neutralizing the active site of the antigen; while other antibodies require complement
protein binding to target the pathogen for an immune response. The MRA-878 antibody,
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which binds Pfs230, interferes with transmission by complement-mediated cell lysis
(Healer 1997, Read 1994). This antibody interacts with complement proteins in human
serum, so it requires either a human antibody constant region to interact with complement
or some alternative. This problem can be solved by designing diabodies with one binding
domain for the Pfs230 antigen and one for human IgG. This technique has been explored
in the lab of Dr. Greg Winter in which bispecific diabodies were produced (Kontermann
1997). Their complement-recruiting antibody domain effectively binds human C1q, a
subunit of the C1 complex of the classical complement pathway, and produces efficient
cell lysis. For non-complement-mediated antibodies, their transmission-blocking activity
may also be increased by the addition of a complement-binding domain. This would
target them for immune response in addition to their normal neutralizing activity.
An alternative to adding a C1q-binding scFv domain is adding a human constant
domain to the construct. Such di-diabodies have previously been created: they consist of
two diabodies with immunoglobulin G CH3 constant domains associated with them (Lu
2003). The resulting molecule is tetravalent and has the normal complement-binding
domain of a human antibody (Figure 2.2). Constructs like these could be very useful for
future antimalarial research. Divalent diabodies could be produced with two different
anti-Plasmodium binding domains combined in the same structure, and this approach
should exhibit both a greater avidity, due to its four binding domains,as well as an
increased affinity for Plasmodium, due to the binding of two different antigens.
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Secretion of single-chain variable fragment antibodies
No single secretion system has been proven to work for all protein constructs, and
attaining a working secretion system for any given protein requires a trial-and-error
approach (Choi 2004). It is not known which secretion systems will function in Asaia.
Some secretion systems move proteins by translocating the denatured amino acid chain
linearly though the general secretion (Sec pathway) pore complex, while others
translocate fully folded protein directly into the periplasm through the twin-arginine
translocase (Tat pathway). Since these systems require the protein to fold in different
environments, specifically the cytosol or the periplasmic space, the proteins exported by
these pathways may behave differently.
A common secretion signal used in scFv secretion is the pelB signal (Winter
MRC laboratory). The pelB signal directs proteins through a Type II secretion pathway
which exports protein using the Sec pore complex into the periplasm, where it can refold
and form disulphide bonds in the oxidizing environment of the periplasmic space before
export from the cell by poorly understood mechanisms (Saier 2006). The pelB signal
peptide has been demonstrated to export fully functional scFv molecules from
recombinant bacterial strains (Bisi 2011).

MATERIALS AND METHODS
Media and antibiotics
Top10 F' E. coli cells were used for cloning and plasmid propagation. The Top10
F' cells were cultured in standard Luria Bertani (LB) broth (10 g Tryptone, 5 g NaCl, 5 g
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yeast extract, in a final volume of 1 L distilled water) or LB agar (LB broth plus 15 g/L
agar). For selection of plasmids with kanamycin, media was supplemented with 30 μg/ml
kanamycin; likewise, gentamycin was used at 50 μg/ml, and ampicillin was used at 100
μg/ml. All E. coli cultures were grown at 37 °C, with agitation for liquid broth cultures.
Pantoea agglomerans was cultured in the same media as E. coli.
Asaia sp. bacteria were cultured in Mannitol broth (5 g yeast extract, 3 g peptone,
25 g mannitol, in a final volume of 1 L distilled water) or Mannitol agar (Mannitol broth
plus 15 g agar). Media was adjusted to pH 6.5 before sterilization. For selection of
plasmids with kanamycin, media was supplemented with 120 μg/ml kanamycin. All
Asaia cultures were grown at 30 °C, with agitation for liquid broth cultures.

Growth of hybridoma cell lines
The hybridoma lines which produce transmission-blocking antibodies were
obtained from MR4 Malaria Research Institute (MR4, ATCC, Manassas, VA). They were
obtained through the MR4 as part of the BEI Resources Repository, NIAID, NIH,
deposited by LH Miller, A Saul. Cells were grown in vented T-flasks in a 5% CO2
incubator at 37 °C. Growth media used was Advanced MEM media (Gibco, Thermo
Fisher Scientific, Waltham, MA #12492) with 10% heat-inactivated fetal bovine serum
(ATCC, Manassas, VA 30-2021), 0.2% sodium bicarbonate, 100 U/ml penicillin, 0.1
mg/ml streptomycin, 10 μl of 1M L-glutamine, and 50 μM 2-mercaptoethanol. Cells were
passed when near confluency at a 1:3 rate into new T-flasks. Cells were stored by adding
100 μl of sterile DMSO to 900 μl of resuspended confluent cell culture and by slow
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freezing using a Nalgene cryo freezing container (Nalgene, Rochester, NY #5100-0001)
that cools at 1 °C per min in a -80 °C freezer. Cells were placed in liquid nitrogen for
long term-storage.

Hybridoma line RNA extraction and reverse-transcription
A total of 5x106 cells were harvested from each hybridoma line, and RNA was
extracted with TRI Reagent using the company protocol for animal cells (Molecular
Research Center Inc., Cincinnati, OH http://mrcgene.com/?s=tri+reagent). This wholecell RNA was purified on a poly-dT column that isolated only the mRNA present in the
samples by binding their polyA tails (polyA mRNA Isolation Kit, New England Biolabs,
Ipswich,

MA,

#S1560S,

https://www.neb.com/protocols/1/01/01/isolation-of-mrna-

s1560). This step eliminated the large amounts of ribosomal RNA present in whole-cell
RNA extracts. The purified mRNA was reverse transcribed with a cDNA synthesis kit
following the standard protocol (Fermentas, Thermo Fisher Scientific, Waltham, MA
#K1611, http://www.thermoscientificbio.com/uploadedFiles/Resources/coa_k1611.pdf).

Amplification of H and L chain variable regions from hybridoma cDNA
Three sets of degenerate primers designed for mouse antibody variable regions
were used to amplify the antigen-binding domains of the heavy and light chain of each
antibody via PCR (Barbas 2001). The protocols laid out in this text were followed, except
with reduced volumes for each reaction of 25 μl. The goal was not to create a phage
display library but to simply isolate the unique clone that is produced by each hybridoma
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line. PCR was performed using Phusion polymerase (New England Biolabs, Ipswich,
MA, #M0530). The PCR primers in these reactions were identical to the published
primers, with one modification which was the addition of a NotI restriction digestion site
to five of the primers (Table 2.2). The resulting fragments were size-separated on 1%
agarose gel, extracted using a Zymoclean Gel DNA Recovery Kit (Zymo Research,
Irvine, CA #D4002), and used as templates in an overlap extension PCR (Figure 2.3).
This PCR reaction connected the antibody gene fragments by a DNA sequence encoding
a flexible linker, which should allow the heavy and light chain protein fragments to fold
into their proper orientation and align their binding domains as in a standard antibody.
These constructs were created in two forms, with both long and short linkers between the
domains (Figure 2.4).
The proteins produced with these different linkers assemble into alternative
formats. Those with a long linker will be able to fold back on themselves, aligning the
heavy and light chain variable domains, and produce a single antibody binding domain
(Figure 2.1). Those with a short linker will be more rigid, and will require two copies of
the protein which will dimerize, forming a diabody. This is a divalent antibody fragment
which has two antibody binding domains, increasing its avidity.

Cloning svFv genes into expression vectors
Each overlap extension PCR product was cloned into the pDB48 plasmid (Bisi
2011) by restriction digestion and ligation. The PCR products and pDB48 plasmid were
digested to completion with the AscI and PacI restriction enzymes, and the plasmid was
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treated with calf intestinal phophatase. The PCR products were ligated into the linearized
plasmid using T4 DNA ligase at 16 °C overnight. The ligated DNA was transformed into
Top10 F' E. coli cells and selected on LB media containing 50 μg/ml gentamycin. These
insertions placed the scFv genes in-frame with the pelB leader sequence at the N-terminal
end and with the 6-His and Myc epitope tags at the C-terminal end. Clones isolated from
this selection were verified by sequencing to ensure that no mutations were introduced.
Gene design is shown in Figure 2.5.

TA cloning antibody variable fragments and sequencing
The PCR products produced using degenerate primers to amplify the variable
regions of each antibody and overlap PCR were TA cloned into the pCR2.1-TOPO vector
using a standard kit and protocol (Invitrogen Thermo Fisher Scientific, Waltham, MA
#45-0641). The cloning reactions were selected in Top10 F' E. coli on LB media
supplemented with 100 μg/ml ampicillin and 100 μg/ml X-gal.
The TA cloned antibody variable region fragments were sequenced using the
vector primers in the pCR2.1-TOPO plasmid, M13 forward (-20) and M13 reverse.
Sequences were aligned using the DNASTAR program SeqMan to assemble the full gene
fragments.

Gene optimization for prokaryotic expression
Some genes can be inserted in bacterial expression vectors and heterologous
production can be achieved without any further alteration of the sequence. Since the scFv
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constructs produced in that way did not express and secrete functional antibodies, the
scFv gene sequences were modified to allow them to translate more efficiently in the
heterologous hosts, E. coli, P. agglomerans, and A. bogorensis.
To increase efficiency of a gene expressed in a heterologous host, the codons that
determine the amino acid sequence were changed to better suit the codon usage of the
heterologous host. The gene sequence of the hybridoma antibody genes were optimized
for expression by changing the nucleotide sequence of each codon to the most commonly
used codon for that amino acid in E. coli. This was achieved by selecting the codon usage
table for E. coli into the Graphical Codon Usage Analyzer (http://gcua.schoedl.de) and by
using the gene analyzer to change the codons of each gene sequence to the most
frequently-used codons from the E. coli usage table. scFv gene sequences are shown in
Figures 2.6 through 2.9.
The anti-Pfs48/45 scFv gene was codon harmonized. Codon harmonization is the
process of calculating the percent usage of each particular codon in the gene's original
species and changing the codons in the harmonized gene to a matching percent usage
codon in the heterologous host species (Angov 2008, Figure 2.10). This allows a protein
to be translated at the same rate of speed as if it had naturally occurred. Translation speed
can have an effect on protein folding, as regions of slow translation have been
demonstrated to permit the ribosome to pause, thus allowing a portion of the protein to
fold prior to continuing (Thanaraj 1996). A fully optimized gene will be translated at the
fastest rate possible by the ribosome; therefore it could miss critical pauses where the
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nascent protein may need time to stop and achieve the correct conformation before
translation resumes. The codon-harmonized anti-Pfs48/45 is shown in Figure 2.11.
Allowing the ribosome to translate a heterologous protein at the same rate as it
would in the native organism should prevent the product from misfolding. This can
potentially reduce degradation of the protein, prevent aggregation, and increase
solubility. Misfolded protein can have a large impact on the bacteria which express it, and
this burden can cause growth inhibition (Rosano 2009, Kudla 2009). This is an important
consideration for a paratransgenic expression construct, because the bacteria must
reliably compete against wild type bacteria in the mosquito midgut while still producing
enough scFv protein to be effective during an infective blood meal.

mRNA 5' UTR structure
The 5'-UTR folding free energy of the mRNA molecule was taken into account
while optimizing and harmonizing the gene sequences. Both the UTR and part of the
open reading frame (ORF) directly following it can have an impact on translation
initiation of a gene transcript (Kozak 2005). The Shine-Delgarno sequence on an mRNA
transcript may become obscured if there is a complementary sequence capable of forming
a hairpin with it, preventing the ribosome from binding the RNA and locating the start
codon. Probable hairpin-forming structures were identified by entering sequences into the
mFold webserver RNA secondary structure predictor (SUNY Albany, Albany, NY
http://mfold.rit.albany.edu/?q=mfold). The hairpin structure of the MRA316 antiPfs48/45 RNA is shown in Figure 2.12, and it has a ΔG of -49.60 kcal/mol. The
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coding sequence was altered accordingly to remove the hairpin-forming sequence while
retaining the encoded amino acid sequence (Figure 2.13). A hairpin at the 5' end of the
mRNA can cause a significant decrease in the amount of protein produced, with a
significant drop-off occurring when the free energy of a hairpin reaches -8 kcal/mol or
lower (Kudla 2009). Codons in the beginning of the ORF for the optimized antibody
genes were adjusted to eliminate potential hairpins that could decrease protein translation.

Expression plasmid construction and molecular cloning
The expression vector used to express protein in multiple host bacteria was
constructed using the backbone of pBBR1MCS-2, a broad-host range plasmid containing
an origin of replication originally isolated in Bordetella and has been proven to function
in Asaia (Kovach 1995). Other features on the plasmid include a mobilization element for
conjugal transfer and the lacZ alpha gene containing a multiple cloning site (MCS). The
plasmid has the kanamycin resistance marker, neomycin phosphotransferase, which is
useful for selection since it is one of the few antibiotics that Asaia are susceptible to.
The lacZα gene of pBBR1MCS-2 (Figure 2.14) was replaced by bacterial
recombination with a new cloning site that I designed (Figure 2.15). Primers were
designed to amplify the ampicillin resistance gene (bla) encoding beta-lactamase and
extend this to have a translational enhancer preceding the ORF, an NdeI restriction site at
the beginning of the gene, and five other unique restriction sites following the gene. The
primers included 40 nucleotides of homology to the pBBR1MCS-2 plasmid on each end
of the amplified product which are required for recombination the primers are listed in
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Table 2.2 as “pBBR rec F” and “pBBR rec R”. The bla gene was amplified by PCR from
pSC189 (Chiang 2002) using these primers and purified by gel-extraction using a Zymo
kit (Zymo Research, Irvine, CA #D4002). The pBBR1MCS-2 plasmid was purified from
E. coli using a Qiagen miniprep kit (Qiagen, Germantown, MD, #27104). The
pBBR1MCS-2 plasmid was linearized by digestion with the EcoRI and BamHI
restriction enzymes to completion.
Fifty ng of the linear plasmid and 50 ng of the PCR product were co-transformed
into MG1655 E. coli cells, which were incubated in non-selective LB media for 1.5 h at
37 °C to allow for the bacteria to recombine the two DNA fragments. This culture was
plated on selective LB media containing ampicillin. The resulting colonies from this
selection contained the new plasmid named pNB20 (Figure 2.16), which now had a
specific set of restriction sites with which to modify the expression cassette.
The pNB20 plasmid was further modified by changing the promoter region for
beta-lactamase to the neomycin phosphotransferase promoter (PnptII). This promoter is
constitutively active and has high activity in Asaia sp. as demonstrated by its effective
use expressing green fluorescent protein (Favia 2007). The PnptII region of pHM2-GFP
(Favia 2007) was amplified by standard PCR using primers that add NsiI and NdeI
restriction sites to the ends of the amplicon (primers “PnptII F NsiI” and “PnptII R
NdeI”). This PCR product and pNB20 were each digested to completion with the NsiI
and NdeI restriction enzymes, and the plasmid was treated with calf intestinal
phophatase. The PCR product was ligated into the linearized plasmid using T4 DNA
ligase at 16 °C overnight. The ligated DNA was transformed into Top10 F' E. coli cells
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and selected on LB media containing ampicillin and kanamycin. Clones isolated from
this selection were verified by sequencing to ensure there were no mutations introduced.
The new plasmid created was named pNB51 (Figure 2.17).

Vector construction
The anti-Pfs25 scFv was initially synthesized with an optimized pelB leader
sequence at the N-terminal end followed by an AscI restriction digest site and with 6-His
and Myc epitope tags at the C-terminal end of the gene for western blot detection. This
gene was further flanked with restriction enzyme sites NdeI and BamHI at the N- and Cterminal ends, respectively. The plasmid bearing the synthesized gene and the plasmid
pNB20 were digested using the NdeI and BamHI restriction enzymes, and the antibody
gene was then ligated into pNB20 3' to the lac promoter. This plasmid was called pNB39
(Table 2.1), and it was used for further cloning of antibody effectors.
Other optimized or harmonized antibody scFv genes were digested from plasmid
DNA using the AscI and EcoRI restriction digest sites and ligated into the pNB39
plasmid in-frame with the PelB leader to replace the anti-Pbs25 scFv gene. The resulting
plasmids were called pNB37 (anti-Pfs48/45 scFv) and pNB38 (anti-Pfs230 scFv) (Figure
2.18). An anti-BSA scFv gene from pDB51 (Bisi 2011) was also cloned into pNB39 by
PCR amplification using primers “BSA F AscI” and “BSA R EcoRI” and by directionally
cloning into the same site. The anti-BSA plasmid was called pNB55.
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Insertion of GFP into secretion plasmids
The GFP gene was amplified from pHM2GFP and inserted into pNB20 to both
test for the expression activity of the promoters in Asaia, as well as to observe protein
activity. gfp was amplified using standard PCR with the primers “GFP F NdeI” and “GFP
R EcoRI.” These PCR products along with purified plasmids pNB20 and pNB51 were
digested using the NdeI and EcoRI restriction enzymes, and the plasmid was treated with
calf intestinal phophatase. The PCR products were ligated into the linearized plasmid
using T4 DNA ligase at 16 °C overnight. The ligated DNA was then transformed into
Top10 F' E. coli cells and selected on LB media containing 30 μg/ml kanamycin. The
produced plasmids were called pNB49 (with lac promoter) and pNB50 (with nptII
promoter). Clones isolated from this selection were verified by sequencing to ensure
there were no mutations introduced, and confirmed under fluorescence microscopy to
verify expression of the gfp gene. These plasmids were subsequently purified and
introduced into Asaia bogorensis competent cells. Fluorescence activity of the GFP
protein produced in Asaia was visualized under excitation conditions with 395 nm light.

Cloning secretion signals from acetic acid bacteria
Since the Asaia genome was not yet sequenced, signal peptides from two related
species of acetic acid bacteria were tested for activity in Asaia. Proteins identified as
secreted in the psortdb database (http://db.psort.org) from Gluconobacter oxydans and
Gluconacetobacter diazotrophicus were selected, and their secretion signals were
identified by processing the amino acid sequences using the SignalP4.1 software
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(www.cbs.dtu.dk/services/SignalP) artificial neural network Hidden Markov models
(Nielsen 1997). This program is capable of machine learning and pattern recognition,
therefore it utilizes a database of secreted proteins and identifies unknown proteins by
their homologous sequence to the database. Primers were designed to amplify only the
signal peptide gene sequence of these proteins, and to add NdeI and AscI restriction sites
to the 5' and 3' ends of the product, respectively (Table 2.2).
Routine PCR was performed using genomic DNA from Gluconobacter oxydans
or Gluconacetobacter diazotrophicus as template and an individual set of primers for a
given gene. Each of these amplified products was inserted into plasmid pNB39 by
restriction digestion and ligation exactly as described previously, replacing the PelB
secretion signal with each of these newly identified signals. Thirteen unique secretion
signals were cloned in this way and are listed in Table 2.4, and the plasmids are listed in
Table 2.1 as pNB44 through pNB76.

Western blot to detect scFv proteins expressed from inducible promoters
E. coli, P. agglomerans, and A. bogorensis with scFv expression plasmids were
grown to an OD600 of 1.0. Protein production was induced in E. coli by adding 0.5 mM
IPTG to strains that expressed genes under control of the lac promoter, and the culture
was grown for 12 h. Cultures of each strain containing no plasmid were grown for
negative controls, and E. coli expressing the plasmid pDB49 which produces an antibovine serum albumin (anti-BSA) scFv protein were induced as a positive control. To
separate the pellet and supernatant fractions, 100 μl of the cell cultures were pelleted at
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8,000g for 2 min. The pellet was resuspended in 100 μl of 3X Laemmli sample buffer
(BioRad) with 2-mercaptoethanol, and 75 μl of the supernatant was mixed with 25 μl of
Laemmli buffer. These samples were boiled for 8 min to denature the proteins, and 8 μl
of the ColormarkPlus Prestained Protein Ladder (New England Biolabs), 20 μl of each
supernatant protein sample, and 5 μl of each pellet protein sample were loaded into the
wells of a 5% stacking and 10% separating polyacrylamide gel. Proteins were separated
by electrophoresis, transferred onto a 0.45 μm pore size PVDF membrane in a BioRad
transfer apparatus using Tris-Glycine transfer buffer (25mM Tris, 150mM glycine, 10%
methanol) at 95 V for 75 minutes. The PVDF membrane was blocked for 18 h with 1%
BSA TBS-Tween 20 (TBS-T) (50mM Tris-CL, 150 mM NaCl, 0.1% Tween 20, 1% w/v
fraction V BSA, pH 7.5) with agitation at 4 °C. Next, the blocking solution was replaced
with the primary antibody, a mouse anti-myc antibody (Invitrogen 45-0603) 1:5000 in
blocking buffer, and incubated at 4 °C for 24 h with agitation. The primary antibody
solution was removed, and the blot was washed four times in TBS-T for 15 min each
time. Following washes, the secondary antibody, goat anti-mouse HRP (BioRad 1705046), was applied and the blot was incubated for 1 h at room temperature. The wash
steps were repeated, 2 ml of Supersignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific # 34095) was added to the blot and incubated for 5 min. The blot was
exposed to X-ray film (Thermo Scientific 34090) for multiple time exposures ranging
from 10 sec to 10 min and then developed using an automatic developer.
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Northern blot to detect transcription of scFv genes
Digoxigenin-labeled probes were created using the DIG High Prime DNA
Labeling and Detection Starter Kit I (Roche 11745832910). First, each gene to be
identified in the northern blot was amplified by PCR, including the anti-BSA scFv, antiPfs25 scFv, anti-Pfs48/45 scFv, and anti-Pfs230 scFv. Three μg of each template PCR
product were mixed with the DIG High Prime reagent and incubated at 37 °C for 20 h.
Labeling efficiency of each probe was determined by serial dilution of the probes and a
control DIG-labeled control DNA. These were spotted onto a piece of nitrocellulose
membrane, and detected using NBT/BCIP. Spot intensity was compared to that of the
control labeled DNA, and each probe was diluted to the same working concentration as
per the DIG labeling kit instructions.
E. coli Top10 F' cells with expression plasmids as well as control E. coli with no
plasmid were grown at 37 °C to a OD600 of 1.0. Duplicates of each strain tested were
prepared from these cultures, and one of each was induced by the addition of 0.5 mM
IPTG. Cultures were then grown for 1 h at 37 °C. RNA was extracted from each sample
using

TRI

Reagent

using

the

MRC

protocol

for

bacterial

cells

(http://mrcgene.com/?s=tri+reagent). The samples were size separated on a 1% agarose
gel with 0.4% formaldehyde. The bands were transferred to a nitrocellulose membrane by
capillary action using the Turboblotter following standard protocols (Whatman
Schleicher & Schuell). The RNA was UV-crosslinked to the wet membrane using a UV
transilluminator for 1 min with 254 nm light. The full Whatman Turboblotter protocol
can be found at: (https://www.gelifesciences.com/gehcls_images/
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GELS/Related%20Content/Files/1389873234232/litdoc29088931_20140116215520.pdf)
The membrane was probed with the previously prepared DIG-labeled DNA and
hybridized at 44 °C in a Fisherbrand rotisserie hybridization oven following the DIG
labeling kit protocols. Detection of labeled RNA was performed as written in the Roche
kit instruction manual. The DIG labeling kit manual can be found at:
(http://lifescience.roche.com/wcsstore/RASCatalogAssetStore/Articles/05353149001_08.
08.pdf)

RESULTS
Antibody variable region cloning
Three hybridoma lines that produce antibodies against surface proteins Pfs25,
Pfs48/45, and Pfs230 of P. falciparum gametes and ookinetes were obtained from the
MR4 depository, and cDNA was produced from each. Another hybridoma line that
produces antibodies against human IgG (ATCC CRL-1757) was also obtained for
incorporation into divalent diabodies with Pfs230; the proposed diabodies are expected to
allow binding of the anti-Plasmodium scFv to the parasite and to allow the connected
anti-complement scFv to initiate a complement cascade that will destroy the ookinete.
The gene sequences of each antibody's binding domains were identified by PCR
amplification of the variable region of the heavy and light chains from the cDNA. These
variable regions were recombined into single-chain variable fragment (scFv) format
suitable for expression in prokaryotes (Figure 2.1) These gene constructs include a long,
flexible linker sequence connecting the two antigen binding domain that allows the
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protein to align the domains and retain the function of the original antibody protein
complex (Winter, Tomlinson Library).

Antibody variable region sequencing and manipulation
The scFv format genes of these antibodies were cloned using the TA system into
the pCR2.1-TOPO vector and sequenced using standard M13 vector primers. The full
sequence of each antibody was obtained this way (Figures 2.6-2.9), allowing for the
modification of the scFv gene in order to enhance its activity in bacterial hosts. Some
scFv genes cloned directly from mammalian cells can be produced in bacteria; however,
the codon usage of eukaryotes and prokaryotes differ greatly, and optimization for the
expressing organism can have a large impact on protein production (Hannig 1998). The
coding sequences of these genes were altered in two ways. Each of the scFv genes was
optimized for the codon usage of E. coli, using only the most common amino acids from
that host. The only deviation from this optimization was in changes to specific amino
acids that were identified to cause potential RNA hairpin structures that interfere with
translation initiation (Hall 1982).
A second version of the anti-Pfs48/45 antibody was also generated, by comparing
the codon usage of the original gene sequence to the codon frequency in the mouse and
by selecting codons at each site for bacterial expression that match the codon usage
frequency in E. coli. This is called a harmonized gene sequence, and it can possibly aid
the folding of proteins thereby increasing the efficiency of production by harmoniously
replicating the translation speed of the original host (Roy 2009). This allows a nascent
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protein to slow translation when necessary to allow portions of the protein to fold before
translation continues (Angov 2008).

Expression of single-chain variable fragment antibodies in bacterial host organisms
The scFv genes were cloned into expression vectors under control of the lac and
nptII promoters. These constructs fused the scFv gene to the pelB leader sequence from
the Erwinia carotovora pectate lyase gene, which has been successfully used by others to
secrete scFv proteins from E. coli. The C-terminal end of these genes also contained 6His and Myc epitope tags. These plasmids were transformed into E. coli, P. agglomerans,
and A. bogorensis to assess protein production and secretion.
Protein production was not apparent in any of the bacterial strains produced, as
shown by a lack of protein of the predicted size by both Coomassie and western blot
(Figure 2.19). A control strain of E. coli expressing an anti-BSA scFv from either
plasmid pDB51 or pDB49 was used as a positive control for western blot detection, and
that protein was detected normally.

Transcription of gene constructs in E. coli
Due to a lack of protein production from expressing strains, a northern blot was
conducted to determine if the problem was related to transcription. RNA was prepared
from different expression constructs, and mRNA transcripts of the scFv gene sequences
were identified using a digoxigenin labeling reaction. All strains that contained plasmids
expressing scFv genes produced mRNA of the correct predicted size (Figure 2.20).

50

Activity of lac and nptII promoters in Asaia
Expression plasmids were constructed with the pBBR origin of replication,
kanamycin resistance marker, and the gfp gene either under the control of the lac
promoter or the nptII promoter (Figures 2.21 and 2.22). These gene constructs did not
have any modifications such as secretion signals or tags, and the promoters were identical
to previous expression constructs. The plasmids were transformed into Asaia, and strains
expressing each were viewed under a fluorescence microscope. The lac promoter
produced a very faint amount of fluorescence, whereas the nptII promoter produced a
strong signal (Figure 2.23).

Testing secretion signals from species related to Asaia
Secretion signals were tested from two close relatives of Asaia bogorensis in the
family Acetobacteraceae: Gluconobacter oxydans and Gluconacetobacter diazotrophicus
since the Asaia genome was not yet sequenced. Thirteen genes from these species were
selected from a list of known secreted proteins on the psortdb database (db.psort.org), and
their

secretion

signals

were

identified

using

the

SignalP4.1

algorithms

(www.cbs.dtu.dk/services/SignalP). The leader peptides for the thirteen genes were
amplified from genomic DNA and cloned into scFv expression plasmids in-frame with
both the anti-BSA scFv and the anti-Pfs25 scFv. The complete list of genes from which
secretion signals were cloned and their amino acid sequence are listed in Table 2.4.
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These plasmids were transformed into Asaia competent cells, and protein
production was assessed by western blot (Figures 2.24 and 2.-25). Despite the use of
secretion signals from closely-related species, no protein production was detected.

DISCUSSION
Malaria remains a significant cause of human mortality and morbidity in the
world, and new techniques to combat the disease are necessary to supplement current
interventions. In this work, new effector molecules, which can potentially be secreted by
paratransgenic bacteria living within anopheline mosquito hosts, were generated. These
proteins are single-chain variable fragment (scFv) antibodies that should be capable of
binding to surface proteins of Plasmodium falciparum and interfering with the parasite's
development. The genes for these scFv effectors were tested for protein expression and
secretion from E. coli and from two mosquito midgut symbionts, Asaia bogorensis and
Pantoea agglomerans.

Novel scFv effector molecules
Heavy and light chain variable binding domain regions for three antimalarial
antibodies known to interfere with P. falciparum within the mosquito midgut were cloned
from hybridoma lines and sequenced. These variable region genes were recombined into
genes designed to produce single-chain variable fragment antibodies within heterologous
hosts. Such molecules only contain the binding domain of the heavy and light antibody
chains and are much smaller than a standard antibody. They have a great potential for use

52

as antimalarial effector molecules to combat P. falciparum, the most deadly species of
Plasmodium in humans. Furthermore, the activity of these effector molecules would be
restricted to targeting only the parasite of interest and should not interfere with any other
aspects of the microbiota, as could be the case with some other more general
antimicrobial effectors, like scorpine, that kill a wide range of microorganisms
(Carballer-Lejarazu 2008).

Difficulties in scFv expression and secretion
Despite multiple attempts to express and to secrete these scFv proteins in E. coli,
A. bogorensis, and P. agglomerans, no success was achieved. The genes proved to be
properly transcribed in the heterologous hosts; however, no protein was detected by
either Coomassie-stained protein gels or by western blot targeting the Myc epitope tag of
the protein. There can be issues involved with protein expression at multiple points in the
process, during translation, protein folding, or secretion. Not all promoters will function
in all bacteria: the lac promoter is known to function in E. coli and P. agglomerans, but
no protein was produced even from IPTG-induced cells. Indeed, transcription does not
seem to be a problem with these constructs, as evidenced by the northern blot which
shows full length products from each construct tested.
There could be a problem during translation of the proteins, although that would
be unlikely to cause a complete lack of protein considering that multiple gene
combinations were attempted, including different effectors and different N-terminal
signal sequences. Incorrect protein folding is a common problem in heterologously
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expressed proteins, especially for scFv antibodies (Maeng 2011). Single-chain antibody
fragments are less stable than natural antibodies, and stability engineering is a concern
(Worn 2001). These proteins require the formation of disulphide bonds in the periplasm
to retain their correct structure. The PelB secretion signal has been used extensively for
the export of scFv molecules from bacterial cells (Mergulhao 2005), and it utilizes the
general secretory (Sec) pathway which translocates the protein into the periplasm before
it leaves the cell entirely. Typically, this is a beneficial pathway for scFv secretion,
because the protein can form disulphide bonds in the oxidizing environment while it
passes through the periplasm (Popplewell 2005). The Sec translocon transfers proteins in
an unfolded conformation that requires proteins to refold within the periplasm and this
fact may prevent the proteins designed in this study from folding properly and hence be
degraded by cellular proteases (Dalbey 2012).
Visual analysis of transformed bacterial colonies containing these plasmids
showed unusual phenotypes such as a raised morphology and greater transparency than in
wild type cells. These phenotypes could be indicative of problems with the membrane of
the cell caused by incorrect translocation and “clogging” of the membrane, causing the
cells to rupture or activate some sort of stress response. The GFP expression plasmids
used in Asaia were proven to function quite well with the nptII promoter and only
slightly with the lac promoter; therefore, the negative results from expression plasmids
utilizing the nptII promoter to express either GFP or scFv genes with secretion signals
indicates that the problem lies in the secretion system used to translocate these proteins.
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They are likely being transcribed and translated but are degraded by cellular proteases
due to problems at the cell membrane.

Conclusions
Single-chain variants of mouse monoclonal antibodies have been cloned and
sequenced successfully; however, the proteins were not expressed properly by any
bacteria transformed with diverse expression plasmids utilizing different secretion
signals, promoters, and gene variants. Secretion in Gram-negative bacteria involves many
different pathways that translocate proteins by very different mechanisms. These scFv
genes likely require a different secretion signal or mechanism to successfully export the
protein safely, without detriment to the bacteria. The PelB leader sequence secretes
proteins using the general secretory (Sec) pathway of prokaryotes. This pathway
translocates proteins into the periplasm post-translationally, where they must refold.
Twelve of the cloned leader peptides from G. oxydans and G. diazotrophicus were Secdependent, and one was Tat-dependent. Constructs with any of these signals failed to
produce detectable protein. It is possible that a native secretion signal from Asaia would
allow the proteins to be translated and exported from the cell correctly. Unfortunately, the
Asaia genome was not sequenced at the time of these experiments, only genomes from
related species were available. The scFv gene constructs cloned were retained for future
use after a new secretion system is identified that functions well in Asaia.
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Figure 2.1. Forms of antibodies. From left to right: a natural IgG antibody, a single
chain antibody utilizing only the antigen binding domains from IgG, a diabody with two
IgG binding domains back-to-back, and a single chain antibody fused with a folding
chaperone. Both the scFv and diabody can be expressed in prokaryotes, and they can also
accomodate added fusion proteins, like the Skp molecular chaperone depicted here. Skp
is a trimeric periplasmic protein chaperone of Gram-negative bacteria which can increase
the avidity of a scFv molecule by increasing the number of binding domains in a single
protein complex and by aiding in the correct folding of the protein in the periplasm
(Wang and Xiang 2013). Antimicrobial peptides, such as the Shiva1 antimicrobial, can
also be fused to the scFv to complement its function by creating a single protein that acts
against Plasmodium in two different ways (Wang 2013).
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Figure 2.2. Di-diabody. The structure of a di-diabody, which consists of two diabodies
held together by CH3 constant domains. This molecule has a greater avidity than standard
scFv constructs that contain just a single binding domain and provides complementfixing functionality by the natural CH3 domain interaction.
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Figure 2.3. Overlap extension PCR. The heavy and light chain variable regions of each
antibody were separately amplified from cDNA using degenerate primer sets (primers ab
and cd, above). Primers b and c share a region of homology. This allows the two products
(products AB and CD) to act as primers for the opposite strand in a new PCR reaction in
which both products are included as templates and external primers (primers a and d) are
used.
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A.

B.

Figure 2.4. Antibody variable region PCR and overlap extension PCR. A.) One
percent agarose gel showing separation of light and heavy chain antibody variable
fragments amplified from MRA315, anti-Pfs25 antibody, one of the three antiPlasmodium hybridomas. These are the PCR products later used in sequencing reactions
to obtain sequence and to run overlap-extension PCR. The lanes are: 1.) kappa variable
region (Vk) short linker, 2.) Vk long linker, 3.) lambda variable region (Vl) short linker,
4.) Vl long linker, and 5.) heavy chain variable region (Vh). Separate primer sets were
used to amplify the Vk and Vl antibodies, and since each hybridoma line will only
produce a single light chain that will be either Kappa or Lambda. B.) The successful
overlap extension PCR of the fragments from Part A. 1.) scFv with a short linker
sequence, and 2.) scFv with a long linker sequence. These products consist of singlechain antibody genes, which were gel-purified and inserted into an expression vector to
attempt expression of the un-modified gene construct. Similar products were amplified
from MRA 316, anti-Pfs48/45 and MRA878, anti-Pfs230.
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Figure 2.5. Single-chain antibody construct. This is the first open reading frame (ORF)
design for each scFv construct as cloned in pDB48. There are multiple restriction sites
built into the gene construct for the ease of switching scFv or other protein effectors in
and out. These are located on either side of the PelB leader, and the C-terminal tag region
so either the entire ORF can be moved or the specific protein between them can be
replaced. Later, these gene constructs were modified to include different promoters and
leader peptides (Figure 2.14).
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Pfs48/45 hair
Pfs48/45 orig

1 CCAACCTGCTGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCTGTATCTCT
CCA CC GC GAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCTGTATCTCT
1 CCAGCCGGCCGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCTGTATCTCT

60
60

Figure 2.6. Nucleotide sequence of the 5' end of anti-Pfs48/45 scFv hairpin fix. This
is the nucleotide sequence of the 5' end of the anti-Pfs48/45 scFv that was modified to
prevent the formation of possible translation-blocking RNA hairpins. Pfs48/45 hair =
modified gene sequence. Pfs48/45 orig = original gene sequence.
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Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig
Pfs25 opt
Pfs25 orig

1 ATGAAATATCTGCTGCCGACCGCCGCTGCTGGACTGCTGCTGCTGGCTGCTCAACCTGCT
ATGAAATATCTGCTGCCGACCGCCGCTGCTGGACTGCTGCTGCTGGCTGCTCAACCTGCT
1 ATGAAATATCTGCTGCCGACCGCCGCTGCTGGACTGCTGCTGCTGGCTGCTCAACCTGCT

60
60

61 ATGGCCGGCGCGCCTCCTTCTTCGATGTTCGCCTCTCTGGGTGACCGTGTATCCCTGTCT 120
ATGGCCGGCGCGCC CC TC TC ATGTT GCCTCTCTGGG GAC G GT
CT TCT
61 ATGGCCGGCGCGCCACCATCGTCCATGTTTGCCTCTCTGGGAGACAGAGTCAGTCTCTCT 120
121 TGCCGTGCTTCTCAGGACATTCGTGGGAATCTGGATTGGTTCCAACAAAAACCGGGGGGT 180
TG CG GCT TCAGGACATT G GG AAT T GA TGGTT CA CA AAACC GG GG
121 TGTCGGGCTAGTCAGGACATTAGAGGTAATTTAGACTGGTTTCAGCAGAAACCAGGTGGA 180
181 ACGATTAAACTGCTGATCTATTCGACCTCTAACCTAAATTCTGGTGTTCCGAGCCGCTTT 240
AC ATTAAACT CTGATCTA TC AC TC AA TAAATTCTGGTGT CC
G TT
181 ACTATTAAACTCCTGATCTACTCCACATCCAATTTAAATTCTGGTGTCCCATCAAGGTTC 240
241 AGTGGATCTGGTTCTGGTAGCGACTATTCTCTGACCATCTCTTCACTGGAGAGCGAGGAC 300
AGTGG
TGG TCTGG
GA TATTCTCT ACCATC
CT GAG
GA GA
241 AGTGGCAGTGGGTCTGGGTCAGATTATTCTCTCACCATCAGCAGCCTAGAGTCTGAAGAT 300
301 CTGGGGGATTATTATTGTCTGCAACGCAACGCTTATCCGCTGACCTTTGGTAGTGGTACA 360
TGGG GA TATTA TGTCT CA CG AA GC TATCC CT AC TT GG
GG ACA
301 TTGGGAGACTATTACTGTCTACAGCGTAATGCGTATCCTCTCACGTTCGGGTCGGGGACA 360
361 AAACTGGAAATCAAAAGCTCCGGTGGTGGAGGAAGTGGCGGGGGAGGCGGAGGTTCTTCT 420
AA TGGAAAT AAA CTC GGTGG GG GG
GGCGG GG GG GG GGTTC TCT
361 AAGTTGGAAATAAAATCCTCTGGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCT 420
421 CGTTCAAGCCTGGAAGTTCAACTGGTGGAATCTGGTGGTGGTCTGGTTCAACCGGGTGGT 480
G TC
CCT GA GT CAACTGGTGGA TCTGG GG GG T GT CA CC GG GG
421 AGATCTTCCCTCGAGGTGCAACTGGTGGAGTCTGGAGGAGGCTTAGTGCAGCCTGGAGGG 480
481 TCACAGAAACTGAGCTGTGCTGCTAGTGGTTTCACCTTTAGCGATTATGGTATGGCGTGG 540
TC CAGAAACT
CTGTGC GC
TGG TTCAC TT AG GA TA GG ATGGCGTGG
481 TCCCAGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTGACTACGGAATGGCGTGG 540
541 TTTCGTCAGGCCCCTGGAAAAGGCCCTGAATGGGTGGCGTTTATCAACAATCTGGCCTAT 600
TTTCG CAGGC CC GG AA GG CCTGA TGGGT GC TT AT AA AAT TGGC TAT
541 TTTCGACAGGCTCCAGGGAAGGGGCCTGAGTGGGTAGCATTCATTAATAATTTGGCATAT 600
601 AGCATCTATTATGCCGACACCGTTACTGGTCGTTTTACGATCTCTCGTGAGAATGCCAAA 660
AG ATCTA TATGC GACAC GT AC GG CG TT AC ATCTCT G GAGAATGCCAA
601 AGTATCTACTATGCAGACACTGTGACGGGCCGATTCACCATCTCTAGAGAGAATGCCAAG 660
661 AACACCCTGTATCTGGAGATGTCTAGCCTGCGTTCCGAGGATACTACGATGTATTATTGT 720
AACACCCTGTA CTGGA ATG
AG CTG G TC GAGGA AC AC ATGTA TA TGT
661 AACACCCTGTACCTGGAAATGAGCAGTCTGAGGTCTGAGGACACAACCATGTACTACTGT 720
721 GCCCGTGGTAACCTGTATTATGGGCTGGACTATTGGGGTCAAGGGACAACACTGACTGTT 780
GC G GG AA CT TA TA GG CT GACTA TGGGG CAAGG AC AC CT AC GT
721 GCAAGGGGGAATCTTTACTACGGTCTAGACTACTGGGGCCAAGGCACCACTCTCACAGTC 780
781 AGTAGCGCCAAAACAACACCGCCTAGCGTCTATCCGCTGGCTGCGGCCGCACACCATCAT 840
GCCAAAAC ACACC CC
GTCTATCC CTGGC GCGGCCGCACACCATCAT
781 TCCTCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCGCGGCCGCACACCATCAT 840
841 CATCATCATGGCGCCGCTGAACAGAAACTGATCTCGGAGGAAGATCTGAACGGAGCTGCC 900
CATCATCATGGCGCCGCTGAACAGAAACTGATCTCGGAGGAAGATCTGAACGGAGCTGCC
841 CATCATCATGGCGCCGCTGAACAGAAACTGATCTCGGAGGAAGATCTGAACGGAGCTGCC 900
901 TAA 903
TAA
901 TAA 903

Figure 2.7. Nucleotide sequence of the anti-Pfs25 scFv. This is the nucleotide sequence
of the scFv designed from sequence data of the MRA315 hybridoma line (MR4,
Manassas, VA). Pfs25 orig = original sequence. Pfs25 opt = optimized gene.
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Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig
Pfs48/45 opt
Pfs48/45 orig

1 GGCGCGCCACAACCTGCTGAACTGGACATCGTGCTGACCCAATCGCCTGCTTCCCTGGCC
GGCGCGCC CA CC GC GA CT GAC T GTG T AC CA TC CCTGCTTCC T GC
1 GGCGCGCCCCAGCCGGCCGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCT

60
60

61 GTATCACTGGGACAACGTGCTACCATCTCTTATCGTGCCTCCAAAAGCGTTTCTACGAGT 120
GTATC CTGGG CA G GC ACCATCTC TA G GCC CAAAAG GT
TAC
T
61 GTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCT 120
121 GGTTATTCCTATATGCACTGGAACCAACAAAAACCGGGACAGCCTCCTCGTCTGCTGATT 180
GG TAT
TATATGCACTGGAACCAACA AAACC GGACAGCC CC G CT CT AT
121 GGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATC 180
181 TATCTGGTGTCGAACCTGGAAAGTGGTGTGCCTGCCCGTTTCTCCGGATCTGGATCTGGG 240
TATCT GT TC AACCT GAA TGG GT CCTGCC G TTC
GG
TGG TCTGGG
181 TATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGG 240
241 ACTGATTTTACCCTGAACATTCACCCTGTGGAAGAGGAAGATGCCGCCACCTATTATTGC 300
AC GA TT ACCCT AACAT CA CCTGTGGA GAGGA GATGC GC ACCTATTA TG
241 ACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGT 300
301 CAACACATTCGTGAGCTGACACGCTCTGAAGCTGGTACAAAACTGGAGATCAAAAGCTCT 360
CA CACATT G GAGCT ACACG TC G AG GG AC AAACTGGA ATCAAA CTCT
301 CAGCACATTAGGGAGCTTACACGTTC-GGAGGGGGGACCAAACTGGAAATCAAATCCTCT 359
361 GGTGGTGGTGGAAGTGGTGGTGGTGGAGGTGGTTCTTCTCGTTCTAGCCTGGAAGTCATG 420
GGTGG GGTGG
GG GGTGGTGG GGTGGTTC TCT G TCT CCT GA GT ATG
360 GGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCTAGATCTTCCCTCGAGGTGATG 419
421 CTGGTCGAATCTGGTCCTGACCTGGTTAAACCTGGTGCTTCCGTGAAAATTTCCTGTAAA 480
CTGGT GA TCTGG CCTGACCTGGT AA CCTGG GCTTC GTGAA AT TCCTG AA
420 CTGGTGGAGTCTGGACCTGACCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAG 479
481 GCGAGCGGGTATTCCTTCATCAACTATTATATGCACTGGGTTAAACAGAGCCACGGCAAA 540
GC
GG TATTC TTCAT AA TA TATATGCACTGGGT AA CAGAGCCA GG AA
480 GCTTCTGGTTATTCATTCATTAATTACTATATGCACTGGGTGAAGCAGAGCCATGGAAAG 539
541 TCACTGGAATGGATTGGTCGTGTTAATCCTCAGAATGGCGGTACACGTGACAATCAGAAA 600
CT GA TGGATTGG CG GTTAATCCTCAGAATGG GGTAC G GACAA CAGAAA
540 AGCCTTGAGTGGATTGGACGAGTTAATCCTCAGAATGGTGGTACTAGGGACAACCAGAAA 599
601 TTCAAAGGCAAAGCCATCTTTACGGTGGACAAATCGTTCAATACAGCGTATATGGAACTG 660
TTCAA GGCAA GCCAT TTTAC GT GACAA TC TTCAA ACAGC TATATGGAACT
600 TTCAAGGGCAAGGCCATATTTACTGTAGACAAGTCATTCAACACAGCCTATATGGAACTA 659
661 CGTTCACTGACCTCGGAGGACTCTGCTGTGTATTATTGTGCCCGTGAAGTCCACTATGAT 720
CG
CTGAC TC GAGGACTCTGC GT TATTA TGTGC CG GA GT CA TA GA
660 CGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCACGAGAGGTTCATTACGAC 719
721 GAGGCGCTGGATTATTGGGGTCAAGGCACCTCTGTAACCGTTTCTAGCGCCAAAACAACA 780
GAGGC TGGA TA TGGGGTCAAGG ACCTC GT ACCGT TC
GCCAAAACAACA
720 GAGGCTTTGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACA 779
781 CCGCCTAGCGTTACAAGTGCGGCCGC 806
CC CC
GT AC AGTGCGGCCGC
780 CCCCCATCTGTCACTAGTGCGGCCGC 805

Figure 2.8. Nucleotide sequence of the anti-Pfs48/45 scFv. This is the nucleotide
sequence of the scFv designed from sequence data of the MRA316 hybridoma line (MR4
Manassas, VA). Pfs48/45 orig = original gene sequence. Pfs48/45 opt = optimized gene
sequence.
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Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig
Pfs48/45 harm
Pfs48/45 orig

1 GGCGCGCCCCAGCCCGCGGAACTTGATATCGTCCTAACGCAGTCACCGGCGAGCCTAGCA
GGCGCGCCCCAGCC GC GA CT GA T GT TAAC CAGTC CC GC
C TAGC
1 GGCGCGCCCCAGCCGGCCGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCT

60
60

61 GTATCACTGGGTCAGCGCGCGACCATTTCCTATCGCGCGAGCAAGAGTGTCAGTACGTCA 120
GTATC CTGGG CAG G GC ACCAT TC TA G GC AGCAA AGTGTCAGTAC TC
61 GTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCT 120
121 GGCTACAGTTACATGCATTGGAATCAACAGAAGCCTGGTCAGCCTCCGCGCCTTCTTATT 180
GGCTA AGTTA ATGCA TGGAA CAACAGAA CC GG CAGCC CC G CT CT AT
121 GGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATC 180
181 TACTTGGTAAGCAATTTAGAGAGCGGGGTCCCGGCGCGCTTTAGTGGCAGTGGGTCAGGG 240
TA T GTA CAA TAGA
GGGGTCCC GC G TT AGTGGCAGTGGGTC GGG
181 TATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGG 240
241 ACGGATTTTACCCTTAATATTCACCCGGTGGAAGAAGAAGACGCGGCAACCTACTATTGT 300
AC GA TT ACCCT AA AT CA CC GTGGA GA GA GA GC GCAACCTA TA TGT
241 ACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGT 300
301 CAGCACATTCGTGAGCTGACACGCTCTGAAGCGGGTACTAAACTGGAGATCAAAAGCTCT 360
CAGCACATT G GAGCT ACACG TC G AG GGG AC AAACTGGA ATCAAA CTCT
301 CAGCACATTAGGGAGCTTACACGTTC-GGAGGGGGGACCAAACTGGAAATCAAATCCTCT 359
361 GGTGGTGGTGGAAGTGGCGGGGGTGGTGGTGGATCATCTCGTTCTAGCCTGGAGGTGATG 420
GGTGG GGTGG
GGCGG GGTGG GGTGG TC TCT G TCT CCT GAGGTGATG
360 GGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCTAGATCTTCCCTCGAGGTGATG 419
421 CTGGTTGAATCTGGTCCTGATCTGGTGAAACCGGGGGCGTCCGTGAAAATAAGCTGCAAA 480
CTGGT GA TCTGG CCTGA CTGGTGAA CC GGGGC TC GTGAA ATA CTGCAA
420 CTGGTGGAGTCTGGACCTGACCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAG 479
481 GCGTCAGGGTACTCCTTTATCAACTATTACATGCATTGGGTGAAACAGAGCCACGGTAAA 540
GC TC GG TA TC TT AT AA TA TA ATGCA TGGGTGAA CAGAGCCA GG AA
480 GCTTCTGGTTATTCATTCATTAATTACTATATGCACTGGGTGAAGCAGAGCCATGGAAAG 539
541 AGCTTAGAATGGATCGGTCGAGTAAACCCGCAGAACGGGGGGACGCGCGATAATCAGAAG 600
AGC T GA TGGAT GG CGAGT AA CC CAGAA GG GG AC G GA AA CAGAA
540 AGCCTTGAGTGGATTGGACGAGTTAATCCTCAGAATGGTGGTACTAGGGACAACCAGAAA 599
601 TTTAAAGGCAAAGCGATATTCACGGTAGATAAATCGTTTAATACGGCGTACATGGAGCTA 660
TT AA GGCAA GC ATATT AC GTAGA AA TC TT AA AC GC TA ATGGA CTA
600 TTCAAGGGCAAGGCCATATTTACTGTAGACAAGTCATTCAACACAGCCTATATGGAACTA 659
661 CGGAGCCTGACGTCAGAAGATTCAGCTGTCTACTATTGTGCACGAGAAGTACACTATGAT 720
CG AGCCTGAC TC GA GA TC GC GTCTA TA TGTGCACGAGA GT CA TA GA
660 CGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCACGAGAGGTTCATTACGAC 719
721 GAAGCGTTGGATTATTGGGGGCAAGGTACCTCCGTCACCGTCAGCTCCGCGAAGACGACG 780
GA GC TTGGA TA TGGGG CAAGG ACCTC GTCACCGTC CTC GC AA AC AC
720 GAGGCTTTGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACA 779
781 CCGCCTTCAGTCACGAGTGCGGCCGC 806
CC CC TC GTCAC AGTGCGGCCGC
780 CCCCCATCTGTCACTAGTGCGGCCGC 805

Figure 2.9. Nucleotide sequence of the codon-harmonized anti-Pfs48/45 scFv. This is
the nucleotide sequence of the scFv designed from sequence data of the MRA316
hybridoma line (MR4 Manassas, VA). Pfs48/45 orig = original gene sequence. Pfs48/45
harm = codon harmonized gene sequence.
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Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig
Pfs230 opt
Pfs230 orig

1 GGCGCGCCACAACCGGCTGAACTGGATATCGTTATGACCCAGAGCCACAAATTCATGAGT
GGCGCGCC CA CCGGC GA CT GA AT GT ATGACCCAG
CACAAATTCATG
1 GGCGCGCCCCAGCCGGCCGAGCTCGACATTGTGATGACCCAGTCTCACAAATTCATGTCC

60
60

61 ACCAGCGTCCGTGACCGTGTTAGTATCACGTGTAAAGCGTCCCAGGACGTGGGAACAGCG 120
AC
GT G GAC G GT AG ATCAC TG AA GC
CAGGA GTGGG AC GC
61 ACATCAGTAAGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGGGTACTGCT 120
121 GTAGCATGGTATCAGCAAAAACCGGGACAGTCACCGAAACTGCTGATCTATTGGGCATCA 180
GTAGC TGGTATCA CA AAACC GG CA TC CC AAACT CTGAT TA TGGGCATC
121 GTAGCCTGGTATCAACAGAAACCAGGTCAATCTCCTAAACTACTGATTTACTGGGCATCC 180
181 ACACGCCATACTGGTGTGCCGGACCGTTTCACCGGATCTGGAAGCGGAACCGATTTTACC 240
AC CG CA ACTGG GT CC GA CG TTCAC GG
TGGA
GG AC GATTT AC
181 ACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACT 240
241 CTGACGATTTCTAACGTTCAAAGCGAGGACCTGGCCGATTATTTCTGCCAACAGTATAGC 300
CT AC ATT
AA GT CA
GA GAC TGGC GATTATTTCTG CA CA TATAGC
241 CTCACCATTAGCAATGTGCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAGC 300
301 ATCTATCCTCCGCTGACCTTTGGAGCAGGCACAAAACTGGAGCTGAAACACATCCGTGAA 360
ATCTATCCTCCGCT AC TT GG GC GG AC AA CTGGAGCTGAAACACAT CGTGA
301 ATCTATCCTCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAACACATTCGTGAG 360
361 CTGACCCGTTCTGAAGCAGGCACGAAACTGGAGATTAAAAGCTCGGGTGGTGGAGGTTCG 420
CTGAC CG TCTGAAGC GG AC AAACTGGAGAT AAAAGCTC GGTGGTGG GG
361 CTGACACGCTCTGAAGCGGGTACTAAACTGGAGATCAAAAGCTCTGGTGGTGGTGGAAGT 420
421 GGAGGCGGGGGAGGTGGTTCTTCTCGTTCTAGCCTGGAGGTGATGCTGGTAGAATCTGGT 480
GG GG GG GG GGTGG TC TCTCGTTCTAGCCTGGAGGTGATGCTGGT GAATCTGGT
421 GGCGGGGGTGGTGGTGGATCATCTCGTTCTAGCCTGGAGGTGATGCTGGTTGAATCTGGT 480
481 CCTGGTGGTAGCAGTCGTTCTAGTCTGGAAGTCAAACTGGTGGAAAGCGGCGGTGGTCTG 540
CCTGGTGGT C T G TCT
CT GA GT AA CTGGTGGA
GG GG GG T
481 CCTGGTGGTTCCTCTAGATCTTCCCTCGAGGTGAAGCTGGTGGAGTCTGGGGGAGGCTTA 540
541 GTCCAACCTGGCGGTTCTCTGAAACTGAGTTGTGCTGCCTCTGGTTTCACTTTTAGCAAC 600
GT CA CCTGG GG TC CTGAAACT
TGTGC GCCTCTGG TTCACTTT AG AAC
541 GTGCAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAAC 600
601 TATTATATGAGCTGGGTTCGCCAGACGCCTGAAAAACGCCTGGAATGGGTTGCCTATATC 660
TATTA ATG
TGGGTTCGCCAGAC CC GA AA G CTGGA TGGGT GC TA AT
601 TATTACATGTCTTGGGTTCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTCGCATACATT 660
661 TCAAGCGGCGGTGGAAGCACTTATTATCCTGACAGCGTCAAAGGCCGTTTTACCATTAGC 720
AG GG GGTGG AGCAC TA TATCC GACAG GT AA GG CG TT ACCAT
C
661 AGTAGTGGTGGTGGTAGCACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCTCC 720
721 CGTGACAATGCCAAAAACACGCTGTATCTGCAGATGTCTAGCCTGAAAAGCGAGGACACA 780
G GACAATGCCAA AACAC CTGTA CTGCA ATG
AG CTGAA
GAGGACACA
721 AGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAAGTCTGAGGACACA 780
781 GCCATGTATTATTGTACCCGCCAAGAATGGTCACCATGGTTCGCTTATTGGGGTCAAGGA 840
GCCATGTATTA TGTAC G CA GAATGGTC CC TGGTT GCTTA TGGGG CAAGG
781 GCCATGTATTACTGTACAAGACAGGAATGGTCCCCCTGGTTTGCTTACTGGGGCCAAGGG 840
841 ACCCTGGTTACAGTTTCTGCTGCCAAAACCACACCTCCGTCTGTTACAAGTGCGGCCGC 899
AC CTGGT AC GT TCTGC GCCAAAAC ACACC CC TCTGT AC AGTGCGGCCGC
841 ACTCTGGTCACTGTCTCTGCAGCCAAAACAACACCCCCATCTGTCACTAGTGCGGCCGC 899

Figure 2.10. Nucleotide sequence of the anti-Pfs230 scFv. This is the nucleotide sequence
of the scFv designed from sequence data of the MRA878 hybridoma line (MR4 Manassas,
VA). Pfs230 orig = original gene sequence. Pfs230 opt = optimized gene sequence.
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comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig
comp opt
comp orig

1 GGTGGGGGTGGTTCTATTGTTATGACACAGAGCCCGGCAACGCTGAGTGTAACGCCTGGT
ATTGT ATGAC CAGAGCCCGGC AC CTGAG GT AC CC GG
1 ---------------ATTGTGATGACCCAGAGCCCGGCGACCCTGAGCGTGACCCCGGGC

60
45

61 GATAGTGTTAGCCTGAGCTGTCGTGCTTCTCAATCAATCGGGAATAATCTGCACTGGTAT 120
GATAG GT AGCCTGAGCTG CG GC
CA
AT GG AA AA CTGCA TGGTAT
46 GATAGCGTGAGCCTGAGCTGCCGCGCGAGCCAGAGCATTGGCAACAACCTGCATTGGTAT 105
121 CAGCAAAAAAGCCATGAAAGCCCTCGTCTGCTGATCAAATATGCCAGCCAGTCCATTAGC 180
CAGCA AAAAGCCATGAAAGCCC CG CTGCTGAT AAATATGC AGCCAG CATTAGC
106 CAGCAGAAAAGCCATGAAAGCCCGCGCCTGCTGATTAAATATGCGAGCCAGAGCATTAGC 165
181 GGCATTCCTAGCCGTTTTAGTGGCAGTGGTAGTGGTACGGATTTTACCCTGATTATCAAC 240
GGCATTCC AGCCG TTTAG GGCAG GG AG GG AC GATTTTACCCTGATTAT AAC
166 GGCATTCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGATTATTAAC 225
241 AGCGTGGAAACCGAAGATTTCGGCATGTATTTCTGCCAACAGACCAACATTTGGCCGTAT 300
AGCGTGGAAACCGAAGATTT GGCATGTATTT TGCCA CAGACCAACATTTGGCCGTAT
226 AGCGTGGAAACCGAAGATTTTGGCATGTATTTTTGCCAGCAGACCAACATTTGGCCGTAT 285
301 ACCTTTGGTGGAGGGACAAAACTGGAGATTAAA------GGTGGTGGCGGTTCTGGTGGT 354
ACCTTTGG GG GG AC AAACTGGA ATTAAA
GG GG GGCGG
GG GG
286 ACCTTTGGCGGCGGCACCAAACTGGAAATTAAAAGCAGCGGCGGCGGCGGCAGCGGCGGC 345
355 GGTGGA-TCTGGAGGAG-----GCGGTTCTGAAGTTCAGCTGCAGCAAAGTGGAGCCGAG 408
GG GG
C G AG AG
GC G
GAAGT CAGCTGCAGCA AG GG GC GA
346 GGCGGCGGCGGCAGCAGCCGCAGCAGCCTGGAAGTGCAGCTGCAGCAGAGCGGCGCGGAA 405
409 CTGGTTCGTTCTGGAGCATCAGTTCGCCTGAGTTGTACAGCAAGCGGCTTCAACATCAAA 468
CTGGT CG
GG GC
GT CGCCTGAG TG AC GC AGCGGCTT AACAT AAA
406 CTGGTGCGCAGCGGCGCGAGCGTGCGCCTGAGCTGCACCGCGAGCGGCTTTAACATTAAA 465
469 GACTATTATATCCATTGGGTGAAACAGCGCCCTGAGCAAGGCCTGGAGTGGATCGGGTGG 528
GA TATTATAT CATTGGGTGAAACAGCGCCC GA CA GGCCTGGA TGGAT GG TGG
466 GATTATTATATTCATTGGGTGAAACAGCGCCCGGAACAGGGCCTGGAATGGATTGGCTGG 525
529 ATCGACCCTGAAGATGGCGACACCGAATATGCCCCAAAATTCCAAGACAAAGCGACCATG 588
AT GA CC GAAGATGGCGA ACCGAATATGC CC AAATT CA GA AAAGCGACCATG
526 ATTGATCCGGAAGATGGCGATACCGAATATGCGCCGAAATTTCAGGATAAAGCGACCATG 585
589 ACGGCGGATACAAGCTCTAATACTGCTTATCTGCAACTGCGTCGTCTGACAAGCGAGGAT 648
AC GCGGATAC AGC
AA AC GC TATCTGCA CTGCG CG CTGAC AGCGA GAT
586 ACCGCGGATACCAGCAGCAACACCGCGTATCTGCAGCTGCGCCGCCTGACCAGCGAAGAT 645
649 ACAGCGGTCTATTATTGTAACACGTGGCGTGGCTATGGAAACTATGACAGCATGGACTAT 708
AC GCGGT TATTATTG AACAC TGGCG GGCTATGG AACTATGA AGCATGGA TAT
646 ACCGCGGTGTATTATTGCAACACCTGGCGCGGCTATGGCAACTATGATAGCATGGATTAT 705
709 TGGGGTCAGGGAACCTCTGTTACCGTGTCTAGCGCCAAAACAACACCTCCGTCAGTGACT 768
TGGGG CAGGG ACC
GT ACCGTG
AGCGC AAAAC AC CC CCG
GTGAC
706 TGGGGCCAGGGCACCAGCGTGACCGTGAGCAGCGCGAAAACCACCCCGCCGAGCGTGACC 765
769 AGTGGCGGGGGAGGCTCA 786
AG
766 AGC--------------- 768

Figure 2.11. Nucleotide sequence of the anti-human complement scFv. This is the
nucleotide sequence of the scFv designed from sequence data of the CRL1757 hybridoma
line (ATCC, Manassas, VA). The original sequenced gene is aligned to the codonoptimized gene sequence. Comp orig = original gene sequence. comp opt = optimized
gene sequence.
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Figure 2.12. Codon usage. This is the codon usage determination of the original antiPfs48/45 gene sequence as compared to mouse codon usage throughout the genome. The
frequency of each codon in the sequence is displayed by the bar immediately above it.
Red is used to indicate those codons occurring at or below a 15% frequency. Such rare
codons determine where the ribosome slows translation, and they tend to occur in groups.
Figure continued on next two pages.
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Figure 2.12 continued. Codon usage. This is the codon usage determination of the
original anti-Pfs48/45 gene sequence as compared to mouse codon usage throughout the
genome. The frequency of each codon in the sequence is displayed by the bar
immediately above it. Red is used to indicate those codons occurring at or below a 15%
frequency. Such rare codons determine where the ribosome slows translation, and they
tend to occur in groups. Figure continued on next page.
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Figure 2.12 continued. Codon usage. This is the codon usage determination of the
original anti-Pfs48/45 gene sequence as compared to mouse codon usage throughout the
genome. The frequency of each codon in the sequence is displayed by the bar
immediately above it. Red is used to indicate those codons occurring at or below a 15%
frequency. Such rare codons determine where the ribosome slows translation, and they
tend to occur in groups.
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Figure 2.13. RNA hairpin-forming region of the anti-Pfs48/45 scFv gene. The
predicted free energy at the start of the scFv gene was -49.60 kcal/mol, which is far lower
than the -9 kcal/mol necessary to arrest translation. This hairpin-forming region was
altered to prevent the formation of these secondary structures.
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Figure 2.14. Bacterial recombination cloning protocol. The linearized pBBR1MCS-2
plasmid and bla PCR product with 40 nucleotides of homology to the vector on each end
(shown in blue) were transformed into MG1655 E. coli competent cells. Native E. coli
recombination functions combine the two pieces of DNA into a circular plasmid. The
plasmid was selected by plating on LB medium with ampicillin, guaranteeing activity of
the inserted bla gene.
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Figure 2.15. pBBR1MCS-2. The vector pBBR1MCS-2 from (Kovach 1995), which was
modified to create protein expression vectors. ori = replication origin. oriT = origin of
transfer. neo = neomycin phosphotransferase, kanamycin resistance. lacZ alpha = βgalactosidase alpha fragment.
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Figure 2.16. Plasmid constructs generated. The recombination product that replaced
lacZ in pBBR1MCS-2 with bla, a new multiple cloning site, and a translational enhancer.
ori = replication origin. oriT = origin of transfer. neo = neomycin phosphotransferase,
kanamycin resistance. bla = beta lactamase, ampicillin resistance. enh = translational
enhancer. Plac = promoter from the lac operon.
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Figure 2.17. Plasmid constructs generated. The pNB20 plasmid with the lac promoter
replaced by the nptII promoter. ori = replication origin. oriT = origin of transfer. neo =
neomycin phosphotransferase, kanamycin resistance. bla = beta lactamase, ampicillin
resistance. enh = translational enhancer. PnptII = promoter from neomycin
phosphotransferase.
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Figure 2.18. Modular scFv gene constructs. The plasmid pNB39 was produced by
cloning the synthesized anti-Pfs25 scFv gene into plasmid pNB20. Afterwards, both the
promoter and signal peptide were replaced to create a variety of protein/signal
combinations using the gene fragments and promoters shown above. The gene fragments
inserted or removed were directionally cloned using the restriction enzyme sites shown at
the top of this figure. Ultimately, the gene constructs built and tested included the lac
promoter with anti-BSA scFv and each leader peptide (Table 2.1 pNB55 and pNB59-66),
the lac promoter with anti-Pfs25 scFv and the 5 Gluconobacter leader peptides (Table
2.1 pNB44-48), the nptII promoter with anti-Pfs25 scFv and each leader peptide (Table
2.1 pNB57 and pNB67-76), and both lac and nptII promoters with gfp (Table 2.1 pNB49
and pNB50). PnptII = promoter from neomycin phosphotransferase. Plac = promoter
from the lac operon.
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Figure 2.19. Protein production by E. coli and P. agglomerans expressing optimized
scFv secretion constructs using the PelB leader. Protein was detected by an anti-Myc
antibody from pellet and supernatant fractions of liquid bacteria culture. “pel” = pellet
and “sup” = supernatant. The predicted size of the positive control HlyA-secreted scFv
from pBS49 (Bisi 2011) is 60 kDa, and the predicted sizes of the PelB-secreted pNB39
product, anti-Pfs25 scFv, and the pNB38 product, anti-Pfs230 scFv, are each
approximately 26 kDa. No protein was detected using either secretion construct, but the
positive control was present.
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Figure 2.20. Northern blot of RNA from E. coli strains expressing scFv genes. RNA
was extracted from induced E. coli cultures expressing various scFv proteins and using
different promoters. Each culture produced the correct size transcript as predicted. Each
sample had two lanes, the first lane of each was uninduced sample, and the second was
induced with IPTG for those plasmids under control of the lac promoter. Samples are: 1.)
E. coli negative control, 2.) pDB51 anti-BSA scFv potitive control, 3.) pMAL MRA316
anti-Pfs48/45 scFv 4.) pDB48 anti-Pfs48/45 scFv, 5.) pBBR anti-Pfs48/45 scFv, 6.)
pBBR anti-Pfs230 scFv clone 22, 7.) pBBR anti-Pfs230 scFv clone 23

77

Figure 2.21. pNB49. The GFP gene was inserted into plasmids pNB20 and pNB51 to
produce plasmids for the expression of GFP by either the lac promoter (pNB49) or the
nptII promoter (pNB50). ori = replication origin. oriT = origin of transfer. neo =
neomycin phosphotransferase, kanamycin resistance. gfp = green fluorescent protein. enh
= translational enhancer. Plac = promoter from the lac operon.
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Figure 2.22. pNB50. Expression vector with gfp driven by the promoter from neomycin
phosphotransferase. ori = replication origin. oriT = origin of transfer. neo = neomycin
phosphotransferase, kanamycin resistance. gfp = green fluorescent protein. enh =
translational enhancer. Plac = promoter from the lac operon.
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A.

B.

Figure 2.23. Expression of GFP by Asaia bogorensis. Asaia containing GFP expression
plasmid constructs were viewed under a fluorescence microscope under excitation
wavelength light of 395 nm. A.) Asaia transformed with the pNB49 plasmid, which has
the gfp gene transcribed by the lac promoter, showed no fluorescence signal. B.) Asaia
transformed with the pNB50 plasmid, which has the gfp gene transcribed by the nptII
promoter, showed a strong fluorescence signal.
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Figure 2.24. Protein production of Asaia expressing heterologous scFv secretion
constructs using leader peptides from related species. Western blot detection of
protein from Asaia strains containing scFv secretion constructs with Gluconobacter and
Gluconacetobacter leader peptides. “pel” = pellet and “sup” = supernatant. The predicted
sizes of the scFv constructs were 26 kDa. No protein was detected in pellet or supernatant
fractions.
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Figure 2.25. Protein production of Asaia expressing heterologous scFv secretion
constructs using leader peptides from related species. Western blot detection of
protein from Asaia strains containing scFv secretion constructs with Gluconobacter and
Gluconacetobacter leader peptides. “pel” = pellet and “sup” = supernatant. (+) = antiBSA scFv positive control protein expressed in E. coli, ~33kDa. The predicted sizes of
the other scFv constructs were ~26 kDa. No protein was detected in pellet or supernatant
fractions.
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Table 2.1. Plasmids used in this study
Plasmid

Relevant Characteristics
R

pBBR1MCS-2 Kan , pBBR origin, oriT, MCS, used for plasmid construction

Source
Kovach 1995

pSC189

AmpR; used to amplify the beta lactamase (bla) gene

pHM2-GFP

KanR; used to amplify the neomycin phosphotransferase (nptII) promoter Favia 2007

pNB20

KanR; pBBR1MCS-2 w/ beta-lactamase and translational enhancer

pNB51

KanR;

pNB20 w/ promoter region changed to P nptII

R

Chiang 2002
this study
this study

MRA315

Amp ; codon optimized MRA315 anti-Pfs25 scFv as synthesized

this study

MRA316

AmpR; codon harmonized MRA316 anti-Pfs48/45 scFv as synthesized

this study

MRA316opt

AmpR; codon optimized MRA316 anti-Pfs48/45 scFv as synthesized

this study

MRA878

R

this study

R

Amp ; codon optimized MRA878 anti-Pfs230 scFv as synthesized

IgG scFv

Amp ; codon optimized anti-human IgG scFv as synthesized

this study

pNB20

KanR; pBBR1MCS-2 with a novel cloning site

this study

pNB21

KanR; pNB20 with an AscI restriction site added for cloning purposes.

this study

pDB48

R

Bisi 2011

R

Gent ; pelB-AscI-6His-myc-STOP cloned in pMQ64 MCS

pDB51

Gent ; pelB-Anti-BSA scFv (positive control for experiments)

Bisi 2011

pDB49

AprR; hlyA-Anti-BSA scFv (positive control for experiments)

Bisi 2011

pVDL9.3

CamR; production of hlyB and hlyD transporters

(Tzschaschel
1996)

pNB39

KanR; pNB20 with anti-Pfs25 scFv insert

this study

pNB38

KanR;

pNB20 with anti-Pfs230 scFv insert

this study

pNB37

KanR;

pNB20 with anti-Pfs48/45 scFv insert

this study

pNB44

KanR; anti-Pfs25 scFv with G. oxydans endonuclease I signal peptide

this study

pNB45

KanR;

anti-Pfs25 scFv with G. oxydans endonuclease II signal peptide

this study

pNB46

KanR;

anti-Pfs25 scFv with G. oxydans poly phosphate porin signal peptide

this study

pNB47

KanR;

anti-Pfs25 scFv with G. oxydans aminopeptidase signal peptide

this study

pNB48

KanR; anti-Pfs25 scFv with G. oxydans acid phosphatase signal peptide

this study

pNB49

KanR;

this study

pNB20 with Plac GFP

R

pNB50

Kan ; pNB20 with PnptII GFP

this study

pNB55

KanR;

this study

pNB57

KanR; pNB51 with PnptII G. diazotrophicus levansucrase signal, Pfs25 scFv

this study

pNB59

KanR;

pNB55 with G. diazotrophicus organic solvent tolerance signal peptide

this study

pNB60

KanR;

pNB55 with G. diazotrophicus poly phosphate porin signal peptide

this study

pNB61

KanR;

pNB55 with G. diazotrophicus endonuclease II signal peptide

this study

pNB39 with anti-BSA scFv
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pNB62

KanR; pNB55 with G. diazotrophicus aminopeptidase signal peptide

this study

pNB63

KanR; pNB55 with G. diazotrophicus phospholipase signal peptide

this study

pNB64

KanR;

pNB55 with G. diazotrophicus acid phosphatase signal peptide

this study

pNB65

KanR;

pNB55 with G. diazotrophicus endonuclease I signal peptide

this study

pNB66

KanR;

pNB55 with G. diazotrophicus levansucrase signal peptide

this study

pNB67

KanR; pNB57 with G. diazotrophicus organic solvent tolerance signal peptide

this study

pNB68

KanR;

pNB57 with G. oxydans aminopeptidase signal peptide

this study

pNB69

KanR;

pNB57 with G. ozydans endonuclease I signal peptide

this study

pNB70

KanR;

pNB57 with G. oxydans endonuclease II signal peptide

this study

pNB71

KanR; pNB57 with G. diazotrophicus aminopeptidase M28 signal peptide
R

this study

pNB72

Kan ; pNB57 with G. diazotrophicus polyphosphate porin signal peptide

pNB73

KanR;

pNB57 with G. diazotrophicus invasion-associated locus B signal peptide this study

pNB74

KanR;

pNB57 with G. diazotrophicus phospholipase C signal peptide

pNB75

KanR; pNB57 with G. diazotrophicus glycoside signal peptide

this study

pNB76

KanR;

this study

pNB57 with G. diazotrophicus putative aminopeptidase signal peptide
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this study
this study

Table 2.2. Oligonucleotides used in this study
Oligo

Sequence 5' - 3'

Purpose

Vκ 5' Sense Primers
MSCVK-1

GGG CCC AGC CGG CCG AGC TCG AYA TCC AGC TGA CTC AGC
C

antibody V-region
amplification
(Barbas 2001)

MSCVK-2

GGG CCC AGC CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C

''

MSCVK-3

GGG CCC AGC CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT
C

''

MSCVK-4

GGG CCC AGC CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C

''

MSCVK-5

GGG CCC AGC CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT
C

''

MSCVK-6

GGG CCC AGC CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT
C

''

MSCVK-7

GGG CCC AGC CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT
C

''

MSCVK-8

GGG CCC AGC CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA
C

''

MSCVK-9

GGG CCC AGC CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT
C

''

MSCVK-10

GGG CCC AGC CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT
C

''

MSCVK-11

GGG CCC AGC CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C

''

MSCVK-12

GGG CCC AGC CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C

''

MSCVK-13

GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK
C

''

MSCVK-14

GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG
A

''

MSCVK-15

GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW
T

''

MSCVK-16

GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC
C

''

MSCVK-17

GGG CCC AGC CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C

''

VΚ 3' REVERSE PRIMERS, SHORT LINKER
MSCJK12-B

GGA AGA TCT AGA GGA ACC ACC TTT KAT TTC CAG YTT GGT
CCC

''

MSCJK4-B

GGA AGA TCT AGA GGA ACC ACC TTT TAT TTC CAA CTT TGT
CCC

''

MSCJK5-B

GGA AGA TCT AGA GGA ACC ACC TTT CAG CTC CAG CTT GGT
CCC

''

VΚ 3' REVERSE PRIMERS, LONG LINKER
MSCJK12-BL GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC
ACC GCC ACC AGA GGA TTT KAT TTC CAG YTT GGT CCC

''

MSCJK4-BL

''

GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC
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ACC GCC ACC AGA GGA TTT TAT TTC CAA CTT TGT CCC
MSCJK5-BL

GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC
ACC GCC ACC AGA GGA TTT CAG CTC CAG CTT GGT CCC

''

VΛ 5' SENSE PRIMER
MSCVL-1

GGG CCC AGC CGG CCG AGC TCG ATG CTG TTG TGA CTC AGG
AAT C

''

VΛ 3' REVERSE PRIMER, SHORT LINKER
MSCJL-B

GGA AGA TCT AGA GGA ACC ACC GCC TAG GAC AGT CAG TTT
GG

''

VΛ 3' REVERSE PRIMER, LONG LINKER
MSCJL-BL

GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC
ACC GCC ACC AGA GGA GCC TAG GAC AGT CAG TTT GG

''

VΗ 5' SENSE PRIMERS
MSCVH1

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG CTT CAG
GAG TC

''

MSCVH2

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG CTB CAG
CAG TC

''

MSCVH3

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG CTG AAG
SAS TC

''

MSCVH4

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR CTG CAA
CAR TC

''

MSCVH5

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG CTB CAG
CAR TC

''

MSCVH6

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR CTG CAG
CAG TC

''

MSCVH7

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC GTG AAG
CAG TC

''

MSCVH8

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS STG GTG
GAA TC

''

MSCVH9

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG YTG GTG
GAG TC

''

MSCVH10

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG SKG GTG
GAG TC

''

MSCVH11

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM CTG GTG
GAG TC

''

MSCVH12

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG CTG ATG
GAR TC

''

MSCVH13

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR CTT GTT
GAG TC

''

MSCVH14

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT CTC
GAG TC

''

MSCVH15

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR STT GAG
GAG TC

''

MSCVH16

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT CTR AAA
GWG TST G

''
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MSCVH17

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA CTV CAG
CAR CC

''

MSCVH18

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAC TTG GAA
GTG TC

''

MSCVH19

GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG GTC ATC
GAG TC

''

VΗ 3' REVERSE PRIMERS
MSCG1ab-B

CCT GCG GCC GCA CTA GTG ACA GAT GGG GST GTY GTT TTG
GC

antibody V gene
amplification and
cloning with NotI
restriction site

MSCG3-B

CCT GCG GCC GCA CTA GTG ACA GAT GGG GCT GTT GTT GT

''

MSCM-B

CCT GCG GCC GCA CTA GTG ACA TTT GGG AAG GAC TGA CTC
TC

''

OVERLAP EXTENSION PRIMERS
RSC-F sense

GAG GAG GAG GAG GAG GAG GCG GGG CCC AGC CGG CCG AGC
TC

RSC-B reverse GAG GAG GAG GAG GAG GAG CCT GCG GCC GCA CTA GTG

''
''

pBBR rec F

ggaattgtgagcggataacaatttcacacaggaaacagctTTAACTTTAAGAAGG bacterial
AGactgCATATGagtattcaacatttccg
recombination to
generate pNB20

pBBR rec R

taacaaaaatttaacgcgaattttaacaaaatattaacgcGAATTCggatccGGC
CGGCCcctgcaggTTAATTAAggtctgacagttaccaatgc

PnptII F NsiI TAatgcatAACCGGAATTGCCAGCTGGG

PnptII R
NdeI

taCATATGTTTTTCCTCCTTATAAAGTTAATC

Gd
TACATATGGCGCATGTACGCCGAAAAG
levansucrase F
NdeI

''
nptII promoter
directional cloning
in pNB51
''
Gluconacetobacter
diazotrophicus leader
cloning

Gd
TAGGCGCGCCATTCCCTTGCGCCAGCGCAC
levansucrase R
AscI

''

Gd TrbJ F
NdeI

TACATATGAAATACGGCATGCGTCTTTATG

''

Gd TrbJ R
AscI

TAGGCGCGCCGTTCGCACCGTCATACAC

''

Gd
TACATATGCGTTCCATGCCCC
aminopeptidas
e F NdeI

''

Gd
TAGGCGCGCCCGGCGCCCACGGGGAC
aminopeptidas
e R AscI

''

Gd IalB F
NdeI

''

TACATATGAAACTTTTCACTCCTG
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Gd IalB R
AscI

TAGGCGCGCCATGCGTCGAGGCCTGGGCCAC

''

Gd OSP F
NdeI

TACATATGATGCCGATCCTGATGTC

''

Gd OSP R
AscI

TAGGCGCGCCCTGGACCTGCGCATGGG

''

Gd
TACATATGGCCACACGCAGAGATTTC
phospholipase
C F NdeI

''

Gd
TAGGCGCGCCATTCGGTGCAATGGCGAAAG
phospholipase
C R AscI

''

Gd Peptidase
M28 F NdeI

TACATATGCCCCCCCATCGTC

''

Gd Peptidase
M28 R AscI

TAGGCGCGCCCCACGGGGACGCGGCATGCG

''

Gd glycoside
F NdeI

TACATATGACCGGGTTCCGTCCATC

''

Gd glycoside
R AscI

TAGGCGCGCCCAGACCGCCGGCCGAAG

''

GFP F NdeI

TACATATGAGTAAAGGAGAAG

GFP R EcoRI

TAGAATTCCTATTTGTATAGTTCATCCATGCC

gfp gene cloning
''

GluconoEndon ATCATATGCGCTTTCTGATTGCCGTTTTAC
uc 1-5’ NdeF

Gluconobacter
oxydans leader
cloning

GluconoERnd ATGGCGCGCCTGCGATGGCTGGAGATGTG
onuc1 leader
Asc R

''

GluconoAPho ATCATATGTCCATGAAGCGCGTACAAC
s 5’ NdeF

''

GluconoAPho ATGGCGCGCCCGCAGAAGAAGACGCTGCCAGCC
s leader AscR

''

GluconoAmPe ATCATATGACACAGAAGACATTCCC
p 5’ NdeF

''

GluconoAmPe ATGGCGCGCCGGCATGACCGGTGACCGGAG
p leader AscR

''

GluconoEndon ATGATATGAATTTCCTGTCGTATCTTC
uc 2 5’ NdeF

''

GluconoEndon ATGGCGCGCCAGCCTGCGCCGGAAGCACGA
uc2 leader
AscR

''

GluconoPolyP ATCATATGGTTTTTTCTTTCCGCCG
hosPorin 5’
NdeF

''

GluconoPolyP ATGGCGCGCCGGCCCGGGCATGGCCACAAAGAG
hosPorin
leader AscR

''
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Table 2.3. Bacterial strains used in this study
Strain

Genotype

Purpose

E. coli K-12
MG1655

F- lambda- ilvG- rfb-50 rph-1 (McKenzie
2006)

bacterial
recombination

E. coli Top10 F'

F´{lacIq, Tn10(TetR)} mcrA Δ(mrr-hsdRMS- molecular cloning
and plasmid
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1
propagation
araD139 Δ(ara leu) 7697 galU galK rpsL
(StrR) endA1 nupG (from life technologies
#C3030-03) (Durfee 2008)

Asaia SF2.1

wild type (from Guido Favia, University of
Camerino, Italy) (Favia 2007)

gene expression,
paratransgenesis

Pantoea
agglomerans

wild type (Gavini 1989)

gene expression,
paratransgenesis

Gluconobacter
oxydans

wild type (ATCC cat# 33448) (Angyal 1996) amplification of
leader peptides

Gluconacetobacter wild type (ATCC cat# 49039) (Yamada 1997) amplification of
diazotrophicus
leader peptides

89

Table 2.4. Secretion signals cloned from acetic acid bacteria
Protein

leader sequence

Path

Species

acid phosphatase

MSMKRVQRAKSGLAVLLSGSILLPSVGLAASSSA

Sec

G. oxydans

aminopeptidase

MTQKTFPRRSLFLATVLTAVLLAPVTGHA

Sec

G. oxydans

endonuclease I

MRFLIAVLLACTSPAIA

Sec

G. oxydans

endonuclease II

MNFLSYLPICALLVVLPAQA

Sec

G. oxydans

polyphosphate porin MVFSFRRTTALLATTTLVSLLPLCGHARA

Sec

G. oxydans

TrbJ

MKYGMRLYVTIGVISITIISSARAQWAVYDGAN

Sec

G. diazotrophicus

phospholipase C

MATRRDFLKYALLSGAAGGASLLSDPIRRAFAIAPN Tat

G. diazotrophicus

organic solvent
tolerance

MMPILMSRRLFRPARGQRSQARGTLLAAGLLGSTF Sec
LGAVIQVHRAHAQVQ

G. diazotrophicus

peptidase M28

MPPHRPRAALVSAMLLAAASPAHAASPW

Sec

G. diazotrophicus

levansucrase

MAHVRRKVATLNMALAGSLLMVLGAQSALAQGN Sec

G. diazotrophicus

invasion-associated MKLFTPVPLVAVIGGAAAALTLGVAYSGHSGPGVA
locus B
QASTH

Sec

G. diazotrophicus

glycoside hydrolase MTGFRPSHVLVIACLVCLVMAGGAARAASAGGL

Sec

G. diazotrophicus

aminopeptidase
m28

Sec

G. diazotrophicus

MRSMPPHRPRAALVSAMLLAAASPAHAASPWAP

Secretion signals were cloned in-frame with expression constructs by PCR amplification
with primers and directional cloning by restriction enzyme digestion and insertion into
plasmids. Secretion signal pathways identified using PRED-TAT
(http://www.compgen.org/tools/PRED-TAT/).
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Chapter 3
Fighting malaria with engineered symbiotic bacteria from
vector mosquitoes
Sibao Wang, Anil K. Ghosh, Nicholas Bongio, Kevin A. Stebbings, David J. Lampe,
and Marcelo Jacobs-Lorena
Reprinted from Proceedings of the National Academy of Sciences, Vol.109, No. 31,
Sibao Wang, Anil K. Ghosh, Nicholas Bongio, Kevin A. Stebbings, David J. Lampe, and
Marcelo Jacobs-Lorena, Fighting malaria with engineered symbiotic bacteria from vector
mosquitoes. pages 12734-12739., Copyright (2012) with permission from PNAS.

CHAPTER 3 ATTRIBUTIONS



I performed the molecular cloning of hemolysin secretion constructs and tested
them for secretion by western blot.



Kevin A. Stebbings, an undergraduate in Dr. Lampe's laboratory, was mentored
by me and contributed to the molecular cloning and testing of secretion
constructs.



Sibao Wang, a post-doc in Dr. Marcelo Jacobs-Lorena's laboratory, conducted
transmission-blocking assays.



Anil K. Ghosh, a post-doc in Dr. Marcelo Jacobs-Lorena's laboratory, performed
the immunofluorescence assays.
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INTRODUCTION
Malaria is one of the most lethal infectious diseases. Close to half of the
population of the world is at risk, about 300–500 million contract the disease annually,
and about 1.2 million people die of malaria every year (Murray 2012). Continuous
emergence of mosquito insecticide resistance and parasite drug resistance, combined with
the lack of an effective malaria vaccine, severely limits our ability to counteract this
intolerable burden (Enayati 2010, Trape 2011). New weapons to fight the disease are
urgently needed.
Unlike the other two major infectious diseases (AIDS and tuberculosis) that are
transmitted directly from person to person, transmission of Plasmodium, the causative
agent of malaria, strictly depends on the completion of a complex developmental cycle in
vector mosquitoes (Ghosh 2000). A mosquito may ingest on the order of 103 to 104
gametocytes from an infected human that quickly differentiate into male and female
gametes that mate to produce zygotes, which, in turn, differentiate into 102 to 103 motile
ookinetes. Ookinetes then migrate within the blood bolus until they reach the midgut
epithelium, where they then traverse and differentiate into oocysts. Upon maturation,
each oocyst releases thousands of sporozoites into the hemocoel, followed by invasion of
the mosquito salivary glands. The transmission cycle is completed when the infected
mosquito bites the next vertebrate host and delivers some of the sporozoites with the
saliva (Whitten 2006). Clearly, a severe bottleneck occurs during the mosquito midgut
stages of parasite development: even in areas of high transmission, mosquitoes typically
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carry five or fewer oocysts (Whitten 2006). This bottleneck makes the mosquito midgut a
prime target for intervention (Eappen 2004, Drexler 2008).
One option to interfere with parasite transmission is to genetically modify
mosquitoes for midgut expression of “effector genes” that inhibit parasite development.
Past evidence suggests that this strategy works successfully in the laboratory (Ito 2002,
Isaacs 2011, Marrelli 2007, Corby-Harris 2010). However, one unresolved challenge is
how to drive transgenes into wild mosquito populations. Various genetic drive
mechanisms have been proposed to accomplish this goal (Chen 2007, Windbichler 2011),
but these are technically very challenging, and it is not clear in what time frame they will
succeed. An important additional challenge faced by genetic drive approaches, in general,
is that anopheline vectors frequently occur in the field as reproductively isolated
populations, thus posing a barrier for gene flow from one population to another.
An alternative strategy to deliver effector molecules is to engineer symbiotic
bacteria from the mosquito midgut microbiome to produce the interfering proteins
(paratransgenesis) (Durvasula 1997). A key strategic consideration is that the mosquito
microbiome (Pumpuni 1996, Straif 1998) resides in the same compartment where the
most vulnerable stages of malaria parasite development occur (Drexler 2008). Moreover,
bacteria numbers increase dramatically (hundreds- to thousands-fold) after ingestion of a
blood meal (Pumpuni 1996), and output of anti-Plasmodium effector molecules from
engineered bacteria can be expected to increase proportionally.
Paratransgenesis has shown promise for the control of other insect-borne disease
(Durvasula 1997). Chagas disease caused by the parasitic protozoan Trypanosoma cruzi
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is transmitted by the triatomid bug, Rhodnius prolixus. In proof-of-concept experiments,
an obligate commensal Gram-positive bacterium was genetically modified to secrete
cecropin A, a peptide that kills Trypanasoma cruzi, making the bug refractory to the
parasite (Durvasula 1997). Our previous study using the rodent malaria parasite
Plasmodium berghei and the Anopheles stephensi vector mosquito suggested that
recombinant Escherichia coli expressing on their surface either a dimer of the salivary
gland and midgut peptide 1 (SM1) or a modified phospholipase reduced oocyst formation
(Riehla 2007). Yoshida et al. 2001 also showed that recombinant E. coli expressing a
single-chain immunotoxin significantly reduces P. berghei oocyst density in A. stephensi
mosquitoes. One limitation of these earlier experiments is that they used E. coli, an
attenuated laboratory bacterium that survives poorly in the mosquito gut (Riehla 2007). A
second limitation was that the recombinant effector molecules either remained attached to
the bacterial surface (Riehla 2007) or formed an insoluble inclusion body within the
bacterial cells (Yoshida 2001), thus preventing diffusion of the effector molecules to their
parasite or mosquito midgut targets.
Here, we describe a substantially improved strategy to deliver effector molecules
by engineering a natural symbiotic bacterium Pantoea agglomerans(previously known as
Enterobacter agglomerans) to secrete antimalaria proteins in the mosquito midgut. We
found that the development of the human parasite Plasmodium falciparum and the rodent
parasite P. berghei in the mosquito was efficiently suppressed by up to 98%.
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MATERIALS AND METHODS
Mosquito and Parasite Maintenance.
We used two mosquitoes (A. gambiae Keele strain and A. stephensi Dutch strain)
and two parasites P. falciparum strain NF54 and P. berghei ANKA 2.34. Mosquitoes and
parasites were maintained as described in SI Text.

Bacterial Introduction into Mosquitoes via Sugar Meals.
P. agglomerans were introduced into mosquitoes by feeding them with cotton pads
soaked with a bacteria suspension (109 cells/mL) in 5% (wt/vol) sugar as described in SI
Text.

Plasmid Construction and Protein Expression.
The synthesized DNA encoding anti-Plasmodium effector molecules were optimized
with the P. agglomerans preferred codon usage. Plasmid construction, bacterial genetic
transformation, and verification of protein secretion using Western blot analysis were
performed as described in SI Text.

P. falciparum Transmission-Blocking Assays.
Recombinant bacterial suspensions [1 × 109 cells/mL of 5% (wt/vol) sugar]
soaked in cotton pads were fed to 2-d-old A. gambiae for 24 h, which were then starved
for 8 h and allowed to feed for 30 min on a P. falciparum NF54 gametocyte–containing
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blood meal. Fully engorged mosquitoes were separated within 24 h. Success of parasite
infection was evaluated by counting oocyst numbers at 8 d postinfection.

P. berghei Transmission-Blocking Assays.
Different groups of bacteria-fed mosquitoes were allowed to feed on the same P.
berghei–infected mouse for 6 min and then maintained at 19 °C at 80% relative humidity.
Success of parasite infection was evaluated by counting oocyst numbers at 14 d
postinfection.

Immunofluorescence Assays.
Recombinant P. agglomerans bacteria expressing (SM1)2 were introduced to 2-dold A. gambiae females via sugar meal (1 × 109cells/mL) for 24 h. The mosquitoes were
then allowed to feed on a noninfected mouse for 30 min. Midgut sheets were prepared at
18 and 24 h after blood feeding and fixed overnight in 4% (wt/vol) paraformaldehyde at 4
°C, washed in PBS, and blocked with 4% (wt/vol) BSA at 4 °C. The gut sheets were then
probed with anti-SM1 peptide antibody (1:1,000), followed by Alexa Fluor–conjugated
goat anti-rabbit IgG (Sigma; 1:1,000). Nuclei were stained with 4′,6-diamidino-2phenylindole (DAPI).
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RESULTS
Administration of Transgenic P. agglomerans via Sugar Meals and Rapid
Proliferation After a Blood Meal.
P. agglomerans is a natural symbiotic bacterium whose occurrence is widespread
in anopheline mosquitoes (Pumpuni 1996, Straif 1998, Riehle 2007). Our strain was
originally isolated from midguts of an Anopheles gambiae laboratory colony and
subsequently further selected for improved adaptation to the A. gambiae and A. stephensi
midgut environments (Riehle 2007). To examine recombinant P. agglomerans
colonization and survival in the mosquito midgut, we transformed P. agglomerans with a
highly stable plasmid pPnptII:gfp (Stiner 2002) that expresses green fluorescent protein
(GFP). We found the GFP-tagged bacteria were easily administered to mosquito midguts
via sugar meals (Figure S1). Midguts of female mosquitoes that had been fed GFPtagged P. agglomerans became strongly fluorescent after ingestion of a blood meal
(Figure 3.1 A and B), indicating rapid bacteria proliferation. To quantify the dynamics
of bacteria numbers, mosquitoes that had been fed GFP-tagged P. agglomerans were
dissected at different times after a blood meal and midgut homogenates were plated on
selective kanamycin-containing plates. Bacteria numbers increased dramatically by more
than 200-fold during the first 2 d after a blood meal (Figure 3.1C). Thereafter, bacteria
numbers decreased to about prefeeding levels, presumably because the majority was
excreted together with the remnants of blood digestion.
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Recombinant P. agglomerans Strains Efficiently Secrete Anti-Plasmodium Effector
Molecules.
As mentioned previously, for maximum effectiveness of intervention, it is crucial
that the effector molecules be secreted from the engineered bacteria to allow diffusion to
the parasite or mosquito midgut targets. We used the E. coli hemolysin (Hly)A system
(Fernandez 2000, Tzschaschel 1996, Fernandez 2001) to promote protein secretion from
P. agglomerans. This type 1 secretion system requires three components to form a
membrane pore (inner membrane components HlyB and HlyD and outer membrane
component TolC). The HlyB–HlyD complex recognizes the C-terminal secretion signal
of HlyA to guide direct export of HlyA-fusion proteins from the bacterial cytoplasm into
the extracellular environment bypassing the periplasmic space (Figure S2A).
We used the HlyA secretion system to test the following anti-Plasmodium
effector molecules (Table S.1): (i) two copies of the 12-aa SM1 peptide [(SM1)2], which
binds to the luminal surface of the mosquito midgut and blocks ookinete midgut invasion
(Ghosh 2001); (ii) a mutant phospholipase mPLA2 that inhibits ookinete invasion,
probably by modifying the properties of the midgut epithelial membrane (Moreira 2002);
(iii) a single-chain immunotoxin (pbs21scFv-Shiva1), composed of a single-chain
monoclonal antibody (scFv) targeting the P. berghei major ookinete surface protein
pbs21 and linked to the lytic peptide Shiva1 (Yoshida 2001); (iv) a chitinase propeptide
(Pro) that inhibits the enzyme and blocks ookinete traversal of the mosquito peritrophic
matrix (Bhatnagar 2003); (v) a synthetic antiparasitic lytic peptide, Shiva1 (Jaynes 1988);
(vi) a scorpion (Pandinus imperator) antimalaria lytic peptide, scorpine, which has
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hybrid properties of the lytic peptides cecropin and defensin (Conde 2000); (vii) four
copies of Plasmodium enolase–plasminogen interaction peptide (EPIP) [(EPIP)4] that
inhibits mosquito midgut invasion by preventing plasminogen binding to the ookinete
surface (Ghosh 2011); and (viii) a fusion peptide composed of Pro and EPIP (Pro:EPIP).
All genes were synthesized with the P. agglomerans preferred codon usage (Table S2)
and cloned in frame with an E-tagged C-terminal secretion signal domain of HlyA in a
high-copy expression vector (Figures S2B and S3). The resulting plasmids were
individually transformed into P. agglomerans together with the low-copy plasmid
pVDL9.3 coding for HlyB and HlyD (Fernandez 2000). Constitutive expression and
secretion of a fusion protein of the predicted size by each recombinant P. agglomerans
strain were verified by Western blot analysis (Figure 3.2A). The smaller sized peptides
[(EPIP)4, Shiva1, and Pro:EPIP] were more abundant in the culture supernatant than the
larger sized proteins (mPLA2 and pbs21fsFv-Shiva1) (Figure 3.2A). The recombinant P.
agglomerans strain expressing (EPIP)4 had the highest secretion level, appearing to be
more efficient than the recombinant strain carrying the parental E-HlyA plasmid (Figure
3.2A). In vivo secretion of anti-Plasmodium effector molecules in the mosquito midgut
was confirmed by use of immunofluorescence assays that detected the binding of the
bacteria-produced SM1 peptide to the midgut epithelial surface (Figure 3.2B). Control
midguts from mosquitoes fed on recombinant P. agglomerans expressing E-tagged HlyA
alone (HlyA) had no fluorescence above background.
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Recombinant P. agglomerans Strains Efficiently Impair P. falciparum Development
in Mosquitoes.
To assess the effectiveness with which recombinant bacteria interfere with the
development of the human malaria parasite P. falciparum in mosquitoes, recombinant P.
agglomerans were administered to mosquitoes via cotton pads soaked with bacteria
suspended in 5% (wt/vol) sucrose solution. Thirty-two hours later, mosquitoes were
provided a P. falciparum–infected blood meal. Success of parasite development was
evaluated by counting oocyst numbers on day 8 after the infectious blood meal. Initial
experiments were conducted to evaluate the inhibition potential of recombinant P.
agglomerans secreting a chitinase propeptide (Pro) compared with administration of the
synthetic propeptide mixed with the blood meal. The propeptide inhibits Plasmodium
chitinase activity and, thus, prevents crossing of the peritrophic matrix, resulting in
decreased number of ookinetes that reach the midgut epithelium (Bhatnagar 2003). As
shown in Figure S4, inhibition by P. agglomerans expressing the propeptide was
effective, on the order of 59% inhibition in highly infected mosquitoes (also see
comments concerning infection intensity under Discussion). Next, we evaluated the
inhibitory capacity of the various recombinant P. agglomerans strains. As shown in
Figure 3.3, the recombinant P. agglomerans strain expressing E-tagged HlyA alone did
not significantly inhibit oocyst formation compared with minus bacteria controls.
Recombinant P. agglomerans expressing mPLA2, Pro:EPIP, or Shiva1 had a 85%, 87%,
and 94% decrease in oocyst numbers, respectively. Recombinant P. agglomerans
expressing scorpine or (EPIP)4 had the highest inhibition (98%) of oocyst formation
(Figure 3.3). Importantly, infection prevalence (percentage of mosquitoes that have one
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or more oocysts) was 90% in −Bact (control) mosquitoes and was reduced to 14% in
mosquitoes carrying scorpine-secreting bacteria, representing an 84% transmissionblocking potential.
To evaluate the persistence of the inhibitory effect, we compared oocyst numbers
in mosquitoes that were fed the same batch of infective blood meal at either 2 d (our
standard procedure) or 4 d after bacterial administration. These experiments also
evaluated the effect of mixing bacteria expressing two different effector proteins, [shiva1
+ (EPIP)4] and [scorpine + (EPIP)4], on inhibition of P. falciparum infection. As shown
in Figure 3.4, inhibition of oocyst development was similar at both time points. Thus, the
inhibitory effect of the bacteria lasts for at least 4 d after bacteria administration. Also,
inhibition by a mixture of bacteria expressing two effectors (Figure 3.4) was similar to
that of bacteria expressing a single effector (Figure 3.3). Possible reasons for this are
considered under Discussion.

Recombinant P. agglomerans Strains Efficiently Impair P. berghei Development in
Mosquitoes.
We also evaluated the effectiveness of recombinant P. agglomerans strains to
inhibit development of the rodent malaria parasite P. berghei in A. stephensi mosquitoes.
Mosquitoes harboring various recombinant bacterial strains were allowed to feed on the
same P. berghei–infected mouse, followed by determination of oocyst numbers on day 14
post infection. The recombinant P. agglomerans strain expressing (SM1)2 reduced mean
oocyst counts by 68%, an equal mixture of bacteria expressing pbs21scFv-shiva1 +
(EPIP)4 reduced oocyst counts by 79%, and a mixture of scorpine- and (EPIP)4101

expressing bacteria reduced oocyst counts by 83% (Figure 3.5), despite relatively high
infection rates (>60 oocysts per midgut; also see Discussion). No significant reduction
was observed in the presence of the recombinant P. agglomerans strain expressing Etagged HlyA alone (HlyA).

Recombinant P. agglomerans Strains Do Not Affect Mosquito Longevity.
A recombinant bacterium with minimal fitness cost to mosquitoes is also an
important factor for the success of future field applications. To examine the impact of
recombinant P. agglomerans strains expressing anti-Plasmodium molecules on mosquito
lifespan, mosquitoes were fed on sugar alone or on various recombinant P. agglomerans
and, 32 h later, were allowed to feed on a noninfected mouse. Thereafter, mortality was
monitored twice daily. No significant differences in mosquito lifespan was detected
among any of the mosquito groups (Figure 3.6), suggesting these recombinant antiPlasmodium products pose no obvious negative impact on mosquito fitness in laboratory
conditions.

DISCUSSION
Although current malaria control strategies targeting the mosquito vector and the
parasite have helped alleviate the malaria burden in many endemic areas (Greenwood
2008), the emergence and rapid spreading of insecticide-resistant mosquitoes and drugresistant parasites undermine such efforts (Trape 2011). The Malaria Eradication
Research Agenda (malERA) consultative group recently noted that malaria eradication
will not be achieved without help of novel control tools (Baum 2011). Here, we report on
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an alternative strategy to deliver antimalaria effector molecules to the mosquito midgut
via engineered symbiotic bacteria.
The mosquito midgut serves as a prime target for blocking parasite transmission
with engineered bacteria for two main reasons: (i) the most vulnerable part of the
Plasmodium cycle in the mosquito and a bottleneck in parasite numbers occur in the
mosquito midgut lumen (Whitten 2006); and (ii) the midgut compartment is shared
between Plasmodium and the mosquito microbiome, directly exposing parasites to
compounds secreted by resident bacteria. Furthermore, the number of bacteria in the
mosquito midgut increases dramatically (by two to three orders of magnitude) after
ingestion of a blood meal, consequently increasing the output of effector molecules
produced by recombinant bacteria. The drop in recombinant bacteria number at 3 d after
the blood meal (Figure 3.1C) is of no consequence to the effectiveness of intervention
because most of ookinete invasion of the mosquito midgut occurs at 24 to 36 h after the
blood meal.
Symbiotic bacteria are thought to be beneficial to their insect hosts by providing
nutritional supplements, tolerance to environmental perturbations, and manipulation of
host immune homeostasis (Weiss 2011). In recent years, the relationship between
symbionts and their hosts has attracted increasing attention from the perspective of
engineering symbionts to combat pathogens (Durvasula 1997, Riehle 2007, Rao 2005).
Several bacterial species have been identified from the midgut of field-collected
anophelines, mostly Gram-negative proteobacteria and enterobacteria (Straif 1998, Wang
2011). A recent study found that the bacterial population structure of laboratory-reared
adult mosquitoes is similar to that of field mosquitoes, suggesting that the mosquito gut
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harbors its microbiome in a selective way (Wang 2011). A nonpathogenic bacterium P.
agglomerans was reported as a dominant symbiotic bacterium in different mosquito
species in Kenya and Mali (Straif 1998) and also found in laboratory-reared A. stephensi,
A. gambiae, and Anopheles albimanus mosquitoes (Pumpuni 1996, Riehle 2007). It also
occurs in the desert locust Schistocerca gregaria (Dillon 2002) and the honey bee Apis
mellifera (Loncaric 2009). A possible source of P. agglomerans for mosquitoes in the
field is flower nectar, given that this bacterium was found on plant surfaces and blossoms
(Andrews 2000, Pusey 2002, Pusey 1997). These considerations are relevant to future
efforts to introduce recombinant bacteria into field mosquito populations. Importantly, P.
agglomerans strains have been used as microbial control agents against the plant disease
fire blight in the United States (Pusey 2002). These facts make P. agglomerans an
excellent candidate for delivery of antimalarials to mosquitoes in the field.
Our data demonstrate that five potent anti-Plasmodium effector molecules
secreted by P. agglomerans are able to efficiently inhibit P. falciparum development
during early sporogony. The availability of multiple effector proteins, each acting by a
different mechanism, greatly reduces the probability of selection of resistant parasites.
Initial experiments indicated that mixing bacteria that secrete different effector molecules
had no additive effect on inhibition of Plasmodium development (Figures. 3.4 and 3.5).
This may be because the number of bacteria expressing each effector is cut in half in the
mixture fed to mosquitoes.
Perhaps more important than the inhibition of oocyst formation [up to 98% for
scorpine and (EPIP)4] are the data on prevalence. The percentage of P. falciparum–
infected mosquitoes was 90% in controls and was reduced to 14–18% in mosquitoes
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carrying scorpine or (EPIP)4 transgenic bacteria. This would represent an 80–84%
reduction in the proportion of infected mosquitoes. The effectors appear to be similarly
efficient in controlling a human and a rodent parasite, raising the possibility that they also
will be effective in the control of other human parasites such as Plasmodium vivax.
We note that in the field, mosquitoes carry a mean of five oocysts or fewer in
their midguts (Whitten 2006). In some experiments, mosquitoes fed with blood
containing high P. falciparum gametocytemia produced abnormally high oocyst numbers
(mean >200 oocysts) (Figure S5). However, even under these conditions, inhibition of
parasite development was highly significant and in line with the results presented in
Figure 3.3, although the extent of inhibition was lower (up to 68% inhibition for
mosquitoes carrying scorpine-secreting bacteria).
There are around 460 species of anopheline mosquitoes, over 100 of which are
suitable vectors for human malaria (Raghavendra 2011). Very few of these have been
genetically transformed (Coutinho-Abreu 2010). We found that the effector molecules
investigated in this study are equally effective with A. gambiae (an African mosquito)
and with A. stephensi (an Asian mosquito). The paratransgenesis strategy may well be
“universal” as effectiveness does not appear to be influenced by mosquito species.
Moreover, the fact that many major vector anopheline species exist as reproductively
isolated populations (cryptic species) imposes an important technical barrier for the
introduction of transgenes into mosquito populations in the field but does not affect the
paratransgenesis strategy. It is important to note that paratransgenesis is compatible with
current mosquito control tools (insecticides, population suppression) and even with
genetically modified mosquitoes. Should the technical barriers for transgene introgression
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into mosquito populations be solved, we envision the concomitant application of both
strategies (genetically modified mosquitoes and paratransgenesis), because they can
complement each other. However, more work lays ahead before this approach can be
implemented in the field. One key issue is how to effectively introduce engineered
bacteria into mosquitoes in the field. Our preliminary results suggest that this could be
accomplished by placing baiting stations (cotton balls soaked with sugar and bacteria
placed in clay jars) around villages where malaria is prevalent. Another important
challenge is the resolution of regulatory, ethical, and social issues related to the release of
genetically modified organisms.
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Figure 3.1. Transgenic P. agglomerans rapidly proliferate in the midgut after a
blood meal. GFP-tagged P. agglomerans were administered to 2-d-old A. gambiae via a
sugar meal, and, 32 h later, the insects were fed on blood. (A) Visualization of GFPtagged bacteria in the midgut at 24 h after a blood meal. The upper midgut is from a
mosquito that had been fed GFP-tagged bacteria, and the lower midgut was from a
control mosquito that did not feed on recombinant bacteria. A differential interference
contrast image (Right) is paired with a fluorescent image (Left). (B) GFP-fluorescent
bacteria recovered from a mosquito midgut. (C) Population dynamics of GFP-tagged P.
agglomerans as a function of time after a blood meal. Fluorescent bacteria were fed to
mosquitoes as described above, and midguts were dissected at the indicated times after a
blood meal. Fluorescent bacteria colony-forming units (CFUs) were determined by
plating serially diluted homogenates of midguts on LB/kanamycin agar plates. Data were
pooled from three biological replicates.
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Figure 3.2. The engineered P. agglomerans strains efficiently secrete antiPlasmodium effector proteins. (A) Western blot analysis. Culture supernatants were
concentrated using Amicon Ultra-4 Centrifugal Filter Units. Aliquots originating from
the same volume of supernatant were fractionated by SDS/PAGE and subjected to
Western blot analysis using a rabbit anti-E-tag antibody. The supernatant from
nontransformed P. agglomerans (WT) served as a negative control. Images were taken
using the same exposure time. (B) In vivo binding of the secreted SM1 peptide to the
mosquito midgut epithelium. A. gambiae were fed on sugar solution containing
recombinant P. agglomerans strains expressing either the (SM1)2 or E-tagged HlyA
alone (HlyA) and then fed on mouse blood. Midguts were dissected 18 or 24 h after
blood meal, opened into a sheet, fixed, and incubated with an anti-SM1 antibody,
followed by incubation with a fluorescent secondary antibody. Nuclei were stained with
DAPI (blue). The differential interference contrast (DIC) images of the same field are
shown to the right.
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Figure 3.3. Inhibition of P. falciparum development in vector mosquitoes by
recombinant P. agglomerans strains. A. gambiae mosquitoes were fed on 5% (wt/vol)
sugar solution supplemented with either PBS (−Bact) or recombinant P. agglomerans
strains and 32 h later fed on a P. falciparum–infected blood meal. Oocyst numbers were
determined 8 d after blood meal. Each dot represents the oocyst number of an individual
midgut and horizontal lines indicate mean values. Data were pooled from four biological
replicates. Recombinant P. agglomerans strains were engineered to express the E-tagged
HlyA leader peptide alone (HlyA) or mPLA2, Pro:EPIP, Shiva1, scorpine, and (EPIP)4
(Table S1), fused to HlyA (Figure S3), as indicated. Inhibition, inhibition of oocyst
formation relative to the −Bact control; Mean, mean oocyst number per midgut; Median,
median oocyst number per midgut; N, number of mosquitoes analyzed; Prevalence,
percentage of mosquitoes carrying at least one oocyst; Range, range of oocyst numbers
per midgut; Tbp, transmission-blocking potential: 100 − {(prevalence of mosquitoes fed
with recombinant P. agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}.
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Figure 3.4. Comparison of P. falciparum development between mosquitoes that fed
on an infectious blood meal at either 2 or 4 d after administration of recombinant P.
agglomerans. A. gambiae females were fed on 5% (wt/vol) sugar solution supplemented
with either PBS (−Bact) or recombinant P. agglomerans strains as follows: HlyA, P.
agglomerans expressing the E-tagged HlyA leader peptide alone; Shiva1 + (EPIP)4 or
scorpine + (EPIP)4 (Table S1), a mixture of the two recombinant bacteria in equal
numbers. Two days (2 dpPa) or 4 d (4 dpPa) after administration of bacteria, mosquitoes
were fed on a P. falciparum–infected blood meal. Oocyst numbers were determined 8 d
after the blood meal. Each dot represents the oocyst number of an individual midgut and
horizontal lines indicate mean values. Data were pooled from three biological replicates.
% Inhibition, inhibition of oocyst formation relative to the −Bact control; Mean, mean
oocyst number per midgut; Median, median oocyst number per midgut; N, number of
mosquitoes analyzed; Prevalence, percentage of mosquitoes carrying at least one oocyst;
Range, range of oocyst numbers per midgut.
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Figure 3.5. Inhibition of P. berghei development in mosquitoes harboring
recombinant P. agglomerans strains. A. stephensi females were fed on 5% (wt/vol)
sugar solution supplemented with either PBS (−Bact) or recombinant P. agglomerans
strains engineered to express E-tagged HlyA alone (HlyA), (SM1)2, pbs21scFvShiva1/(EPIP)4 (50–50 mixture) or scorpine/(EPIP)4 (50–50 mixture)] (Table S1 and
Figure S3) and 32 h later the five groups of mosquitoes were fed on the same P. bergheiinfected mouse. Plasmodium infections were evaluated 14 d after infection. Each dot
represents the number of oocysts in an individual midgut. Horizontal lines indicate mean
values. Data pooled from three biological replicates. N, number of mosquitoes analyzed;
Range, range of oocyst numbers per midgut; Prevalence, percentage of mosquitoes
carrying at least one oocyst; Mean, mean oocyst number per midgut; Median, median
oocyst number per midgut; Inhibition, inhibition of oocyst formation relative to the −Bact
control.
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Figure 3.6. Impact of recombinant P. agglomerans strains on lifespan of Anopheles
gambiae females. A. gambiae mosquitoes were fed on 5% (wt/vol) sugar solution
supplemented with either PBS (−Bact), or recombinant P. agglomerans strains as
follows: HlyA, P. agglomerans expressing the E-tagged HlyA leader peptide alone;
Shiva1 + (EPIP)4 or scorpine + (EPIP)4, a mixture of the two recombinant bacteria in
equal numbers (Table S1 and Figure S3). Thirty two hours later, mosquitoes were fed
on a noninfected mouse, and mosquito survival was measured twice daily. Data were
pooled from three independent experiments. There was no significant difference in
survivorship among the groups.
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Chapter 4
Identification of secretion signals from Asaia sp. SF2.1, a
mosquito midgut bacteria
ABSTRACT
Bacteria chosen for paratransgenesis in mosquitoes must be selected from among
the group of symbiotic species that inhabit the mosquito midgut. Previous experiments
used Pantoea agglomerans to secrete antimalarial proteins into the midgut environment
(Wang 2012). This species secreted antimalarial proteins in high amounts and
demonstrated effective parasite killing in vivo. This species, however, has no drive
mechanism that will cause the the paratransgenic organism to remain in the mosquito
population long-term or to spread the bacteria within a population of mosquitoes from
one individual to another. Bacteria of the genus Asaia, first discovered in plant nectar, are
much better candidates for paratransgenesis (Yamada 2000, Favia 2008). The bacterial
strain Asaia sp. SF2.1, which was originally isolated from Anopheles stephensi
mosquitoes, has been successfully cultured and manipulated in the lab (Favia 2007).
These bacteria are prime candidates for paratransgenesis due to the ease with which they
can be introduced into a population of mosquitoes and the rate at which they can spread
throughout a population (Damiani 2008).
In order to utilize Asaia for paratransgenesis against malaria, certain tools must be
available for their manipulation. One important tool is a secretion system that will allow
the bacteria to transport the antimalarial proteins outside the cell. To make use of these
bacteria, a functional genetic screen was used to identify native secretion signals in
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Asaia. Novel secretion signals were demonstrated both to mediate the secretion of active
proteins and peptides from Asaia into the mosquito midgut and to inhibit the invasion of
Plasmodium into host tissues.

BACKGROUND
Bacteria of the genus Asaia are Gram-negative, rod-shaped, peritrichously
flagellated, acetic acid bacteria belonging to the α-proteobacteria. They were initially
isolated from the flower nectar of Indonesian orchid trees and plumbago plants (Yamada
2000). Since their discovery, Asaia have been found in many plant-feeding insects,
including anopheline mosquitoes that acquire the bacteria by feeding on nectar (Chouaia
2010).
Asaia is ideal to use for paratransgenesis in anopheline mosquitoes due to its
beneficial microbial ecology in the host. Asaia stably associates with anopheline
mosquitoes and is present in the female midgut and salivary glands, which are important
targets for transmission-blocking interventions, as well as in the male reproductive tract,
which aids in the dissemination of the bacteria through the mosquito population (Favia
2007, Damiani 2010). Asaia is transmitted from male to female during copulation, and
from mother to progeny during egg laying, which can potentially facilitate the spread of
paratransgenic strains released in the wild (Damiani 2008). The bacteria can survive the
shedding of the meconium following the mosquito's transformation until the mosquito is
a mature adult (Damiani 2008). The meconium is a peritrophic matrix within the larval
midgut that, when shed, removes all of the contents of the midgut, thereby sterilizing it
(Moll 2001).
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Asaia is a very widespread genus and has been identified in diverse genera and
orders of sugar-feeding insects (Crotti 2009). Strains of Asaia taken from one insect
species can be transferred to other insect species and colonize their body tissues (Crotti
2009). Due to its ability to colonize a variety of species, Asaia may be important for other
insect-related problems that could be solved by paratransgenesis, such as other insectvectored human diseases or agricultural crop diseases.
The microbiota of mosquitoes play a large role in immunity, particularly against
Plasmodium infection (Dong 2009, Boissiere 2012). The microbiota of the mosquito
affects transcriptional activation of immune-related genes, increasing expression of
certain anti-Plasmodium factors (Dong 2009). Asaia has a mutually beneficial symbiosis
with anopheline mosquitoes; it inhabits the environment of the midgut and proliferates
upon the female mosquito taking a blood meal. The mosquito benefits from its
association with the bacteria because Asaia naturally induces an increased immune
response against Plasmodium (Capone 2013). This natural immune stimulation makes
Asaia ideal for the addition of further antimalarial molecule delivery.
Paratransgenesis involves altering the host's phenotype through genetic
modification, with modification occurring to the symbiont of the host organism rather
than to the host itself. Paratransgenic bacteria that can combat malaria will provide the
host mosquito with added defense against invasion of the Plasmodium parasite. The
research presented here aimed to identify secretion signals that can be used in Asaia to
enable the bacteria to secrete antimalarial proteins directly into the mosquito midgut
where they could inhibit the sexual life stages of the parasite.
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To create paratransgenic strains of Asaia, a functional secretion system is needed
that will allow the bacterium to translocate diverse antimalarial proteins, such as
enzymes, single-chain antibodies, and antimicrobial peptides, outside the cell. Asaia are
Gram-negative bacteria; they have two cell membranes through which transport must
take place for a protein to be secreted. This would be easily managed if the bacteria were
capable of utilizing any of the commonly-used secretion systems for lab-cultured
bacteria. However, my previous work has demonstrated that the Type I hemolysin
secretion system cannot be easily inserted into a plasmid or transposon for use in Asaia
(Bongio, unpublished results). The hemolysin system requires multiple proteins that
compose the secretory complex in the membrane, including HlyB, HlyD, and TolC, and
the fitness cost of producing so many proteins may make the modified organism unable
to compete against wild type bacteria (Fernandez 2000).
Common secretion signals have been tested in Asaia, including the E. coli Type II
OmpA and TolB leader peptides, as well as the PelB leader from Erwinia carotovora.
These signals do not function in Asaia (Bisi, personal communication). Thirteen Type II
signal sequences from the closely-related species Gluconobacter oxydans and
Gluconacetobacter diazotrophicus were cloned into expression vectors and tested for
activity in Asaia, but none mediated secretion (this dissertation, Chapter 2).
Due to the failure of both the hemolysin transport system and secretion signal
peptides, the identification of a native Asaia protein secretion pathway was necessary.
Accordingly, a genetic screen was used to directly identify proteins that are either
secreted or surface displayed in Asaia. The E. coli alkaline phosphatase enzyme (PhoA)
was used as a tool to detect protein secretion. When PhoA is secreted past the inner
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membrane, it can cleave 5-bromo-4-chloro-3'-indolyl phosphate (BCIP), producing a blue
color. Including BCIP in the growth media allowed for a quick and easy screen for blue
colonies. By creating random gene fusions with phoA, it was possible to detect which
fusion proteins were secreted from the cell, since they would translocate the PhoA protein
as well, resulting in the blue color phenotype.

MATERIALS AND METHODS
Media and antibiotics
Top10 F' E. coli cells were used during the molecular cloning and plasmid
propagation stages of the experiments. The Top10 F' cells were cultured in standard Luria
Bertani (LB) broth (10 g Tryptone, 5 g NaCl, 5 g yeast extract, in a final volume of 1 L
distilled water) or LB agar (LB broth plus 15 g/L agar). For selection of plasmids with
kanamycin, media was supplemented with 30 μg/ml kanamycin. All E. coli cultures were
grown at 37 °C, with agitation for liquid broth cultures.
Asaia SF2.1 bacteria were cultured in Mannitol broth (5 g yeast extract, 3 g
peptone, 25 g mannitol, in a final volume of 1 L distilled water) or Mannitol agar
(Mannitol broth plus 15 g/L agar). Media was adjusted to pH 6.5 before sterilization. For
selection of plasmids with kanamycin, media was supplemented with 120 μg/ml
kanamycin. All Asaia cultures were grown at 30 °C, with agitation for liquid broth
cultures.
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BCIP selection of secreting strains of bacteria
To identify the secretion of protein constructs in bacterial colonies, media was
supplemented with 5-bromo-4-chloro-3'-indolyl phosphate (BCIP). E. coli was screened
on LB media supplemented with 25 μg/ml BCIP. Asaia was screened on Mannitol agar
supplemented with 25 μg/ml BCIP and 25 μg/ml Na2HPO4. Sodium phosphate was
included in the media as an inhibitor of the natural phosphatase activity demonstrated by
wild type Asaia to reduce false positives.

Genomic library construction and screening
The phoA gene was inserted in pNB51 in such a way that genomic DNA can be
cloned 5' to it to allow gene fusions. phoA was amplified by PCR from E.coli K12
genomic DNA using primers “PhoA F NdeI” and “PhoA R PacI” (Table 4.3). The
product was directionally cloned into the expression vector pNB51 replacing the betalactamase gene, to create a plasmid with a cloning site usable for gene fusions with phoA,
named pNB90 (Figure 4.1).
Asaia gDNA was partially digested with the MseI restriction enzyme and the
expression vector pNB90 was fully digested with the NdeI restriction enzyme. Digested
genomic DNA was size-selected for fragments 2-4 kb in size by gel electrophoresis,
recovered, and ligated into the NdeI site of pNB90 to create a fusion library between
phoA and Asaia genomic inserts. The library was transformed into E. coli Top10 F'
electrocompetent cells and plated on LB agar containing 30 μg/ml Kanamycin and 25
μg/ml BCIP, and grown 12 h at 37°C.
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The library was screened in E. coli due to growth restrictions of Asaia on
selective media and the inefficiency of DNA transformation into Asaia. Approximately
0.9% of colonies turned blue after 1 day of growth at 37 °C. More than 200,000 clones
were collected and pooled to provide over 100-fold coverage of the 3.53 Mb genome, and
these were stored in 50% glycerol at -80 °C to make the library.
Individual blue colonies were inoculated into 5 ml LB broth supplemented with
kanamycin and grown at 37 °C for 12 h. Plasmid DNA was extracted from these cultures
using a Qiagen plasmid miniprep kit. One hundred and sixty blue clones were plasmid
prepped and sequenced using the primer “PhoA seq R1” (Table 4.3). Each sequence read
was identified by a BLAST search (NCBI) for the closest related homologous protein
identity.
The 160 library clones resulted in 16 unique identified genes, and one plasmid for
each unique clone (Table 4.2, all pNB91.* plasmids) was transformed into Asaia cells.
These were plated on selective media to confirm that secretion functions similarly to the
activity seen in E. coli.

Western blot detection of secreted proteins from phoA library clones
Asaia liquid cultures were grown to an OD600 of 1.5. Protein samples were
prepared from these by centrifuging 1 ml of the culture at 12,000 RPM in a desktop
centrifuge. From the supernatant fraction, 750 μl was removed, mixed with 250 μl of 3X
Laemmli sample buffer (BioRad, Hercules, CA, #161-0737), and boiled for 10 minutes.
Eight μl of the Colormark plus prestained protein ladder (New England Biolabs, Ipswich,
MA, #p7712), and 20 μl of each protein sample were loaded into wells of a 5% stacking
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and 10% separating polyacrylamide gel. Proteins were separated by electrophoresis at
120 V for 1 h, then transferred onto a PVDF membrane in a BioRad transfer apparatus
using Tris-Glycine transfer buffer (25mM Tris, 150mM glycine, 10% methanol) at 95 V
for 75 minutes. The membrane was blocked with a 4% bovine serum albumin (BSA)
TBS-T solution (50 mM Tris-CL, 150 mM NaCl, 0.1% Tween20, 4% w/v fraction V
BSA, pH 7.5) for 3 h at 4 °C with agitation. The blocking buffer was then replaced with
the primary antibody solution containing rabbit polyclonal anti-bacterial alkaline
phosphatase 1:50,000 (Abcam, Cambridge, England, ab7319-1) in blocking buffer and
incubated overnight at 4 °C. The next day, the membrane was washed four times in TBST for 15 min each time. Following washes, the secondary antibody was applied, goat
anti-rabbit HRP (BioRad, Hercules, CA, 170-5046), and the blot was incubated for 1 h at
room temperature. The wash steps were repeated, then 2 ml of Supersignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific, Waltham, MA, # 34095) was added
to the blot and incubated for 5 minutes. The blot was exposed to X-ray film (Thermo
Scientific, Ipswich, MA, #34090) and developed using an automatic developer.

ELISA to detect PhoA in cell culture fractions
Asaia expressing the PhoA secretion constructs were grown to OD600 of 1.5, then
centrifuged. Supernatant, live cell, and cell lysate fractions were isolated and bound to
wells in a 96-well plate overnight at 4 °C. These plates were washed three times with
Tris-buffered saline (TBS) (50mM Tris-CL, 150 mM NaCl, pH 7.5), then blocked by
adding 200 μl of 2% BSA TBS (TBS with 2% w/v fraction V BSA) and incubating 2 h at
room temperature. This was washed again three times with TBS, then 100 μl of a 1/3000
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dilution of anti-BAP-HRP (bacterial alkaline phosphatase) antibody (Abcam, Cambridge,
England, ab7319-1) in 2% BSA TBS was added to each well and incubated for 1 h at
room temperature. The plate was washed 8 times with TBS-Tween20 0.1% for 2 minutes
per wash. To visualize the protein, 50 μl of 1-Step Ultra TMB-ELISA (Thermo
Scientific, Ipswich, MA, #34028) was added and incubated for 10-20 min at room
temperature. HRP from the bound antibodies reacts with the TMB substrate to produce a
blue color (Figures 4.2 and 4.3).

p-Nitrophenyl phosphate plate assay for PhoA activity
Asaia expressing the PhoA secretion constructs were grown to OD600 of 1.5, then
centrifuged. Supernatant, live cell, and cell lysate fractions were isolated and bound to
wells in a 96-well plate overnight at 4 °C. PhoA activity was detected by rinsing the
plates with PBS, and adding 100 μl of p-Nitrophenyl phosphate (PNPP) substrate (Sigma
Aldrich, St. Louis, MO, #P7998). PhoA cleaves the phosphate group from PNPP
substrate, producing a yellow color (Figures 4.2 and 4.3).

Cloning of anti-Plasmodium effector genes into secretion constructs
A new plasmid was generated to modify the identified secretion constructs to
include a cloning site into which anti-Plasmodium effector genes could be inserted. First,
the phoA gene was amplified by PCR using primers “PhoA F NdePacSbf” and “PhoA R
Fse” (Table 4.3). This PCR product and the pNB51 plasmid were digested to completion
with the NdeI and FseI restriction enzymes, and the plasmid was treated with calf
intestinal phosphatase. The PCR product was ligated into the linearized plasmid using T4
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DNA ligase at 16 °C overnight. The ligated DNA was transformed into top10 E. coli cells
and selected on LB media containing kanamycin. Clones isolated from this selection
were verified by sequencing to ensure there were no mutations introduced. The new
plasmid created was named pNB92 (Figure 4.4). This plasmid is identical to pNB90
(Figure 4.1), but with the addition of the PacI and SbfI restriction sites for in-frame
insertion of effector genes into the fusion protein construct.
The siderophore receptor and YVTN beta-propeller proteins were amplified by
standard PCR using primers “siderophore F NdeI” and “siderophore R MYC PacI”, or
“YVTN F NdeI” and “YVTN R MYC PacI”, respectively, and directionally cloned into
pNB92 by restriction enzyme digestion and ligation. The resultant gene constructs
contain both the secretion protein, a MYC epitope tag, a cloning site for effector
molecules, and phoA. These plasmids were named pNB93 (Figure 4.5, contains YVTN
beta-propeller repeat) and pNB95 (Figure 4.6 contains TonB-dependent siderophore
receptor). Each of these cloned genes are longer than the predicted proteins in the
genome annotation, perhaps due to mutation. The cloned genes were sequenced to verify
that there are no errors.
Into these plasmids, eleven genes were cloned in-frame, including two control
proteins that are not antimalarial. The cloned genes encoded GFP, anti-bovine serum
albumin (anti-BSA) scFv (Bisi 2011), prochitinase peptide, PLA2, enolase-plasminogen
interacting protein (EPIP)4, Shiva1, anti-Pbs21 scFv-Shiva1, prochitinase-EPIP,
scorpine, (Wang 2012) anti-Pfs48/45 scFv (Chapter 2 page 62) and anti-Pfs25 scFv
(Chapter 2 page 61). Each gene was amplified by PCR using primers that add PacI and
SbfI restriction digest sites to either end of the amplicon (see Table 4.3 for primers used).
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These PCR products were directionally cloned into pNB93 and pNB95 by restriction
enzyme digestion and ligation as described previously to create a set of anti-Plasmodium
secretion constructs (Figure 4.7). Clones were selected on LB agar containing
kanamycin. The YVTN beta-propeller protein constructs would not grow properly in E.
coli, possibly due to lethality of the cloned constructs, therefore following the molecular
cloning and sequence verification, Asaia SF2.1 cells were transformed with each of the
siderophore receptor effector plasmids only, and they were selected for on Mannitol Agar
supplemented with kanamycin.

Western blot detection of protein with MYC epitope tag
Samples were prepared, separated by acrylamide gel electrophoresis, and
transferred to PVDF membrane exactly as described in the western blot protocol for the
detection of secreted proteins from phoA library clones (page 117). The PVDF
membrane was blocked for 18 h with 1% BSA TBS-T (50mM Tris-CL, 150 mM NaCl,
0.1% Tween20, 1% w/v fraction V BSA, pH 7.5) with agitation at 4 °C. Next, the
blocking solution was replaced with the primary antibody, a mouse anti-myc antibody
(Invitrogen, Thermo Scientific, Waltham, MA, #45-0603) 1:5000 in blocking buffer, and
incubated at 4 °C for 24 h with agitation. The primary antibody solution was removed,
and the blot was washed four times in TBS-T for 15 min each time. Following washes,
the secondary antibody, goat anti-mouse HRP (BioRad, Hercules, CA, #170-5046), was
applied, and the blot was incubated for 1 h at room temperature. The wash steps were
repeated, and 2 ml of Supersignal West Femto Maximum Sensitivity Substrate (Thermo
Scientific, Waltham, MA, #34095) was added to the blot and incubated for 5 min. The
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blot was then exposed to X-ray film (Thermo Scientific, Waltham, MA, #34090 ) for
multiple time exposures ranging from 10 sec to 10 min and developed using an automatic
developer (Figure 4.8).

Parasite inhibition testing in Anopheles stephensi mosquitoes
Two-day old Anopheles stephensi adults were collected and separated into cups
with screen lids containing 50 female mosquitoes each. Asaia expressing the siderophore
protein secretion constructs with Pro-EPIP, scorpine, anti-Pbs21-Shiva1, and PLA2
effectors, and a control strain expressing PhoA alone were fed to individual mosquito
cups for 48 h by cotton balls soaked with a mixture containing 1x109 cells/ml of bacteria
in a 5% sugar solution.
The parasitemia of a P. berghei infected female Swiss Webster mouse was
determined by blood smear. A drop of blood was taken from the mouse's tail and placed
on a slide. This was smeared with the edge of another glass slide to create a thin layer of
blood. This slide was fixed in methanol for ten seconds, then transferred to a 10%
Giemsa stain solution: 5 ml Giemsa stock solution (Ricca Chemical Company, Arlington,
TX, #3250-4) plus 45 ml phosphate buffer (0.35g KH2PO4 plus 0.5g Na2HPO4 in a final
volume of 500ml distilled water). This was allowed to stain for 30 min, after which it was
rinsed with tap water and dried. Parasitemia was determined by counting the number of
infected cells and dividing by the total number of cells in a given microscope field. Full
fields were counted until at least 500 cells were evaluated.
After determining the parasitemia, the mouse was sacrificed using a CO2
chamber, and the total blood volume removed by cardiac puncture surgery with a
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heparinized needle (100 μl of 1 mg/ml heparin in PBS, 26 G needle). This blood was
diluted with phosphate buffered saline to reach 5x107 infected cells per 200 μl. A volume
of 200 μl of the diluted blood was immediately injected into three naïve mice
intraperitoneally.
The newly infected mice were checked for infectivity by exflagellation testing 2-3
days post-injection. A drop of blood was extracted from the mouse's tail, and 2 μl of the
blood was combined with 2 μl heparin (1 mg/ml heparin in PBS) and 6 μl exflagellation
media (1 pkg of RPMI 1640 medium (1L / pkg Gibco, Thermo Scientific, Waltham, MA,
#23400-021) with 2mM Hepes, 2mM glutamine in 1L distilled water pH 8.4,
supplemented with 2 g sodium bicarbonate, 50 mg hypozanthine, and 100 μM
xanthurenic acid). The mixture was incubated at 21 °C for 10 min. After incubation, the
entire 10 μl was transferred to a microscope slide and covered with a coverslip. At 100X
magnification, exflagellation events were counted per field, in uncrowded fields that
show only a single layer of cells; these are estimated at 500 cells per field.
The mosquitoes that were previously fed the paratransgenic Asaia strains were
given a P. berghei infective blood meal from a mouse with exflagellation rates of
between 2-3 events per field. The mice were anesthetized by intraperitoneal injection of
150 μl of anesthetising agent (Ketaject [100 mg/ml] 2 ml, acepromazine [10 mg/ml] 1 ml,
saline [0.9% w/v NaCl] 7 ml). The mouse was placed on the screen top of each cup
consecutively, and mosquitoes were allowed to feed for 6 min. Two trials were
performed, each with a control cup fed Asaia expressing a plasmid with no effector, and
two cups that were fed different antimalarial Asaia strains. The infected mosquitoes were
kept at 21 °C with 10% sugar solution for two weeks. Midguts were dissected and stained
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with 0.2% mercurochrome which stains the oocysts. The number of oocysts per midgut
was counted using a light microscope (Figures 4.9-4.11).

Cloning short signal peptides into expression vectors
Leader peptides were identified by predictive algorithms using both the
SignalP4.1 artificial neural network Hidden Markov models (Nielsen 1997), and the
PRED-TAT hidden Markov models (Bagos 2010). The predictions are shown in Figures
4.12-4.15. The leader peptides predicted using the SignalP4.1 and PRED-TAT algorithms
were cloned into pNB92 exactly as described in the generation of plasmids pNB93 and
pNB95, except the primers used were “siderophore F NdeI” “Sider51 R MYC PacI” to
amplify the siderophore receptor signal, or “YVTN F NdeI” and “YVTN34 R MYC
PacI” to amplify the YVTN beta-propeller protein signal. This produced plasmids
pNB124 and pNB125 (Figures 4.16 and 4.17).

Asaia genome prediction of secreted proteins
Asaia SF2.1 gDNA was prepared and sent to ACGT Inc (www.acgtinc.com) to be
sequenced, and the genome was submitted to NCBI (Genbank ID 873348) and annotated
by the NCBI Annotation Pipeline version 2.0 (https://www.ncbi.nlm.nih.gov/
genome/annotation_prok) (Shane 2014). This annotation identified 3,005 total proteincoding genes. The protein amino acid sequences were analyzed using the SignalP4.1
signal peptide prediction software as described previously, however using the
downloaded Linux version of the software that can process large datasets (Nielsen 1997).
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RESULTS
Genetic screen for secreted proteins in Asaia
The genetic screen for secreted Asaia proteins identified sixteen unique genes
(Table 4.1) encoding proteins that are either secreted from the cell or membrane-bound.
Less than 1% of the clones in the genomic library secreted PhoA into the growth medium
and produced a blue phenotype. This is a reasonable number of clones to obtain
considering that half of the inserted DNA will be in the incorrect orientation, and another
two-thirds of the remaining inserts will be in the incorrect reading frame for translation.
Furthermore, only 228 of the 3,005 (7.6% of all genes) proteins in the Asaia genome
were predicted by SignalP4.1 to have signal peptides, which is close to that of E. coli
which has 7.1% of its proteins located in the membrane, periplasm, or secreted. The
sequenced genes were originally identified by homology to secreted or membrane-bound
proteins found in Gluconobacter or Gluconacetobacter, close relatives of Asaia. They
have since been compared to the Asaia SF2.1 genome and have been given the new
designations and shown in Table 4.1.

Activity of cloned genes in Asaia
The unique, cloned plasmids from this screen were transformed into
electrocompetent Asaia cells and plated on Mannitol agar with BCIP and sodium
phosphate. These clones grew at varying rates and showed different levels of phosphatase
activity. Secretion was tested by an ELISA assay which shows the greatest amount of
secreted protein in the supernatant with the siderophore receptor protein and YVTN betapropeller protein fusions (Figure 4.2 top). A multiwell plate assay was prepared, but with
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PNPP substrate added, which turns yellow in the presence of active PhoA (Figure 4.2
bottom). The PNPP assay shows activity of the secreted alkaline phosphatase in both the
siderophore receptor and YVTN beta-propeller supernatant samples. The siderophore
receptor protein construct displays the most active enzymatic activity.
The two best secreting fusion proteins are a siderophore receptor and a YVTN
beta-propeller repeat protein. The siderophore receptor protein is an outer membrane pore
complex that receives siderophores which transport metal ions (Faraldo-Gomez 2003).
The YVTN beta-propeller protein is a structural protein that forms part of a protective S
layer on the outside of the cell (Jing 2002). Each of these proteins is typically localized at
the cell surface.

Cloning effector proteins into secretion constructs
The siderophore receptor and YVTN beta-propeller proteins were amplified by
PCR and cloned into pNB92, creating gene constructs that contain both the secretion
protein, a MYC epitope tag, a cloning site, and PhoA (Figures 4.5 and 4.6). Multiple
antimalarial genes and control genes that are not expected to be harmful to the expressing
strain were cloned into the siderophore receptor plasmid and sequenced to confirm that
there were no mutations. The YVTN beta-propeller protein plasmid was difficult to clone
genes into and cloning attempts produced either no colonies on the selective plates or
only false positives.
Asaia SF2.1 cells were transformed with each of the siderophore receptor effector
plasmids, and these strains were grown in Mannitol broth supplemented with kanamycin
to allow expression of the transgenes. Secretion of the fusion proteins was determined by
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western blot utilizing an antibody against the PhoA protein (Figure 4.8). The bands
detected on this western display degradation of the protein constructs, probably due to
periplasmic proteases. Membrane proteases are important for regulating the turnover of
proteins that are localized in the periplasm or the plasma membrane (Dalbey 2012). The
siderophore receptor protein is most likely mis-folding and unable to anchor in the
membrane properly, therefore that portion of the fusion protein construct is degraded in
the periplasm. A search using the “DAS” transmembrane domain predictor
(http://www.sbc.su.se/~miklos/DAS/maindas.html) with the amino acid sequence of the
cloned gene fragment did not find any such domains. The remainder of each fusion
protein seems to remain intact including the PhoA protein and the anti-Plasmodium
effector proteins and peptides. The protein sizes indicated by the bands highlighted in
Figure 4.8 all correspond with the predicted molecular weight of the effector protein plus
PhoA.

Activity of paratransgenic Asaia against P. berghei
Paratransgenic Asaia SF2.1 strains secreting Pro-EPIP, scorpine, anti-Pbs21Shiva1, and PLA2 effectors by the siderophore fusion protein were tested in vivo for
inhibition of P. berghei invasion within the mosquito host Anopheles stephensi. The
YVTN beta-propeller protein constructs were not able to be transformed into Asaia
SF2.1, and were not tested for activity. The paratransgenic strains were fed to An.
stephensi mosquitoes which were then challenged with an infective blood meal from a P.
berghei infected mouse two days later. Two weeks after the blood meal, the mosquitoes
were dissected and oocysts per midgut were counted. The oocyst counts indicate a
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significant level of parasite killing from the scorpine effector, and a weaker effect from
the anti-Pbs21 scFv Shiva1 effector (Figures 4.9-4.11, oocyst counts in Table 4.6 and
4.7). Both the anti-Pbs21 Shiva1 results and the scorpine results were significant (p-value
0.0006 and <0.0001 respectively).

Increasing the efficiency of constructs
The identified Asaia genes were fully sequenced and analyzed using the SignalP
4.1 algorithms to predict Gram-negative bacterial secretion signals (Figures 4.12 and
4.13). A possible secretion signal was identified in both of the highly active clones, the
TonB-dependent siderophore receptor protein and the YVTN beta-propeller repeat
protein. The sequences were analyzed using the PRED-TAT algorithms as well (Figures
4.14 and 4.15). This set of algorithms identified the YVTN secretion peptide as a Secdependent pathway signal, and the siderophore receptor peptide as a potential Tatdependent pathway signal. These predicted secretion signals were re-cloned into the phoA
expression vector to test the efficacy of secreting a smaller protein this way. The first 51
amino acids from the siderophore receptor protein and the first 34 from the YVTN repeat
protein were chosen to retain a conservative amount of the original protein after the
signal sequence cleavage site. These leaders were directionally cloned into pNB92 inframe with phoA (Figure 4.16 and 4.17). Blue (secreted) clones of each were isolated in
E. coli by screening on LB media containing BCIP.
The truncated secretion constructs were transformed into Asaia and grown in
liquid culture. SDS protein samples of the supernatant and pellet fractions from overnight
cultures of these strains were prepared and analyzed by western blot using an antibody
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against the Myc epitope tag. As seen in (Figure 4.18), the truncated constructs mediate a
high amount of secretion utilizing only the predicted secretion signals. These signal
peptides have not yet been tested for the secretion or activity of antimalarial effector
proteins due to the time needed to clone effector genes and transform Asaia strains with
the plasmids.

Asaia SF2.1 genome prediction of secretion signals
The Asaia SF2.1 genome secretion signal prediction by SignalP4.1 produced 228
hits for proteins which may be secreted by Type II secretion systems (top predictions
listed in Table 4.5). Among the top predictions, there were secreted proteases (peptidyldipeptidase DCP, and gamma-glutamyltranspeptidase), transporter proteins (multiple
TonB dependent receptor proteins, and an ammonium transporter), a folding chaperone
(peptidyl-prolyl cis-trans isomerase), and a digestive enzyme (alginate lyase).
The PhoA genetic screen clones were reevaluated by a protein BLAST search
against the Asaia SF2.1 genome (Table 4.1). The protein previously identified as
homologous to Gluconobacter YVTN beta-propeller repeat protein came up as
‘unidentified protein’ in and NCBI BLAST search of the Asaia SF2.1 genome. It was,
however, identified as a potentially secreted protein in the SignalP analysis of the
predicted proteins. The protein previously identified as homologous to an Acetobacter
outer membrane siderophore receptor came up as ‘unidentified protein’ in the Asaia
SF2.1 genome on NCBI. Although the siderophore receptor protein was not identified in
the genomic prediction for Type II secretion, there were many predictions for other
TonB-associated transporters, similar to the PhoA screen results.
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DISCUSSION
Malaria has plagued mankind throughout history and is a major cause of human
morbidity and mortality annually (WHO 2013). Despite decades of interventions against
the disease, it is still a widespread global problem. New technologies are needed to help
reduce the burden that malaria causes and hopefully eradicate the Plasmodium parasite
entirely.
Bacterial paratransgenesis is a relatively recent technology that has been
successfully used to combat human diseases, including Chagas disease, African sleeping
sickness, HIV, and malaria (Durvasula 1997, De Vooght 2012, Chang 2003, Fang 2012).
For example, Rhodococcus rhodnii was engineered to secrete the antimicrobial peptide
Cecropin A to inhibit the transmission of Trypanasoma cruzi by Rhodnius prolixus, thus
preventing Chagas disease (Durvasula 1997); Sodalis glossinidius was modified to
secrete nanobodies to target the variant surface glycoprotein of Trypanosoma bruci, the
cause of African sleeping sickness (De Vooght 2012); Lactobacillus jensenii was
modified to secrete functional human CD4, which inhibits HIV entry into host T-cells
(Chang 2003); and Pantoea agglomerans was engineered to secrete multiple effector
proteins utilizing the hemolysin secretion system to interfere with transmission of P.
berghei and P. falciparum malaria by anopheline mosquitoes (Wang 2012).
Asaia was proposed as a candidate for antimalarial paratransgenesis due to its
natural microbial ecology that allows it to colonize anopheline mosquito tissues and to
easily transmit itself through the mosquito population (Favia 2007). The primary goal of
this work was to modify Asaia to enable it to secrete proteins into the mosquito midgut
and to hinder the life stages of Plasmodium that develop there following an infective
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blood meal. Interfering with this vulnerable stage of the malaria parasite would prevent
human infection by rendering the mosquito an inhospitable host. The experiments
performed enable the use of the Asaia sp. SF2.1 midgut symbiont of anopheline vector
mosquitoes as a delivery vessel for heterologous effector proteins.

Genetic screen for protein secretion
The results of the alkaline phosphatase fusion library screen produced a list of
sixteen candidate genes that could potentially be useful for secretion of effectors in
paratransgenic constructs (Table 4.1). All of the identified fusion proteins that mediated
secretion were identified as homologous to either secreted or surface-displayed proteins
in related species. These are all logical proteins to expect from a phoA library screen,
since either periplasmic, membrane-bound, surface-displayed, and secreted fusion
proteins can all translocate the PhoA enzyme into the periplasm where it can cleave the
BCIP molecule used for screening (Hoffman 1985). This is the reason that clones
required further testing to determine exactly where each protein was localized: within the
periplasm or secreted from the cell.

Localization and activity of secreted PhoA
The analysis of the activity of PhoA fusion constructs demonstrated a high level
of secretion mediated by the siderophore receptor fusion protein and the YVTN betapropeller fusion protein, both of which are homologs of known bacterial membrane
proteins (Faraldo-Gomez 2003, Jing 2002). The alkaline phosphatase protein that was
secreted into the supernatant by these systems was found to be active by a plate assay
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with PNPP. Since active alkaline phosphatase protein requires disulphide bond formation
to achieve an active conformation (Sone 1997), this means that the secreted proteins must
spend time in the oxidizing environment of the periplasm long enough to allow these
bonds to form before leaving the cell. The PhoA secreted by the siderophore receptor
fusion protein showed a much more robust amount of phosphatase activity which
indicates that the protein may have spent a greater amount of time in the periplasm and
been allowed to achieve the correct conformation and form disulphide bonds. Disulphide
bonds are important for the stability and activity of some single-chain antibody effectors
that could be secreted by paratransgenic strains (McAuley 2007).
The western results (Figure 4.8) show that the effector proteins secreted by the
siderophore receptor pathway remain intact, while the Asaia siderophore receptor fusion
protein is most likely degraded by periplasmic proteases (Dalbey 2012). This is expected,
since the fusion protein should only retain a portion of the original Asaia gene, and it
likely cannot achieve its stable native conformation, nor can it insert into the membrane.
This is not necessarily a problem for delivery of effector molecules from a paratransgenic
organism, however the bulk of the fusion protein is not remaining intact and is simply
wasted energy for the Asaia producing it. These constructs can be reduced in size by
identifying the signal peptide responsible for secretion and eliminating the remainder of
the fusion protein.

Anti-Plasmodium activity in vivo
The use of paratransgenic Asaia in mosquitoes demonstrates that, despite the large
size of the fusion proteins, the Asaia siderophore receptor protein is capable of mediating
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secretion of heterologous proteins outside the cell efficiently enough to supply
antimalarial effector proteins directly into the mosquito midgut environment despite the
large size of the fusion proteins. The significant in vivo anti-Plasmodium results
demonstrate the ability of paratransgenic Asaia to disrupt the critical life stages of
Plasmodium berghei in the Anopheles stephensi mosquito midgut. There were two
significant effectors: (1) scorpine, a peptide effector which disrupts the plasma membrane
of microbes, killing them (Carballer-Lejarazu 2008), and (2) anti-Pbs21 Shiva1, a singlechain antibody-antimicrobial peptide combination which binds to a 21 kDa ookinete
surface protein of P. berghei preventing the transformation from ookinete to oocyst and
which is linked to the Shiva1 toxin, another lytic peptide (Yoshida 2001). The Pbs21Shiva1 effector significantly reduced oocyst numbers by 27.8% as calculated using the
median number of oocyst per midgut, while the scorpine peptide effector significantly
reduced oocyst numbers by 73.5% as calculated by the median number of oocysts per
midgut. The scorpine effector was previously demonstrated to block nearly 100% of
infections in lab tests using the HlyA secretion system in Pantoea agglomerans (Wang
2013).
The anti-Pbs21-Shiva1 and scorpine constructs were re-tested to gain a larger
sample size and to increase the significance of the data. The combined data showed a
32.0% reduction in oocysts by the Pbs21 immunotoxin, and a 80.1% reduction by the
scorpine peptide as calculated by the median number of oocysts. The Pbs21 immunotoxin
reduced prevalence by only 0.3%, but the scorpine construct reduced prevalence by
20.1%, which is a large reduction considering the mean number of oocysts per midgut in
the control mosquitoes was 120.4.
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These experiments waere not ideal, considering the very high number of oocysts
in the control mosquitoes that were fed control Asaia strains not expressing effector
proteins. In the lab, Plasmodium berghei-infected mosquitoes regularly produce a large
number of oocyts regularly, but this does not correlate with the level of infection that
would be seen in other Plasmodium species (Whitten 2006). In the wild, individual P.
falciparum-infected mosquitoes do not achieve infections of this magnitude, so the results
of these tests remain promising. Scorpine and anti-Pbs21-Shiva1 should still be tested for
parasite inhibition in vivo against P. falciparum because they may reduce prevalence
even more. The prevalence of oocysts per mosquito is an important metric for
transmission blocking since even a single oocyst can produce thousands of sporozoites
and make the mosquito infective. To be an effective intervention, a paratransgenic
bacteria strain would need to reduce prevalence to zero in a significant number of
mosquitoes.

Increasing the efficiency of secretion
Due to both the presence of some protein remaining in the periplasm of cells
expressing these secretion constructs and the fitness cost associated with expressing large
proteins, the efficiency of these pathways need to be increased. Accordingly, to achieve
this, the genes for the siderophore receptor protein and the YVTN beta-propeller protein
were analyzed by predictive software to identify the signal peptide which directs protein
transport within the cell.
The siderophore receptor signal sequence is quite long compared to most bacterial
secretion signals. This, along with the amino acid sequence of the signal, indicates that
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the siderophore receptor protein most likely utilizes the twin-arginine translocation (Tat)
pathway (Figure 4.14). Tat pathway signals tend to be longer than signal sequences
targeted to the Sec pathway of Gram-negative bacteria, and the signal sequence from the
siderophore receptor protein is around 51 amino acids long. There is a domain within the
signal sequence which partially matches the conserved amino acids in Tat signal
sequences of other bacteria. The consensus sequence of Tat signals in other bacteria is
Ser/Thr-Arg-Arg-X-Phe-Leu-Lys, where X can be any polar amino acid (Lee 2006). The
region of the siderophore receptor protein from amino acids 22 to 28, Thr-Arg-Arg-LysArg-Pro-Leu, show some similarity to this. Use of the Tat pathway would also be an
explanation for the much higher activity of the alkaline phosphatase protein secreted
using this signal as tested in the PNPP plate assay (Figure 4.3). Proteins secreted by the
Tat pathway are translocated into the periplasm in the folded conformation, thereby
retaining the conformation of the protein as it folded in the cytosol (Lee 2006). This
could be beneficial for certain proteins secreted using this signal that require folding in
the cytosolic environment to achieve the correct conformation.
The YVTN beta-propeller repeat protein is most likely dependent on the general
secretory pathway for its translocation, as was predicted by the PRED-TAT analysis
(Figure 4.15). The leader peptide is short, around 26 amino acids in length and has a
strong hydrophobic domain. This may be the reason that alkaline phosphatase secreted by
this pathway does not have a high level of activity, since proteins secreted using this
pathway are translocated in the unfolded conformation into the periplasm where they
must refold. The Asaia periplasm may not be the correct environment for this to take
place. The difference in PhoA activity secreted by the Sec and Tat leader peptides
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indicate that, in Asaia, PhoA folds best in the cytosol as demonstrated by the 9-fold
increase in activity for protein secreted by the Tat pathway (Figure 4.3).

Asaia genome prediction of secreted proteins
The Asaia SF2.1 secreted proteins which may be secreted by Type II secretion
systems are shown in Table 4.5. Among the top hits in this SignalP4.1 search, there were
secreted proteases: peptidyl-dipeptidase DCP and gamma-glutamyltranspeptidase;
transporter proteins: multiple TonB dependent receptor proteins and an ammonium
transporter; a folding chaperone: peptidyl-prolyl cis-trans isomerase; and an enzyme:
alginate lyase. The enzyme alginate lyase is involved in mannose digestion, and mannitol
media is one of the growth media with which Asaia sp. bacteria can be cultured (Preiss
1962). In the future, it may be useful to use the secretion signals from these various
proteases to attempt to secrete heterologous proteins.
The YVTN protein identified in the genetic screen was hit 152 out of 228
predicted secretion signals from the genome. This leader signal would have been
overlooked if experimental design relied solely on genomic data. Furthermore, the
siderophore receptor protein that was the best candidate isolated from the PhoA library
screen was not identified at all from the genomic analysis. This means that at least two
useful signal sequences would never have been explored if only the bioinformatic
approach had been used. Each method of discovery has benefits and drawbacks, however,
they each provide different results and can be used in conjunction to perform a more
thorough search for secretion signals. The signal peptides identified from the genome
predictions remain to be evaluated.
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There are inherent strengths and weaknesses in each of the genetic screen and the
genomic prediction approaches to secreted protein identification. The genetic screen's
primary benefit is the direct identification of actively transported proteins using any
secretory pathway; the fusion proteins identified can be rapidly tested to determine the
localization and amount of protein no matter what mechanism mediates transport.
Reliance on the secretion of fusion proteins in the genetic screen may cause certain
secreted proteins to be missed due to either the fitness cost associated with the fusion
construct or the lack of necessary secretory proteins that may not be present under the
screen conditions. The genomic prediction's strength is that it can identify any protein
with a type II secretion signal, even those that may not be expressed in a large amount or
that may not always be actively translocated. These proteins can still be identified by
their signal peptide sequences. The weakness of the genomic prediction is the predicted
genes may not be secreted, but instead may be localized in the periplasm or membranebound. Each secretion signal from a genomic prediction would need to be cloned and
tested individually to determine its function.
Conclusions
These positive results have built on the previous proof-of-concept trials with
Pantoea agglomerans by bringing functionality to a new paratransgenic species, Asaia
sp. SF2.1. There is now at least one possible secretion signal that can be used in
paratransgenic Asaia strains to deliver antimalarial proteins into the mosquito midgut
(siderophore receptor signal), and a second that requires further testing to prove useful
(YVTN protein signal). Further signal peptides may be found that are useful if the
genomic data are explored further.
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This research has moved malaria paratransgenesis one step closer to practical use
in the field. Asaia is a more useful symbiont of anopheline mosquitoes than previous
paratransgenic species considered due to its beneficial microbial ecology, and now that it
has been given the capability to secrete heterologous effector molecules, these
characteristics can be taken advantage of. The antimalarial constructs tested in these
experiments prove that Asaia can be effectively modified and used to deliver
heterologous proteins into the mosquito midgut and to inhibit the sexual life stages of P.
berghei malaria.
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Figure 4.1. Plasmid for phoA fusion library construction. A leaderless alkaline
phosphatase gene was cloned downstream of the nptII promoter and translational
enhancer of pNB51. This construct also contains an NdeI restriction site at the start codon
of the phoA gene into which random genes can be cloned in-frame. pBBR ori =
replication origin. oriT = origin of transfer. neo = neomycin phosphotransferase,
kanamycin resistance. ‘phoA = C-terminal domain of alkaline phosphatase, lacking a
secretion signal. enh = translational enhancer. PnptII = promoter from neomycin
phosphotransferase.
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Figure 4.2. PhoA-Asaia protein fusion plasmids expressed in Asaia. The top ELISA
used an anti-PhoA-HRP antibody to detect the presence of the alkaline phosphatase
protein. The Tsr and Ybp fusions show a high amount of protein present in the
supernatant fraction. The bottom plate assay used a PNPP substrate, which turns yellow
when cleaved by active PhoA. Both Tsr and Ybp fusion proteins show activity from the
secreted PhoA, however the Tsr signal is far more robust. Quantitative results are shown
in Figure 4.3. PhoA = alkaline phosphatase. Tsr = TonB-dependent siderophore receptor.
Aap = amino acid permease. Trp = TonB-dependent receptor plug. Gdh = glucose
dehydrogenase. Ybp = YVTN beta-propeller repeat protein. Csy = cellulose synthase.
Amu = aminomutase. Ptp = peptide transport permease.
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0.055
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0.057
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0.057
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Figure 4.3. Secreted protein abundance and activity from PhoA-Asaia protein fusion plasmids expressed in Asaia. Both the ELISA
and PNPP plates were repeated five times, and quantified using a plate reader. Signal intensity was read at 450 nm for the ELISA and at 400
nm for the PNPP assay. Although there was a similar amount of protein secreted by Tsr compared to Ybp, PhoA activity was more than five
times stronger when secreted by Tsr. PhoA = alkaline phosphatase. Tsr = TonB-dependent siderophore receptor. Aap = amino acid
permease. Trp = TonB-dependent receptor plug. Gdh = glucose dehydrogenase. Ybp = YVTN beta-propeller repeat protein. Csy = cellulose
synthase. Amu = aminomutase. Ptp = peptide transport permease.
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Figure 4.4. pNB92. The pNB51 plasmid was modified by cloning ‘phoA into the plasmid
with additional restriction sites 5' to the gene, generating pNB92. pBBR ori = replication
origin. oriT = origin of transfer. neo = neomycin phosphotransferase, kanamycin
resistance. ‘phoA = C-terminal domain of alkaline phosphatase, lacking a secretion
signal. enh = translational enhancer. PnptII = promoter from neomycin
phosphotransferase.
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Figure 4.5. pNB93. The N-terminal domain of ybp was cloned into the pNB51 plasmid
with the addition of a Myc epitope tag and multiple-cloning-site between ybp’ and ‘phoA.
pBBR ori = replication origin. oriT = origin of transfer. neo = neomycin
phosphotransferase, kanamycin resistance. ‘phoA = C-terminal domain of alkaline
phosphatase, lacking a secretion signal. enh = translational enhancer. PnptII = promoter
from neomycin phosphotransferase. ybp’ = N-terminal domain of YVTN beta-propeller
repeat.
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Figure 4.6. pNB95. The N-terminal domain of tsr was cloned into the pNB51 plasmid
with the addition of a Myc epitope tag and multiple-cloning-site between tsr’ and ‘phoA.
pBBR ori = replication origin. oriT = origin of transfer. neo = neomycin
phosphotransferase, kanamycin resistance. ‘phoA = C-terminal domain of alkaline
phosphatase, lacking a secretion signal. enh = translational enhancer. PnptII = promoter
from neomycin phosphotransferase. tsr’ = N-terminal domain of TonB-dependent
siderophore receptor.
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Figure 4.7. Antimalarial effector constructs. Effector genes were cloned in-frame with
the siderophore receptor gene. The first construct depicted above is the basic PhoA
secretion construct pNB95 with no effector. Each of the remaining constructs has a
different protein inserted into the multiple cloning site of the former plasmid. Restriction
sites used to assemble these constructs are shown at top.
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Figure 4.8. Western blot of the supernatant of Asaia cultures detecting proteins
secreted using the siderophore receptor fusion protein. Proteins were detected using a
rabbit polyclonal anti-PhoA primary antibody and goat anti-rabbit HRP secondary. The
red boxes are highlighting the predicted protein size of the full fusion proteins on top, and
the predicted size of the effector molecules plus alkaline phosphatase without the
siderophore receptor protein. All proteins show proteolysis of the native Asaia fusion
protein.
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Figure 4.9. Disruption of Plasmodium berghei development by Pro-EPIP and Pbs21Shiva1 constructs. Three-day old Anopheles stephensi mosquitoes were fed paratransgenic
strains of Asaia expressing either PhoA alone with no secretion signal, or expressing one of the
fusion constructs combining the siderophore receptor protein, an effector protein, and PhoA.
These mosquitoes were then fed on an infective mouse and the parasite was allowed to develop
for 10-14 days. The mosquitoes were then dissected, and oocysts on the midgut were counted for
each individual. Each dot on the chart represents a single midgut count. The median number of
oocysts for each data set is marked with a horizontal line. Inhibition, inhibition of oocyst
formation relative to the −Bact control; Mean, mean oocyst number per midgut; Median, median
oocyst number per midgut; N, number of mosquitoes analyzed; Prevalence, percentage of
mosquitoes carrying at least one oocyst; Range, range of oocyst numbers per midgut; Tbp,
transmission-blocking potential: 100 − {(prevalence of mosquitoes fed with recombinant P.
agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}. Pbs21-Shiva1 effected
significant Plasmodium inhibition of 27.8% calculated using the median.
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Figure 4.10. Disruption of Plasmodium berghei development by scorpine and PLA2
constructs. Three-day old Anopheles stephensi mosquitoes were fed paratransgenic strains of
Asaia expressing either PhoA alone with no secretion signal, or expressing one of the fusion
constructs combining the siderophore receptor protein, an effector protein, and PhoA. These
mosquitoes were then fed on an infective mouse and the parasite was allowed to develop for 1014 days. The mosquitoes were then dissected, and oocysts on the midgut were counted for each
individual. Each dot on the chart represents a single midgut count. The median number of oocysts
for each data set is marked with a horizontal line. Inhibition, inhibition of oocyst formation
relative to the −Bact control; Mean, mean oocyst number per midgut; Median, median oocyst
number per midgut; N, number of mosquitoes analyzed; Prevalence, percentage of mosquitoes
carrying at least one oocyst; Range, range of oocyst numbers per midgut; Tbp, transmissionblocking potential: 100 − {(prevalence of mosquitoes fed with recombinant P.
agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}. The scorpine construct
produced a significant inhibition of 73.5% calculated by the median oocyst number.
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Figure 4.11. Disruption of Plasmodium berghei development by anti-Pbs21-Shiva1
immunotoxin and scorpine constructs. Three-day old Anopheles stephensi mosquitoes were
fed paratransgenic strains of Asaia expressing either PhoA alone with no secretion signal, or
expressing one of the fusion constructs combining the siderophore receptor protein, an effector
protein, and PhoA. These mosquitoes were then fed on an infective mouse and the parasite was
allowed to develop for 10-14 days. The mosquitoes were then dissected, and oocysts on the
midgut were counted for each individual. Each dot on the chart represents a single midgut count.
The median number of oocysts for each data set is marked with a horizontal line. Inhibition,
inhibition of oocyst formation relative to the −Bact control; Mean, mean oocyst number per
midgut; Median, median oocyst number per midgut; N, number of mosquitoes analyzed;
Prevalence, percentage of mosquitoes carrying at least one oocyst; Range, range of oocyst
numbers per midgut; Tbp, transmission-blocking potential: 100 − {(prevalence of mosquitoes fed
with recombinant P. agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}. The
scorpine construct produced a significant inhibition of 73.5% calculated by the median oocyst
number. These are the combined data from the previous trials and repeated trials.
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Figure 4.12. Signal sequence of the siderophore receptor protein. The signal sequence
and cleavage site of Asaia bogorensis siderophore receptor protein were predicted using
the software SignalP4.1 which uses a combination of several artificial neural networks
and hidden Markov models (Nielssen 1997). In red is depicted the C-score, which shows
likely the likely cleavage site of the signal peptide (Nielssen 1997). In green is the Sscore, which shows the predicted signal peptide domain as distinguished from the mature
protein (Nielssen 1997). In blue is the geometric average of the C-score and the slope of
the Y-score, which results in better cleavage site prediction (Nielssen 1997).
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Figure 4.13. Signal sequence of the YVTN beta-propeller repeat protein. The signal
sequence and cleavage site of Asaia bogorensis YVTN repeat beta-propeller protein were
identified using the software SignalP4.1 which uses a combination of several artificial
neural networks and hidden Markov models (Nielssen 1997). In red is depicted the Cscore, which shows likely the likely cleavage site of the signal peptide (Nielssen 1997).
In green is the S-score, which shows the predicted signal peptide domain as distinguished
from the mature protein (Nielssen 1997). In blue is the geometric average of the C-score
and the slope of the Y-score, which results in better cleavage site preduction (Nielssen
1997).
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Figure 4.14. Tat and Sec signal peptide computational prediction for the
siderophore receptor protein. The signal sequence of the siderophore receptor protein
was identified computationally using the PRED-TAT application, which uses a hidden
Markov model to predict both Sec and Tat signal peptides (Bagos 2010). The reliability
score for this prediction is 0.687.
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Figure 4.15. Tat and Sec signal peptide computational prediction for the YVTN
beta-propeller repeat protein. The signal sequence of the YVTN beta-propeller repeat
protein was identified computationally using the PRED-TAT application, which uses a
hidden Markov model to predict both Sec and Tat signal peptides (Bagos 2010). The
reliability score for this prediction is 0.988.
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Figure 4.16. pNB124. This plasmid is identical to plasmid pNB95, except tsr was
truncated to retain only the coding sequence for the 51 aa signal peptide of the
siderophore receptor protein.
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Figure 4.17. pNB124. This plasmid is identical to plasmid pNB93, except ybp was
truncated to retain only the coding sequence for the 34 aa signal peptide of the
siderophore receptor protein.
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Figure 4.18. Western blot demonstrating the secretion of alkaline phosphatase from
Asaia SF2.1 using only the 51 amino acid long siderophore receptor signal or the 34
amino acid long YVTN beta-propeller repeat protein signal sequence. Protein
samples loaded were 15 μl of supernatant from liquid culture (sup), or 5 μl of
concentrated pellet (pel). The bands shown are of the correct predicted size for these
contructs, 54 kDa.
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Table 4.1. Proteins identified from genetic screen for secreted Asaia proteins.
Signal sequences were identified using the PRED-TAT software. Predicted signal
sequences are highlighted in blue. Protein identification is from protein BLAST hits
against the Asaia SF2.1 genome, with related species identity from whole NCBI database
if the result was hypothetical shown in parentheses.
protein identification

Amino acid sequence

Secretion pathway

membrane protein
glycerol transporter
(Mgt)

MTQITVVLLFGITTIHGVTQVGDFYA

Sec-dependent
(0.983 reliability
score)

hypothetical protein
(Acetobacter outer
membrane
siderophore receptor)
(Tsr)

MTLLPRETHDSGRHNPIVAPSTRRKRPLAAGLMSATA Tat-dependent
CVALLHFVSDARAQSVSASETSTIPVNAAKAPAKSKV (0.983 reliability
KVNAQSRSTRARAVSAPVGDAPATSR
score)

major facilitator
transporter (Mft)

MMLARLAHLTYNPHSSFCKINSFSFKLRIYRKMSQLT no signal identified.
SHDNRLVGPYGYSALAIAALIFFAMGFVTWL
transmembrane
domain predicted

carbohydrate porin
(Chp)

MDQMIWRSHTDPNRTISLFGRAMGAPQSDRVPIDFS no signal identified.
LNFGLTFNDPLPYRTDDTFGIGMGYTHVSGALANYD transmembrane
RAVRRYSGAYSPTQGGETYVELTYQYQFTGWMQWQ domain predicted
PDFQYIFNPGGGIPNPSHPDRRL

multidrug ABC
transporter (Mdt)

MEMSIIRSIDVELGQYVKKGQVLAHLDPTITKADIVN no signal identified
LKAQRDSYQATINRLHAEAEGKTFTPDL

TonB-dependent
receptor (Tdr)

MHRYGNLLLSMGLNINRTTLTHNGLSATGTPLLNAQ Sec-dependent
TTAYLTSESPRSKIVLNAYYTLGNWDVNLRQSRYGQ (0.982 reliability
TVGMLTYQDWTPASAICPINGKALRGSNVCFAQFKN score)
TPRWLTDLEIGYRFNQHWHVAVGANNIF

hypothetical protein
MPAYRAITLAAANLTKYNLTTLGFEADNTSQFPIGPV Sec-dependent
(Xanthobacter TonB- LASLNYGGEYYHDSVKTKDQTGYEGSTPSGGRGVG (0.949 reliability
dependent
SAFTQLALNWKIVQLTGALRYDTYHASGSGV
score)
hemoglobin receptor)
(Thr)
cell wall-associated
hydrolase (Cwh)

MLVRSLVSRPYGWGNYNFYNDCSAELRSLLIPFGIL
MPRNSLAQIQATSRTVDLGKEDVEARLDYLV

no signal identified

glucose
MTMLAVRADFTACRNRQVVSFSGAVTDNNSTKEPSG Sec-dependent
dehydrogenase (Gdh) VTRAFDLFTGKLVWVFDPSNPDPNEMPSGDHKYVA (0.718 reliability
NSPNSWITASYDANLGLVYIPTGVQTPDQWGGNRTP score)
DAERYASSVLALHADTGKLAWSYQTVHHDLWDMD
unidentified protein
(Gluconobacter
YVTN beta-propeller
repeat protein) (Ybp)

MKFSHHAFIVSLVGLSLATAQATRAQETPAAPAQAAS Sec-dependent
APATASSAASGVTSQAPASAATTPSAAPSSSATPTSTT (0.988 reliability
AGSTTPASTAPVAPVVQVTPPAATSAATPVAGAVQTIP score)
GMPAVIDPKNIYSETISGKISPAIKDDLARVYVPNLRG

hypothetical protein
(Asaia bogorensis
cellulose synthase
subunit AB) (Csy)

MKHVRHSIAFLESWIDDAHHSPARTAIKTGLISFAILC no signal identified.
MVIAAFVHL
transmembrane
domain predicted
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lysine 2,3aminomutase (Amu)

MLSPRRLRHIIEALSAMPHIQTIRIHSRVPVADPARITS no signal identified
AMLDALETDRALWIVLHANHASEMTGQARAAIRQI
QSRAIPVLSQSVLLRGVNDTEEALEALLRAFVTARIK
PYYLHQLDPAPGTSHFHVPI

peptide ABC
transporter permease
(Ptp)

MIRLALRLRGLSGSGF

hypothetical protein
(Gluconacetobacter
fimbrial assembly
family protein) (Faf)

MQRDVTLPLAAEQDLAAILAYEMDRLTPFDAEALF
no signal identified
WDFIVLRRDEALGQIMLRLSVVPQAPLRPLFERLHLL
EAHPQAIADETGETLIRQPVARPLVTRLSDPRLALPLG
GCTLLACLLLGLFWHQSRVLSGYERQIDALRGPALE

amino acid ABC
transport permease
(Aap)

MALPXSRAMSRFHDSVDXVLGDMMSDGTLQTILRR no signal identified
WNLWTPEMAAMTGDPQRCVRCLLFAWLRYRDAMR
STARLGGAVPPLSRISAHHRQGGGADPCGVGPFHDP

Ribonuclease I (Rns)

MGTYLAERAGLRVRHDDLMAFFRTASQTTLPRALQL no signal identified
RCETDHEGRIVLTQLWFTLAPGKMHLFPAAESYLTSP
QNQDNCPAEFWV

no signal identified
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Table 4.2. Plasmids used in this study
Plasmid

Relevant Characteristics

Source

pNB51

pNB20 w/ promoter region changed to P nptII

this study

pNB90

pNB51 w/ phoA insert used for genomic library construction

this study

pNB91

genomic library of Asaia DNA-phoA fusions

this study

pNB91.1

possible heavy metal transport protein PhoA fusion

this study

pNB91.2

outer membrane siderophore receptor PhoA fusion

this study

pNB91.3

Sugar permease, glucose/galactose transporter PhoA fusion clone

this study

pNB91.4

carbohydrate-selective porin OprB PhoA fusion clone

this study

pNB91.5

HlyD family secretion protein PhoA fusion clone

this study

pNB91.12

TonB-dependent receptor plug PhoA fusion clone

this study

pNB91.14

TonB-dependent hemoglobin receptor PhoA fusion clone

this study

pNB91.17

putative cell wall-associated hydrolase PhoA fusion clone

this study

pNB91.18

Quinoprotein glucose dehydrogenase PhoA fusion clone

this study

pNB91.24

YVTN family beta-propeller repeat protein PhoA fusion clone

this study

pNB91.25

cellulose synthase subunit AB PhoA fusion clone

this study

pNB91.112

L-lysine 2,3-aminomutase PhoA fusion clone

this study

pNB91.113

diguanylate cyclase PhoA fusion clone

this study

pNB91.132

fimbrial assembly family protein PhoA fusion clone

this study

pNB91.136

amino acid transport permease protein PhoA fusion clone

this study

pNB91.141

Rnase I PhoA fusion clone

this study

pNB92

pNB51 w/ phoA insert and MCS for gene fusion construction

this study

pNB93

pNB92 w/ YVTN beta-propeller repeat gene cloned

this study

pNB95

pNB92 w/ siderophore receptor gene cloned.

this study

pNB96

Siderophore receptor - Pro-EPIP - PhoA effector construct

this study

pNB97

Siderophore receptor - scorpine - PhoA effector construct

this study

pNB99

Siderophore receptor - PLA2 - PhoA effector construct

this study

pNB101

Siderophore receptor - prochitinase - PhoA effector construct

this study

pNB102

Siderophore receptor - anti-Pbs21 scFv-Shiva1 - PhoA construct

this study

pNB103

Siderophore receptor - Shiva1 - PhoA effector construct

this study

pNB105

Siderophore receptor - GFP - PhoA effector construct

this study

pNB106

Siderophore receptor - anti-BSA scFv - PhoA effector construct

this study

pNB107

Siderophore receptor - anti-Pfs25 scFv - PhoA effector construct

this study
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pNB108

Siderophore receptor - anti-Pfs48/45 scFv - PhoA effector construct

this study

pNB124

pNB92 w/ the siderophore receptor 51aa signal peptide cloned

this study

pNB125

pNB92 w/ the YVTN beta-propeller 34aa signal peptide cloned

this study
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Table 4.3. Oligonucleotides used in this study
Oligo

Sequence 5' - 3'

PhoA F NdeI

taCATATGcctgttctggaaaaccgggc

PhoA R PacI

taTTAATTAAggtgacaaggcaggaaaccac

PhoA seq R1

cggcagtaatttccgagtcc

phoA directional cloning
for pNB90 library vector
''
sequencing PhoA library
inserts

PhoA F NdePacSbf TACATATGTTAATTAAAACCTGCAGGATGCCTGT
TCTGGAAAACCGGGCTG
PhoA R Fse

Purpose

taGGCCGGCCggtgacaaggcaggaaaccac

siderophore F NdeI TAcatATGCCCAGAGCCGCTCGAC

phoA directional cloning to
generate effector
expression constructs
''
secretory leader protein
directional cloning

siderophore R
MYC PacI

TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCAACAATCGGCGCCTCAGCCTGG

''

YVTN F NdeI

TAcatATGAAGTTTTCACATCACGC

''

YVTN R MYC
PacI

TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCAATGGCATAGGCCACATCATC

''

scorpine F PacI

taTTAATTAAaggctggattaacgaagagaagattc

scorpine R SbfI

taCCTGCAGGaataagacaggggggtgccgc

''

Shiva1 F

taTTAATTAAaatgccgcgttggcgtctgttc

''

Shiva1 R

taCCTGCAGGaacccaccgcacgcgcatc

''

PRO-EPIP F PacI

taTTAATTAAaatggctagcgaagaaccgc

''

PRO-EPIP R SbfI

taCCTGCAGGacccggggctgcctttcac

''

effector gene
directional cloning

Pbs21Shiva F PacI taTTAATTAAaagcgaggtccagctgcagcagag

''

Pbs21Shiva R SbfI taCCTGCAGGaacccaccgcacgcgcatc

''

mPLA2 F PacI

taTTAATTAAaatggctagctggcagatcc

''

mPLA2 R SbfI

taCCTGCAGGagtacttgcgcagatcgaacc

''

EPIP4 F PacI

taTTAATTAAagataaatccctggttaagg

''

EPIP4 R SbfI

taCCTGCAGGagcccggcgagcccttc

''

Prochitinase F PacI taTTAATTAAagaagaaccgcataaggccg

''

Prochitinase R SbfI taCCTGCAGGacttcttgccttcggcgctg

''

Pfs25 F PacI

taTTAATTAAaCCTTCTTCGATGTTCGCCTCtc

''

Pfs R SbfI

taCCTGCAGGaAGCCAGCGGATAGACGCTAGg

''

Pfs48/45 F PacI

taTTAATTAAaCAACCTGCTGAACTGGACATCG

''

Pfs48/45 R SbfI

taCCTGCAGGaACTTGTAACGCTAGGCGGTGTTG

''

GFP F PacI

taTTAATTAAaagtaaaggagaagaacttttcactg
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non-effector gene
directional cloning

GFP R SbfI

taCCTGCAGGatttgtatagttcatccatgccatgtg

''

BSA F PacI

taTTAATTAAaATGGCCGAGGTGCAGCTGTTG

''

BSA R SbfI

taCCTGCAGGaTGCGGCCCCATTCAGATCCTC

''

Sider51 R MYC
PacI

TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC Leader peptide directional
TGTTCCTGTGCCCGTGCGTCACTG
cloning

YVTN34 R MYC
PacI

TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCCTGTGCCGGAGCTGC
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''

Table 4.4. Bacterial strains used in this study
Strain

Genotype

Purpose

E. coli Top10 F'

molecular cloning
F´{lacIq, Tn10(TetR)} mcrA Δ(mrr-hsdRMSmcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 and plasmid
propagation
Δ(ara leu) 7697 galU galK rpsL (StrR) endA1
nupG (from life technologies #C3030-03)
(Durfee 2008)

Asaia SF2.1

wild type (from Guido Favia, University of
Camerino, Italy) (Favia 2007)
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protein expression
and
paratransgenesis

Table 4.5. Secretion signal prediction from Asaia sp SF2.1 genome.
The Asaia sp. SF2.1 genome ORFs were processed using the SignalP4.1 signal
prediction algorithms to identify Type II secretion signals. The secretion signals were
further characterized using PRED-TAT to identify the type of signal used.
Protein
peptidyl-dipeptidase DCP
gamma-glutamyltranspeptidase
hypothetical protein
hypothetical protein
TonB dependent receptor
protein
TonB dependent receptor
protein
hypothetical protein
ammonium transporter
peptidyl-prolyl cis-trans
isomerase
hypothetical protein
hypothetical protein
alginate lyase
hypothetical protein
TonB dependent receptor
protein
hypothetical protein
iron ABC transporter
peroxiredoxin
hypothetical protein
pentapeptide MXKDX repeat
protein
ABC-type phosphate transport
hypothetical protein
copper resistance protein CopB
beta-lactamase
hypothetical protein
Alpha/beta hydrolase family
protein
hypothetical protein
pilus assembly chaperone
tricorn protease-like protein
hypothetical protein
TonB-dependent receptor
gluconolactonase
outer membrane efflux protein
hypothetical protein
polyphosphate-selective porin O
gluconolactonase
cupin
3-carboxymuconate cyclase
cupin

Score
0.936
0.929
0.928
0.924
0.919

Amino Acid Sequence
MPVFRHTAALAAVALPLLSSTALA
MKRVCTRVAALPLLLASISVSSLAQA
MLVFNRRLLTGVAALAMTLSAPAFA
MRSFTRRALAASTFAAAALAVMPVAHA
MKLRKQRHALTLSLFCSPLALLSATAHA

Type
Sec
Sec
Sec
Tat
Sec

0.913

MAISRIRICRASMLLGATILAGASFTAQA

Sec

0.907
0.905
0.904

MFKTRFLPALALTALVAAPVAHA
MSRVFKALAPLALCALPLPAFA
MRLTRPALFCAALISGTTLAAPAFA

Sec
Sec
Sec

0.902
0.901
0.899
0.898
0.893

MVSFPCRLVASTVLLASGLSALPAMA
MKKALPVLAALMLGLPLSAQA
MKKGLFLFPACALASFVAAAHA
MTRFLSLLLVLGALPVAAFA
MKLRHRLIISASLPALLIAAHSAAMA

Sec
Sec
Sec
Sec
Sec

0.888
0.888
0.886
0.884
0.884

MTPRSFAAFAASLPLCFLATTAHA
MRRILFAFALLALASTGSSLA
MKRCFIPVSAALLSLSLAAAVPSAHA
MQVQSFRRWRGAALAALAFAVAPAIAQA
MSFRTLALACAFSSAMLLGAPAFA

Sec
Sec
Sec
Sec
Sec

0.883
0.883
0.882
0.873
0.870
0.870

MQLSRIFGALSLSLALSCGVSHAA
MRFCSALILGLVSCASIAPLHA
MNMRRHTINFLAGLAGTLLLSSGSHA
MVQRRHSFLRLLSVACGLALTAPAWA
MFAFTKSFIAAASLVALAAQPALA
MALARLLLTLCGMGTALA

Sec
Sec
Sec
Sec
Sec
Sec

0.869
0.868
0.868
0.867
0.866
0.863
0.862
0.859
0.859
0.858
0.857
0.855
0.854

Sec
Sec
Sec
Tat
Sec
Tat
Sec
Sec
Sec
Sec
Sec
Tat
Sec

porin
hypothetical protein

0.853
0.852

MKHVFKAALAVSALLAAPALTPAPAFA
MVTLLRKTCALGFLAALIVHQAPAFA
MRLSSLLASTAIASLTLLGLASPPAQA
MMLRRRSALLGLAASWSLGRSSLAFA
MSSSFTHRCLMMLLAGTALA
MNPAMKRRSFLSAASVAPLLGVAGPALA
MATRRNRDAAGRLLLAAAALIVSSGAARA
MAKLRRGAFLAATLFVLPAGTAFA
MTSLPRACRLLLASVSLASLAIATPVRA
MKTRLTLCTLALSLAATLVSPPSYG
MKYLWPLPVFLAFLSTAVMVQA
MKTTISRRSFALGTLGLLGCGTAMA
MFAAYLARPLPCRRTLSSISILAAMMPFTAF
A
MSQTLSSTVLRFFSACLAVSCLTPVAHA
MIRYTALILSLAAPGIAQA
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Sec
Sec

peptidase M61
glucose dehydrogenase
hypothetical protein

0.851
0.850
0.847

hypothetical protein
hypothetical beta-glucosidase
TonB-dependent receptor
thiol:disulphide interchange
protein DsbD
membrane protein
membrane protein
hypothetical protein
Glutaryl-7-ACA acylase
TonB dependent receptor

0.847
0.846
0.846
0.846

peptidase S41
peptidase M16

0.836
0.833

hypothetical protein

0.831

hypothetical protein
hypothetical protein
hypothetical protein
purine nucleoside permease
membrane protein
hypothetical protein
hypothetical protein
hypothetical protein
biopolymer transporter exbB

0.830
0.829
0.829
0.826
0.824
0.823
0.823
0.823
0.823

cadmium transporter
Periplasmic phosphoanhydride
phosphohydrolase
Thiol-disulfide isomerase

0.822
0.818

nuclease
NAD dependent epimerase

0.815
0.814

Inosine-uridine preferring
nucleoside hydrolase
polyisoprenoid-binding protein

0.812

GntR family transcriptional
regulator
murein transglycosylase
phenylacetaldoxime dehydratase
amino acid permease

0.807

toluene transporter

0.803

ABC transporter permease
peptidylprolyl isomerase
aldose 1-epimerase

0.801
0.800
0.792

0.845
0.844
0.840
0.839
0.838

0.816

0.808

0.807
0.806
0.804

MTIRLFRAGTFLAALVLGTHAVSAFA
MRKPALMTATILGGLISATVAFA
MVNHAHSMRPFMFRAAFVGLIALMGYSV
PALA
MLKSFLLLTVAALTGISPALA
MTSSSIARKKYLALAVGMAALLAGSRAIA
MRRITGLVALALAGATSLTTAQA
MARPRGGRQFSSFTAIGLMLRKLSPVVLTL
LAFGSAPAFA
MKTSFKISTALLTGFVAAVAAPVAQA
MSIFSAARFVAASALLASVSLPSLAQA
MIRKLTGAAIALTAMTAVASAHA
MRVGHLTRSMLLVTSCLLGASQALA
MAYVFGRAKLKIGLAICLASATCLWQNFA
HA
MRKARNCLLLSVFSLTPILAWA
MSVLPPLRKALLASSLLVAPTLFVAVSAPS
MA
MMTRPKGLRHRLALSLFLCSVPAGLTAAP
AHA
MSRISLGVFLVLTISPALA
MSVKHSLCAVALLTGALTAAFAGNWCAVA
MRRLMSAGAALVALSAGFAVTPASA
MLPACLASLACVLDLGVASAHA
MRLRTALLAMTSMAAAPTIAMA
MKGWLCALSALPVFLALLAAQA
MLSRLCLGLTAVAGLTFAGASAHA
MMKMHLTKLAALGFALAVSPSLVATNALA
MTRLFRLPALAAPALAVTLAVAQGVVVPAV
ALAQETPAAQPAAPAPDAAAPAPAAPDAA
APAAPGAPAPDAAAPAPGAPAPDAAAPA
MKRVQAIPALLMTVCVTGALLFPAGAQA
MIRALILSLALALGGAGTAQA

Sec
Sec
Sec

MFHRKFGVLTSLALGLSTLSVAAPALTSNV
AYA
MTRRSLFALPALLSVAALTLASKPAQA
MTRPMPQPVPRALKSLSRLGCLMLAMVS
CTTLA
MRCFLASLALAALTIGTASA

Sec

MNVQFRPLPVRQMIALFSVLLPMAGATLA
SA
MKRLALSLPIMCITLAAQPVMA

Sec

MSRVKSLLLTSTLLLLGGCSTHA
MFMKRLSLFLAASALTVLSSSGHA
MALRQHQQSKRPRYATALSLIAGISTLTAFA
APSFA
MFKTCISFSRRAALGVLTTALVSVAALSTP
AHA
MSVFDVRNAALLSLALSMTAGAATAMA
MRISRSIKTLVAGASFLALAACG
MKSAVCLVALAGIMDGAAQA

Sec
Sec
Sec
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Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec

Sec
Sec
Sec

Sec

Tat
Sec
Sec
Sec

Ferrichrome-iron receptor

0.791

MSLLTLSALNPGMPRPRRLALSALLMLSAT
LPCQAFA
MMRPVAFLLAIMLAGSGLSRAHA
MLRVFLSASAVFATLALPLTMAHA
MKPELGLLATLMALPLAPLTAVA
MIGPIIVLMLLVLGVAPALA

Sec

anthranilate synthase subunit I
Endonuclease
sirohydrochlorin ferrochelatase
ArsR family transcriptional
regulator
glycosyl transferase

0.789
0.784
0.784
0.782

Sec

0.773
0.773
0.769
0.768
0.765
0.765
0.764

MMRSRSSSPILVVKRLTMALCMGSAVQPAI
A
MKISALGATLMAATFAVATPAFA
MSPRLSCTALALLALASAPQHARA
MTIPSLSALRRSLLTFVMAGAVTSVSAACA
QS
MKQSAPLRLFLCALGAGTVLMPALATA
MAHDLFMRHFLSSAILVSALSLTACA
MPGFRRGLLALPLLFSIWGSSQARA
MFMKRLSLFLAASALTVLSSSGHA
TRQLIPAIALGLLTGCASA
MNKFLKTLLASTLITGSALSLASGKACA
MKRFIPLSPALLTGFALIGAVAHA

membrane protein
ABC transporter
CTP synthetase

0.777
0.776
0.776

nitrogen utilization protein B
peptidase S10
thioredoxin
phenylacetaldoxime dehydratase
methionine ABC transporter
Xylose ABC transporter
glycosyl transferase family 1
Glycerophosphoryl diester
phosphodiesterase
TonB dependent receptor
Ferrichrome-iron receptor
Type I secretion outer
membrane protein, TolC
precursor
Glutamine cyclotransferase
Dipeptide-binding ABC
transporter, periplasmic
substrate-binding component
Outer membrane vitamin B12
receptor BtuB

0.763
0.762
0.758

MLSRRHALTLGAAGFCAPAFASRSFA
MKTFRIVYGIGLAILLPLGAQAEA
MSAKRVRPSHPLTLIVGMTLACTSAQAQA

0.758
0.757

MKTDQLKAYTSLSVGLIALLNSTTALA
MRLLLVCIASFSGLAMTACLFAPAGLA

0.757

0.778

heat shock protein HtpX

0.756

hypothetical protein
FIG01225103: hypothetical
protein
hypothetical protein
secretory lipase
hypothetical protein
Cysteine desulfurase (EC
2.8.1.7)
FIG00688467: hypothetical
protein
Various polyols ABC
transporter, periplasmic
substrate-binding protein
Levansucrase (EC 2.4.1.10)
Sigma-fimbriae tip adhesin
Heavy metal RND efflux outer
membrane protein, CzcC family

0.756

MRGRYGLILAGLGAVLLAPSLHSQGAQA
MRPMRSLRACLLTGISLAPALGLLPLLPAA
LA
MIINPTRRLSARYRCALLALTSLSFALVPEI
GLAQAGPVSTPPGTVSAPVAPSVPSAERGP
QSPA
MNSPILPPMKHAAASLLALLALGGAARHA
HA

0.755
0.754
0.754
0.753

MRPYPALPALLLLAGSLPCAAHG
MRQLLLIILCALALHGLAGTSRAQS
MRSVLAMMAVSALTLTACA
MTRKLALLAAVALALPAGGLAGVAQA

0.75

MTTSPNRRFLLKSFATGAPALLASSSVAA

0.745

MGAMGLAVAVATLSGAMLASITPAQA

0.757

Sec
Sec
Sec
Sec

Sec
Sec
Tat
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Tat
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Tat
Sec
Sec

0.744
0.744
0.741

MKKSLLLASAALGLGLGAQAKA
MLNLLLAGSMVATFTSQAAFA
MRALAILAIGLCCGLITPAARSACA

0.741

MRARCFLASSLVAVAALAPGARA
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Sec
Sec
Sec

Adenosine deaminase (EC
3.5.4.4)
TonB-dependent receptor
hypothetical protein
peptide chain release factor 2
hypothetical protein
Hypothetical membrane protein

Sec
0.739
0.738
0.73
0.73
0.729
0.728

MLPRILPAFALAVPLVFSSASARA
MRHLRRDLLVFCSAIVMNSVVGAIAAQA
MRHILKIGLAALPLIGLMGGAPMVQA
MLMRPALLFLASLASALGLSACVPAPG
MNKSFLAGLTLVTFLAALPQAHA
MGFSRALAPLVLISSCALTACGSSTPA
MSFSIVRPPIRRRARALLGFTLVVSTSLFVA
GQPHA
MKSASQKTSQRQKSHAGLARALLCIAPLA
LA

hypothetical protein
Outer membrane lipoprotein
OmlA
COG1744: Uncharacterized
ABC-type transport system,
periplasmic component/surface
lipoprotein
hypothetical protein
Ferrichrome-iron receptor

0.728

Gluconolactonase (EC 3.1.1.17)
FIG00687573: hypothetical
protein
Lipid A biosynthesis lauroyl
acyltransferase (EC 2.3.1.-)

0.717

Acid phosphatase
hypothetical protein
Membrane fusion component of
tripartite multidrug resistance
system

0.714
0.714

TonB-dependent receptor

0.705

hypothetical protein
Flagellar L-ring protein FlgH
hypothetical protein
Peptidase

0.702
0.701
0.7
0.699

hypothetical protein
hypothetical protein

0.698
0.698

hypothetical protein

0.698

hypothetical protein
hypothetical protein
hypothetical protein
MISCELLANEOUS; Unknown
Xylose ABC transporter,
periplasmic xylose-binding
protein XylF

0.696
0.696
0.696
0.695

hypothetical protein
Prolyl endopeptidase (EC
3.4.21.26)
D-alanyl-D-alanine

0.693

MFLFRFGFFKMITRTKFFLGALALSTVLAA
PAARA
MKTRFALTLAHAGLLGVSLLAGCADTPAP
QPTQA

0.691
0.691

MKRILMAMTSLVCTTFLPPVVGQALA
MRTRRFLLSGAAGLAVSSQFAFA

0.726

Tat
Sec
Sec
Sec
Sec
Sec
Sec
Tat

0.724
0.724
0.721

0.717

MSLKRPALLTRRGLLAAGGCAALAGRASA
MTRYARQFLPLLAILGTGTALT
MSVSLRAALCLSSLLSAAMVPDALA
MMELKMPLARRGFLTTALGGAVCAALPAR
AATDVTA
MSRSRSRIQSFLRFGSVCLLLGSVSPLLTAC
G

Sec
Sec
Tat
Sec
Sec

0.715

0.712

0.693

MARLALAALSSLPAAMA
MLSPLIMTRPTRSLAAVLLALTCLSPSLVAK
PAQA
MQKVLPVLTALLLSIIPQATLANA
MAYKKPLLFAGCTALVLTGLAWS
MVRRVTLPYRHRGLRQSTLMVALFCTVFA
APAEGLA
MTNPTNFRRSARVLGGLAGLLMLAACEGT
A
MTRFFSRGSLTVLLLLGSCTSLS
MGLVLMLLVGMASQASAHA
MRSLRPSVAALIIGTVLTGMPARA
MQTRNRTVTPGFLTQTRQALPGLFLGCILS
ASALSGCAQA
MRHLLGRTLMAASLIITLPQAMA
MSQQSLRVSLHNRTRAALRRAALATLSVG
ALGLTCHSGMAYA
MDFAERRNGLMIFMKSRLSKSASASLAML
GFSVALAPVPALS
MRRLSGLKLAASVVAVGAAFASHGASA
MTTASFLRTGALAVMLALPALG
MRTYLIAGALALASCVVVTGAFVSPTFA

Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
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Sec

carboxypeptidase (EC 3.4.16.4)
FIG00687971: hypothetical
protein

0.689

FOG: TPR repeat
surface antigen gene

0.688
0.686

Acid phosphatase, class B
hypothetical protein
hypothetical protein
hypothetical protein
Flavodoxin reductases
(ferredoxin-NADPH reductases)
family 1

0.686
0.684
0.684
0.683

TPR domain protein
hypothetical protein

0.681
0.681

hypothetical protein
FIG00687356: hypothetical
protein
TonB-dependent receptor
hypothetical protein
TonB-dependent receptor

0.67

hypothetical protein

0.659

Metallopeptidase

0.659

Rare lipoprotein A precursor
Bll0045 protein
hypothetical protein
Gluconate 2-dehydrogenase (EC
1.1.99.3), membrane-bound,
cytochrome c
probable outer membrane
protein
Heavy metal RND efflux outer
membrane protein, CzcC family
hypothetical protein

0.656
0.656
0.655

hypothetical protein

0.651

hypothetical protein
Potassium efflux system KefA
protein / Small-conductance
mechanosensitive channel
Phosphate-specific outer
membrane porin OprP ;
Pyrophosphate-specific outer
membrane porin OprO
Carboxypeptidase-related
protein
putative hydroxylase

0.649

MAASLAMALVSGGVATA
MQRFSALPVSDRRTLLLGLGALFLTGAAPA
MSHSRFRPLPCAALLGVIGALSACSSPQSP
S
MVAFSRSLPSRFLPPRHPLRFRFRAISAVAS
LALLAHAAPARA

0.648

MSALKRRSALQLLYGLFLVFALSVSTFPAL
A

0.683

0.669
0.667
0.661
0.659

0.654
0.653

MALKLSHGHVLLAGLMLGGAACASSPAL
A
MRFPRCSRALLVASSLLAASSFVPVIGSSLV
TIAHA
MKFSHHAFIVSLVGLSLATAQATRA
MNYSSIVHAVSRRRANRFGRALALASVLG
ATAAGAAHA
MSRRNAFICCLPLMMGLLLLA
MTALLLKRCVMLCAFLMIPHAGFCA
MPGSLFTTPLTRIFTALLFMAPFGTGMAVA
MRRVFLSVSVVIMTLLVSMSEGFAQAPGES
PAVPAMSSGTMTGPTTGSPPPSLA
MQTKHSPLRRVLLASLTAMPLAMVPGAAP
HA
MRSASLLLFLMVLAGCA
MDPPAMPRVPSPAFGLALALLAWQPCPAL
A
MNVPRFFPLMLTAALAATPVLFVPWHAAH
A
MKKSLLFAVSLMCLDSVRAQA
MTHTAFALFCLTCAVGLPGAARA
MLLGAAIILSPVVTNVAAHA
MRRLALGALLALSACSSVQYVPCPTLVTY
SKADQAALA
MTGKFKRTTSLWLGAVSVIALTHQVLPAA
HA
MKSRKRAYSSTERCKKRLRARIGGIALLCT
VLAPKHGAHA
MRPAFFLAVGITAIGVLAAA
MGKLMAFLVGALALTSCNGIDHAACA
MMKRLSLLLATGFTLIGTLAVPPMGHA
MDLRCSKSRWPGARQVRAGSLSVLGLAV
MGATAHA

Sec
Sec
Sec
Tat
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec

0.651
0.651

Tat
Sec
Sec
Tat
Sec

0.647

MRARSLTSLLLLCGVVMPETGFA

0.647
0.646

MSRKTLVVALLASACFALPRLPAGHA
MLCSTSVLAAIPSAMA

Sec

170

Sec

FIG00689409: hypothetical
protein
hypothetical protein

0.645
0.644

MTTRLFAPRFRPAMIKRAALLLLLFQAGYA
QPGHARA
MVRLRGSAITLVSALTLAACATKPVVQR
MPEHRSAYKKNLVVALISSTALFQVSSPSA
LA

TonB-dependent receptor
hypothetical
TRANSMEMBRANE protein
Tiorf138 protein

0.641

hypothetical protein
hypothetical protein
FOG: TPR repeat

0.637
0.636
0.635

TonB-dependent receptor
Soluble lytic murein
transglycosylase precursor (EC
3.2.1.-)

0.633

Carbohydrate-selective porin
Peptidase, T4 family

0.63
0.626

TonB-dependent receptor
Acylamino-acid-releasing
enzyme (EC 3.4.19.1)

0.623

Aldose 1-epimerase (EC 5.1.3.3)
RND efflux system, outer
membrane lipoprotein CmeC
hypothetical protein
Organic solvent tolerance
protein precursor

0.62

hypothetical protein
Cytochrome c-552 precursor
Penicillin acylase (Penicillin
amidase) (EC 3.5.1.11)
Outer-membrane lipoprotein
carrier protein
RND efflux system, outer
membrane lipoprotein CmeC
PilL
hypothetical protein

0.613
0.613

HtrA protease/chaperone protein
Membrane-bound lytic murein
transglycosylase B precursor
(EC 3.2.1.-)
Outer membrane component of
tripartite multidrug resistance
system
Outer membrane component of
tripartite multidrug resistance
system
Putative ABC transporter,
periplasmic sugar binding

0.607

MTVRRGLAATGLAIALAGCAVSGTDGLTA
MKTGYGSRRYYPAKILIGLCLLSLGATGCQ
EGDFNLPKGSAVVAPA
MRGTPSLAAACALIMTGITGCA
MRRLGLAGGCLVPLSLAACTPAPPA
MITPHPDGAKAGKIMTDAMPVRLTPSRKF
RSLALVAATALSIGVGASSPAWA

0.606

MLTRRSILAATAAAPCLYGTSLAGTLGHKG
SAHVHKQATSA

0.606

MRAGSRRRALRGSAAGAVFSLALLSGCDL
A

Sec
Sec
Sec
Sec

0.638
0.637

MRSRLPAITLYGSLACNAALLA
MISLGKAGLTGFFLLCMAPSFSYA
MKRRVLLTCAASLALSGCAIGPNFHRPDM
LRTGGYQSKALPASIHGTTGTGSAGA
MPINRRQILAGLSAGPVLAILSRAAVA
MKHAFGALAIGSGLWAGGALA
MSHDMHHRKTAYSWGNRIVLPRQAACMA
GLMLPLILPCETALA

Sec
Sec
Tat
Sec
Sec
Sec

0.632

0.621

MRGISYFASSNSARAFMLCAMLVAGATFN
PLRA
MLKFKAARGRLPKTRRGQMLGASIGLVSA
FAPTAARA
MKRRAFCLASLAATALA
MLLRSHTLLPSVARKGVFFLIASTCLMSCG
GEALA
MSLLSLSRVRLLGTSLLSLGMGSATLGGVT
LASAQA
MCSPVTNKTPTDKSDTSNRDEARGTSRTR
RSARPIMAIASGSLAAALSLAPAHA

Sec
Sec
Sec
Sec
Tat
Sec

0.62
0.616
0.616

0.612

MVSLPRRLCAFTFAASLLAGCTVGPA
MKNLILLALSIVSCLACTESRA
MSKRRVAHHRRRSWLAASMLAGTVTFGA
IPEADA
MMRRLIPALTLGSLLMGLPLAGVPLEALLC
PQAHA
MRAPLALALLAALALTACGKKSAGQ
MPSSPLTGRRALLQASACAALAACLPRPA
RA

Sec
Tat
Sec
Sec
Tat
Sec

0.612
0.611
0.61
0.609

Tat
Sec
Sec
Sec
Tat
Tat
Sec

0.602
0.598

MRPLLAPLLALLVAGCVA
MTLSRRGFMGVAASLTALTPFASARFSGAH
A
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Tat

protein precursor
Periplasmic thiol:disulfide
interchange protein DsbA
D-alanyl-D-alanine
carboxypeptidase (EC 3.4.16.4)
RND efflux system, outer
membrane lipoprotein, NodT
family
FIG00688280: hypothetical
protein
Peptidyl-prolyl cis-trans
isomerase
hypothetical protein

Tat
0.597
0.594

MSLYRRSFLAAMPALALMPKARA
MQSATKTNLIKVTRAGKARKWSVFTRALL
GAGLGLGTVAVSAPAHA

Sec
Sec

0.594
0.591

MTFSPSRSARRLSLLAACCTPLLSGCFMV
MNVGQKSCLRLLRRPFFSSLTALSLLVGSA
VLAPKAEA

Sec
Sec

0.589
0.588

hypothetical protein
hypothetical protein
FIG01224591: hypothetical
protein
Peptide methionine sulfoxide
reductase MsrB (EC 1.8.4.12)
hypothetical protein
Potassium efflux system KefA
protein / Small-conductance
mechanosensitive channel
permease of oligopeptide ABC
transporter

0.577
0.573

MPALVLLFPGLAAAATAPSPA
MRTAILSRRFAILAVVGLTGLSAGNPA
MTKRVSFRSSRKLLAASACLGMLGLSACG
NPYDPGARA
MRTLPLLAAMLLLACCTHPHPPE

0.573

MSERFKTALKLSLLGMSVGTSLTPVAARA

0.572
0.564

MKFMTSRRQFCFASVCLALSGRAWG
MIVLWALAGLSLLTAMTIASA

0.561

MLSLSRAPNPGATVLTLENRYSARRPFSWC
LLICLLVGSLCLQSGSARA

hypothetical protein

0.546

FIG167255: hypothetical protein
FIG00688799: hypothetical
protein

0.543

hypothetical protein
FIG004453: protein YceG like

0.529
0.526

ATP/GTP-binding site motif A

0.525

Sec
Sec
Sec
Sec
Sec
Sec
Sec
Sec

0.557

MLLAMGALLLLVLGAVAAPLYARA
MSEASASGNKAASAVAMTASSAALACGV
CCVVPLALPA
MKRTGIHALFQTQGHKRVLRLSGLTPVTVI
ALMTASSMPALA

Sec
Sec
Sec

0.535

MARIVSGRVLAGALMGVMLLIGGHSVHA
MTQLSSITIKAASAGRRKGAASRYAALGV
LALLSAPVASAALITPALA
MKRVILALVLLLLLCPAGGA
MLCLRAVASAGASTLSGFWLALYGLGSPA
HA
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Sec
Sec
Sec

Control 1

Pro-EPIP

anti-Pbs21-Shiva1

Control 2

Scorpine

PLA2

44

209

1

0

420

122

126

208

21

82

101

180

259

500

228

21

10

87

99

133

3

0

132

73

66

148

189

242

98

31

157

62

95

24

111

116

115

169

175

248

195

49

87

3

35

24

151

76

93

175

275

95

0

119

242

30

15

60

64

18

142

107

250

280

90

8

76

128

126

2

120

28

211

0

457

0

107

6

90

155

142

1

106

30

427

0

155

174

300

5

101

75

330

45

30

114

53

53

277

251

67

285

149

279

0

6

64

77

9

111

0

324

237

63

135

69

8

0

180

4

196

377

235

133

110

49

18

35

98

0

9

35

149

500

320

126

84

43

130

95

86

88

202

118

126

104

85

250

142

0

83

168

8

122

28

50

357

86

0

286

340

126

50

302

111

221

69

91

267

315

133

7

2

74

78

405

350

200

177

12

82

60

480

166

1

4

45

287

400

93

154

8

55

72

140

139

159

66

156

170

214

136

138

0

79

128

0

57

103

128

357

300

75

24

139

189

52

319

144

65

166

Table 4.6. Oocyst counts from Anti-Plasmodium in vivo testing. Results from
dissection and counting of oocysts with mercurochrome staining.
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Control

Scorpine

anti-Pbs21-Shiva1

24

175

27

2

60

0

26

143

30

38

44

151

28

40

0

0

41

28

28

38

60

51

0

4

120

194

168

28

59

31

93

282

0

8

45

49

287

222

293

0

49

58

157

160

0

21

41

100

101

97

108

4

62

87

24

9

0

18

86

40

36

120

18

5

26

49

68

70

14

47

20

61

125

71

101

44

45

59

80

76

202

98

157

93

58

124

23

130

40

69

82

20

96

44

66

99

178

79

97

95

74

61

54

33

19

63

0

132

167

0

129

178

60

133

0

0

61

144

41

128

Table 4.7. Oocyst counts from repeated Anti-Plasmodium in vivo testing. Results
from dissection and counting of oocysts with mercurochrome staining. These data are
from repeated trials with scorpine and anti-Pbs21-Shiva1 effectors.
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Chapter 5
Summary and future directions

SUMMARY
Malaria is a devastating disease that has significant health and economic
ramifications worldwide. Novel approaches are needed to complement the existing
methods of treatment and prevention in order to eradicate the disease. The mosquito
midgut presents an excellent target for intervention. The work presented here
demonstrates three methods which can be used to interfere with the vulnerable life stages
of Plasmodium in the midgut: (1) The production of new anti-Plasmodium single-chain
antibody effector molecules, (2) the modification of Pantoea agglomerans using the
hemolysin secretion system to interfere with Plasmodium development, and (3) the
discovery of native secretion signals in Asaia bogorensis and their use to modify Asaia
sp. SF2.1 to interfere with Plasmodium development.

Design and construction of single-chain antibody molecules
The three single-chain antibody genes that were synthesized have a potential to be
used in paratransgenic strategies. These scFv molecules specifically target the life stages
of the Plasmodium falciparum parasite within the mosquito and should have no negative
impact on any other organism in the host microbiome, unlike some of the broad-range
antimicrobial effectors used in similar experiments (Barr 1991, Roeffen 1995, 2001). One
drawback to using these particular antibodies is that they bind only to the surface proteins

175

of Plasmodium falciparum (Roy 2009, Stowers 2000, Eksi 2006); therefore they will not
provide any protection against the other species of malaria. Although P. falciparum is the
most virulent Plasmodium species and causes the greatest human mortality of all malariacausing species (WHO 2013), interventions are still needed to combat the other
Plasmodium species: P. knowlesi, P. malariae, P. vivax and P. ovale.
In particular, Plasmodium vivax causes tenacious infections and remains in the
liver of the infected host for years, even after the blood-stage infection appears to have
been cleared (Baird 2012). Hypnozoites, or “sleeping parasites,” lie dormant in the liver
and emerge to reinfect the host, causing relapses of recurring blood infection and malaria
symptoms. Currently, there is no cure for liver stage parasites, making it critical that P.
vivax transmission is prevented before infection occurs (Baird 2012). Monoclonal
antibodies are known to interfere with the P. vivax parasite development, and these could
be converted for use in paratransgenesis as well (Sattabongkot 2003).
The single-chain antibodies presented in this work must be expressed and
subsequently tested for activity against P. falciparum in vivo to assess whether they
provide protection similar to previous paratransgenic constructs (Wang 2012). Antibodies
may be modified to include antimicrobial peptides in the fusion protein that will further
interfere with Plasmodium development and increase the overall inhibitory effect, as is
the case with the anti-Pbs21 scFv with Shiva1 (Yoshida 1999). The combination of
multiple effector molecules would help to prevent parasite evolution against either one,
since a parasite that resists one of the anti-Plasmodium molecules would still be killed by
the activity of the other. Likewise, artemisinin is used in combination with different drugs
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to treat blood-stage malaria infections in order to lessen the possibility of resistance
(Burrows 2013).
Although these antibodies are targeted to specific surface proteins of the parasite,
evolution of resistance should not be as much of a problem as compared to the resistance
that evolves against the drugs used to kill the blood-stage parasite (Hastings 2002).
Because there is a strong bottleneck in the life cycle of Plasmodium within the mosquito
midgut, with less than five oocysts in field-caught mosquitoes on average (Whitten
2006), there is a far lower chance for the parasite to evolve resistance to interventions in
the midgut than for the millions of blood-stage parasites present in an infected individual
to resist antimalarial medications.

HlyA secretion of effectors from Pantoea
Positive transmission-blocking results from Pantoea agglomerans strains
secreting antimalarial effectors into the midgut provide proof of concept that
paratransgenesis in the mosquito to combat malaria is a possibility (Wang 2012).
Scorpine, EPIP4, and Shiva1 secreted by the hemolysin secretion system produced nearly
100% inhibition of P. falciparum oocyst formation in in vivo lab tests and, importantly,
prevalence was reduced nearly 100%, as well. If prevalence could be reduced, then the
mosquitoes would no longer transmit malaria and would not pose a threat to us.
The successful testing of paratransgenic P. agglomerans strains is hopeful for the
future of paratransgenesis in malaria. A large number of vector anopheline mosquito
species are capable of transmitting Plasmodium to humans, and paratransgenic bacteria
could be used as a powerful tool to simultaneously treat these species. Previous
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approaches to transgene expression attempted expression of the effector protein from the
mosquito host tissues (Ito 2001). Although testing of this approach was successful in the
lab, utilization of this technique in the field would require both the genetic modification
of many anopheline species and the subsequent replacement of the wild mosquito
population with the transgenic strains (Raghavendra 2011). Paratransgenesis could solve
this problem because the same bacteria can be introduced to many vector mosquitoes.
This could be accomplished quickly and more easily than the currently used methods of
creating and introducing transgenic mosquito species by feeding the bacteria to wild
mosquitoes mixed into a solution of sugar water.

Genetic screen for secreted proteins in Asaia
Two secretion signals that function in Asaia sp. bacteria were discovered that can
be used to deliver antimalarial proteins into the mosquito host midgut and disrupt the
gamete, zygote, and ookinete stages of Plasmodium that develop there. These signals
include the native Sec-dependent signal from the YVTN beta-propeller repeat protein and
the native Tat-dependent signal from the siderophore receptor protein. These experiments
demonstrate that the siderophore receptor protein signal peptide is capable of secreting a
wide range of proteins from peptides to single-chain antibodies, and therefore, it
represents a great tool for secretion of active effector proteins.
In light of the recent genome sequence of Asaia SF2.1, the secretion signals
identified from the functional genetic screen were compared to the predicted proteins that
were identified using the bioinformatic approaches. The proteins identified in the screen
did not match the top hits from the genome sequence, which would indicate that the best
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predictions made by computer algorithms are either not accurate enough to rely on, or the
secretion mechanisms that they employ will not allow heterologous proteins to be
identified and detected by a genetic screen. The nature of the PhoA genetic screen,
however, allowed for the quick selection of a leader peptide capable of secreting a
heterologous protein and demonstrated the activity of the secreted PhoA protein in a
simple plate assay. This is something that predictive software cannot provide. Therefore,
the cloning and testing of random genes from a list of predicted signals can be a fruitless
endeavor; however, when used in combination with a genetic screen, it can certainly be
useful to have two sets of data to compare.
One of the greatest challenges for a paratransgenic strategy for malaria
intervention is finding a suitable host from which effector molecules can be delivered.
Asaia sp. SF2.1 has an ideal relationship with the anopheline host for malaria
transmission-prevention strategies. This species associates with the midgut, salivary
glands, and reproductive tissues of the host, and they are transmitted from parent to
progeny and from male to female during copulation (Favia 2007, Damiani 2008). These
factors allow Asaia to deliver effector molecules to the midgut, where Plasmodium is
most vulnerable, as well as to the salivary glands where the sporozoite stage of the
parasite resides. This presents an opportunity to target the sporozoite stage of the parasite
with the same effectors used in the midgut or with different effectors that target
sporozoite-specific antigens such as the circumsporozoite protein that coats the outer
membrane of sporozoites (Foquet 2014). Antimicrobial peptides secreted into the salivary
glands could function to provide an extra barrier to transmission if Plasmodium were to
pass through the midgut. Monoclonal antibodies that bind the circumsporozite protein
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target of transmission-blocking vaccines (Foquet 2014) would possibly be useful if they
were converted into single-chain antibodies that could be secreted into the mosquito
salivary glands by Asaia.
Paratransgenic strains of Asaia could be applied against other vector-borne
diseases transmitted by anopheline mosquitoes, such as West Nile virus and Dengue.
There have been effector proteins identified including antibodies targeting mosquito Ctype lectins necessary for Dengue infection and peptides targeting the West Nile Virus
envelope proteins that are known to interfere with the transmission of each (Liu 2014,
Bai 2007). A single paratransgenic strain of Asaia could be engineered to secrete proteins
targeting multiple insect-vectored diseases in areas where multiple diseases are endemic
by expressing the genes as part of an operon. There may be further applications in plants
for paratransgenic Asaia strains to protect crops against pathogens of agricultural
significance due to its association with plant nectar (Yamada 2000). Some plantassociated bacteria have a detrimental effect on cultivation of plants, for example, a
Gluconobacter sp. bacterium reduces plant-pollinator mutualism and lowers the success
rate of seed production in the orange bush monkey-flower (Vannette 2013).
Now that Asaia has been proven to be a viable paratransgenic candidate in the
laboratory setting, further work needs to be done to increase the efficiency of the
transgenic constructs to make them viable for release in the wild for field testing. The
identified native proteins that secrete in Asaia have already had their signal peptides
identified and retested for activity. Constructs that combine these signal peptides and
effector proteins need to be built and tested in vivo to determine if there is a decreased
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fitness cost to the bacteria expressing the protein, as measured by their growth rate in
culture, and to verify that the anti-Plasmodium activity is retained.

FUTURE DIRECTIONS
The antimalarial constructs produced in this body of work have been successful to
an extent. Plasmodium inhibition was achieved, however, more work must be done to
improve the function of these antimalarial paratransgenic strains so that they can be
tested in the field. The identified secretion signals of the siderophore receptor protein and
YVTN beta-propeller protein will need to be cloned in-frame with anti-Plasmodium
genes and compared against the constructs containing the full fusion proteins. Utilizing a
signal peptide rather than a fusion protein for secretion will reduce the protein size
produced so that it requires less resources for the bacteria to produce, and it should
secrete more efficiently. Efficient secretion will prevent the membrane from getting
“clogged” with proteins which is detrimental to the health of the organism.

Transcriptional regulation of transgenes
The expression of transgenes using a strong constitutive promoter has a fitness
cost on the bacterium that cannot be ignored (Rang 2003). The Asaia strains produced in
this study have a decreased growth rate of at least half that of wild type Asaia
(unpublished observations). Such a significant decrease would render the transgenic
strain uncompetitive in the wild and unlikely to remain in the mosquito population
without constant reintroduction due to the competitive fitness disadvantage (Lenski
1998). To counteract this effect, either a weaker promoter could be utilized or a
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conditional promoter that is regulated in some way so it is repressed when not needed. A
promoter that is turned on or off depending on the presence of a blood meal in the
mosquito midgut could regulate the expression of the transgene so that the construct
would have a minimal fitness burden. If such a promoter is identified, it would both allow
the bacteria to compete with the other midgut microbiota normally and activate the antiPlasmodium effector genes only when an infected blood meal is taken by the host.

Maintenance of transgenes without selection
Once efficient constructs are designed for the expression and secretion of
antimalarial effectors, these gene constructs will need to be maintained without antibiotic
selection so they can persist in bacteria living within wild anopheline mosquitoes. The
simplest way to accomplish this is to introduce the transgene into the bacterial
chromosome by a transposon insertion similar to that used in paratransgenic Alcaligenes
sp. (Bextine 2004). These well-established transposons have been utilized in a broad
range of bacterial species including the Tn5 and Himar1 transposon systems (Reznikof
1993, Bextine 2005). Antimalarial effector constructs can be inserted into the
chromosome of Asaia sp. SF2.1 using one of these systems with a single copy of the gene
and without an antibiotic resistance marker.

CLOSING REMARKS
With the progress in anti-Plasmodium paratransgenesis described in this work,
there is a greater possibility for future laboratory tests of paratransgenic Asaia strains.
These can potentially lead to future field testing and eventual use towards malaria
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eradication. Paratransgenic bacteria present one more potential weapon in the arsenal
necessary to combat this deadly disease and will complement both current and future
interventions in the fight for a world without malaria.
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Abstract
Asaia sp. are abundant members of the microbiota of Anopheles sp. mosquitoes, the
principle vectors of malaria. Here we report the draft genome sequence of Asaia sp.
strain SF2.1. This strain is under development as a platform to deliver antimalarial
peptides and proteins to adult female Anopheles mosquitoes.
Asaia sp. SF2.1 is a Gram-negative member of the alpha-Proteobacteria, family
Acetobacteraceae (12). Asaia sp. were first isolated from the nectar of tropical flowers
and subsequently from insect midguts (3, 7, 12, 13). The taxonomy of the genus Asaia is
in flux and we are hesitant to assign Asaia sp. SF2.1 to a specific species, although it
seems to be most closely related to either Asaia bogorensis or Asaia platycodi
(unpublished obervations). Asaia sp. SF2.1 was isolated from a laboratory colony of
Anopheles stephensi where it is extremely abundant in the gut, salivary glands, ovaries
and testes of this insect (5). Asaia sp. have also been uncovered in Anopheles mosquitoes
in the field, especially An. gambiae, the most important vector of malaria in Africa (3, 4,
6). Efforts to genetically engineer Asaia sp. SF2.1 are underway in order to provide a
platform to deliver antimalarial effector molecules to Anopheles mosquitoes in the field
in an effort to block transmission of malaria, a strategy called paratransgenesis (1, 6, 11).
The sequence reported here is the first for the genus.
Sequencing and annotation of the genome of Asaia sp. SF2.1 was performed by ACGT,
Inc. The standard protocol for the NexteraXT DNA sample preparation kit was used.
The purified fragmented DNA was used as a template for a limited cycle PCR using
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Nextera primers and index adaptors. A second library was prepared using the Nextera
Mate Pair Sample Preparation Kit.
In order to generate clusters of DNA, both libraries were sequenced in a paired-end 2 x
150 bp protocol by MiSeq™. The sequence reads passing the Illumina purity filter were
demultiplexed. 4,097,892 standard library reads were generated, giving an average
coverage of 351X based on the 3.5Mb genome. To generate additional mate pair reads, a
second MiSeq run was done using the mate pair library. This run generated 999,241
mate pair reads (86X coverage).
De Novo Sequence Assembly
A 93X coverage subset of the small-insert library and the mate-pair library were
assembled de novo using ABySS (10), Velvet (14), and SOAPdenovo2 (8). The best
Velvet, ABySS, and SOAPdenovo2 contig sets were combined together using CISA (9)
to produce an assembly with 51 contigs. The largest contig is 506 kb, the N50 length is
162 kb, and the total assembly length is 3.5 Mb. The GC content is 59.6%.
Genome Annotation
Annotation of the genome was performed by the NCBI Prokaryotic Genome Annotation
Pipeline version 2.0 (https://www.ncbi.nlm.nih.gov/genome/annotation_prok/). A total
of 3098 genes were predicted using this method, including 3005 protein-coding genes, 44
pseudogenes, 3 rRNAs, and 45 tRNAs.
Nucleotide sequence accession numbers.
This Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank
under the accession AYXS00000000. The version described in this paper is version
AYXS01000000.
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Introduction
The phenotype of any individual organism is the product of a complex interaction of the
genotype and the environment. For insect vectors of plant and animal diseases, the
phenotype of interest is the ability to transmit the pathogen in question. In principle, it
should be possible to modify the vector phenotype to prevent disease transmission in two
ways: by modifying the genotype through transgenesis (i.e., adding or removing genes in
the genome) or by modifying some aspect of the vector’s internal environment. For
vector insects, the environments in question are the tissues and structures necessary for
pathogen replication and transmission. Very often these environments are co-colonized
by symbiotic microorganisms. Manipulation of these microorganisms can lead to a
change in the pathogen transmission phenotype of the insect. Changing the phenotype in
this way is called paratransgenesis. This review will cover efforts to implement
paratransgenesis in mosquitoes and will focus mainly on efforts to control malaria. Two
recent reviews have already covered related material (Coutinho-Abreu et al., 2010; Wang
& Jacobs-Lorena, 2013) therefore we will focus mainly on the microbial ecology of
mosquitoes relevant to paratransgenesis and bacterial genetic tools that may prove useful
in creating paratransgenic bacterial strains suitable for release in the field. Although the
examples used will emphasize mosquitoes, the methods should be generally applicable to
paratransgenesis for other vectors of plant and animal diseases. Other paratransgenesis
systems are covered in this volume (AksoyX, DurvasulaX, FaviaX).
Requirements for successful paratransgenesis.
There are several requirements that must be met for a paratransgenesis program to be
successful.
Microbial ecology: Suitable microorganisms must be identified that live in the vector in
proximity to the pathogen or parasite and that can be cultured in the laboratory. The
microorganisms must be closely associated with the vector in the life stage where
transmission of the disease organisms occurs and the microorganism must be spread
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within the vector population by some means;
Effector molecules: Effectors must be discovered that inhibit the parasite or pathogen
within the vector. The more specific the inhibition, the better since unwanted and
unpredicted interactions with non-target organisms can be reduced;
Effector delivery: The effectors must be delivered from the paratransgenesis organism in
efficacious concentrations and at suitable periods of time;
No fitness costs: There should be no negative fitness effects on either the vector or the
paratransgenic microorganisms.
Stable inheritance: The genes encoding the effectors must be inherited stably by the
microorganisms without selection;
Introduction and spread: A means must be available to introduce and spread the
paratransgenic strains in nature.
Each of these requirements will be discussed below. We would like to point out,
however, that paratransgenesis can be thought of as a category of the emerging field of
synthetic biology which seeks to create new microorganisms with carefully defined
phenotypes. Methods emerging from this field will no doubt find applications within
paratransgenesis programs and the degree to which these methods can be standardized
can only accelerate progress in paratransgenesis.
Mosquito microbial ecology. The microbial ecology of a wide range of insects has
recently been reviewed (Engel & Moran, 2013). The current understanding of the
microbiota of mosquitoes has been recently reviewed as well (Minard et al., 2013a).
The culturable microbiota of mosquitoes has been examined extensively for a number of
mosquito species (Demaio et al., 1996; Pumpuni et al., 1996; Straif et al., 1998;
Gonzalez-Ceron et al., 2003; Pidiyar et al., 2004; Lindh et al., 2005; Rani et al., 2009;
Cirimotich et al., 2011a; Dinparast Djadid et al., 2011; Joyce et al., 2011; ApteDeshpande et al., 2012; Terenius et al., 2012; Ngwa et al., 2013; Valiente Moro et al.,
2013). Because these studies only scored culturable species, they necessarily missed
most of the bacterial species living in or on mosquitoes since most bacterial species are
not easily cultured. Other studies have used PCR to amplify the 16S genes of the midgut
microbiota to create cloned libraries of sequences that provide a look at the unculturable
microbiota (Pidiyar et al., 2004; Lindh et al., 2005; Rani et al., 2009; Ngwa et al., 2013).
As of this writing, only a handful of deep-sequencing metagenomic studies of mosquito
microbiota have been published, most for Anopheles species (Wang et al., 2011;
Boissiere et al., 2012; Osei-Poku et al., 2012). The most important result from these
studies, from a paratransgenesis standpoint, is that there does not appear to be any species
of bacteria that forms an obligate association with mosquitoes, although many are quite
common. Members of the genera Pantoea, Serratia, Enterobacter, and Elizabethkingia
are routinely found in Anopheles sp., for example. Asaia sp. bacteria are also very
common in Anopheles and we direct the reader to a chapter in this volume for more
information on this genus of bacteria (FaviaX). Wolbachia, however, seems to be
naturally absent from Anopheles, in contrast to Aedes sp. where it is widespread in nature.
Wolbachia can be experimentally introduced into Anopheles, albeit with difficulty (Bian
et al., 2013). Minard et al. (2013) contains a comprehensive table listing the genera of
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bacteria found in numerous species of mosquitoes and we direct the reader there for more
information.
The role of the mosquito microbiota is not well understood. Many presumed functions
are reviewed in Minard et al. (2013). Almost certainly, the microbiota are involved in
nutrition, especially in females where they may contribute to the digestion of the blood
meal (Gaio Ade et al., 2011) and both in males and females where they may provide
nutrients in addition to the sugar meals taken by both sexes (Minard et al., 2013b). It has
been clearly demonstrated that the microbiota is involved in immune system activation in
the midgut and that this activation plays a role in the ability of the mosquito to attack
pathogens in the blood meal, especially Plasmodium sp. (Pumpuni et al., 1996; Dong et
al., 2009; Cirimotich et al., 2011b; Sharma et al., 2013). Other roles for the microbiota
include the ability to positively influence egg hatching and to aid in larval growth
(Ponnusamy et al., 2011; Chouaia et al., 2012).
Exactly how mosquitoes acquire their microbiota is not entirely clear, although the
microbiota of mosquitoes changes dramatically depending on the life stage. Wang et al.
(2011), for example, found that the microbiota of larvae and pupae of An. gambiae were
dominated by cyanobacteria, clearly a product of feeding in an aquatic environment, and
the dominant bacteria changed dramatically by the time of adulthood. In some species,
females deposit bacteria on the surface of eggs (i.e, “egg smearing”) and these can be
acquired by larvae (Crotti et al., 2009; Damiani et al., 2010). During metamorphosis, the
microbial community in the midgut is drastically altered and the gut is sterilized or nearly
so via the formation of a meconium (Pumpuni et al., 1996; Moll et al., 2001), although
there is evidence that some bacteria survive transstadially (Damiani et al., 2008). The gut
is repopulated in the adult stage either through bacteria acquired from the water from
which the adults emerge and/or a plant nectar meal taken upon eclosion (Lindh et al.,
2005; Wang et al., 2011; Minard et al., 2013b). Some species of bacteria, namely Asaia
sp., can be passed from males to females during mating (Damiani et al., 2008). The
acquisition, composition, and change of the mosquito microbiota remains an area where
further study is needed. Studies in this area should be able to identify appropriate
microbial species for paratransgenesis and inform strategies on how to spread
paratransgenic strains in nature.
2. Effector molecules
After a suitable bacterial species is chosen for paratransgenesis, a critical step toward
creating paratransgenic strains of bacteria is the isolation of anti-pathogen effectors. In
principle, these can be any molecules that block pathogen development or transmission
from the insect vector and can include proteins, peptides, small molecules, or RNAs. In
this regard, the field of malaria paratransgenesis is rich with effectors and some of these
may prove useful against other diseases. Reviews of anti-malarial effectors have been
recently published (Caljon et al., 2013; Wang & Jacobs-Lorena, 2013). We will briefly
treat each category below.
Proteins. Certain proteins have proved to be anti-malarial. For example, a component of
honey bee venom, phospholipase A2 has demonstrated anti-malarial activity.
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Interestingly, its enzymatic activity is not necessary for its anti-malarial properties since
mutants of it are also active against the parasite (Moreira et al., 2002; Rodrigues et al.,
2008). There is speculation that the protein somehow alters the cell membranes of the
mosquito midgut thereby blocking parasite invasion of that tissue.
A very important class of anti-malarial proteins is antibodies and their derivatives
(Kontermann, 2010). Several monoclonal antibodies have been isolated that bind to
surface proteins of the reproductive stages of malaria parasites and block different parts
of the life cycle within the mosquito (Rener et al., 1983; Quakyi et al., 1987; Barr et al.,
1991). Native antibodies are complex proteins consisting of four polypeptide chains
linked by disulfide bonds. To use these antibodies in a paratransgenic strategy, the genes
that encode the mature antibody must be converted into a single gene that encodes a
protein that retains binding specificity and that can be translated and secreted by bacteria
(Kipriyanov & Le Gall, 2004). Such constructs are called single chain antibodies (scFvs)
and are synthetic constructs that link the heavy chain and light chain variable regions of a
specific antibody into a single open reading frame that, when translated, forms a protein
that can reconstitute the specific binding structure of a mature vertebrate antibody. There
are numerous variations on this basic scFv theme (figure A.1) including single domain
antibodies (containing only the heavy chain binding region and sometimes called
nanobodies), diabodies (constructs that bind to two different antigens), and scFv-toxin
constructs (scFvs that are fused to a toxin gene) (Kontermann, 2010). The first successful
demonstration of paratransgenesis against malaria used this latter kind of construct
secreted by E. coli in Anopheles stephensi to cause a decline in the number of oocysts
formed in the midgut by Plasmodium bergheii, although the effect was weak (Yoshida et
al., 2001). There is an extensive literature on the conversion of vertebrate IgGs to
different single chain forms and we invite readers to explore that literature for specific
applications (Fernandez, 2004).
Peptides. Peptides are another very important class of anti-malarial effectors which may
also be useful against many other pathogens. A major benefit of this class of effector is
that they are typically short, sometimes no more than twenty amino acids in length.
There are two important classes of effector peptides: peptides that directly kill the
parasite and those that interfere with some specific parasite-vector interaction.
Peptides that kill pathogens or parasites have been derived from venoms (for example,
scorpine from scorpion venom) or, more commonly, from peptides that are secreted as
part of the eukaryotic innate immune system. Hundreds of these latter peptides have
been described from many different eukaryotes, only a few of which have been used in
paratransgenesis (Otvos, 2005; Nishie et al., 2012; Vila-Farres et al., 2012). This is,
obviously, a promising area for future research. Indeed, the canonical paratransgenesis
program against Chagas’ disease transmitted by triatomine bugs used cecropin A (a
peptide of the innate immune system of the giant silkmoth, Hyalophora cecropia)
secreted by the Gram-positive bacterium, Rhodococcus rhodnii, to kill Trypanasoma
cruzi (Durvasula et al., 1997).
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Other anti-malarial peptides interfere with some specific interaction between the parasite
and the mosquito host and thus block some important life stage from proceeding. For
example, enolase-plasminogen interacting peptide (EPIP) is a 6 amino acid peptide that,
when supplied in excess in Anopheles midguts, blocks the interaction of plasminogen
with ookinetes (Ghosh et al., 2011). Since the ookinetes cannot invade the midgut wall,
they die and the life cycle of the parasite is aborted. Another antimalarial peptide of this
class is SM1 (salivary gland-midgut peptide 1) which blocks parasite-vector interactions
in both the midgut and salivary glands of mosquitoes (Ghosh et al., 2001).
Small molecules from biosynthetic pathways. Many small molecules are known that kill
malaria parasites ranging from drugs used to kill blood stage parasites (e.g., artemisinin)
to reactive oxygen species. Each of these molecules is the end product of some
multigene biosynthetic pathway. In principle, it should be possible to move the pathway
for these small molecules into a paratransgenesis species. For example, amorpha-4,11diene, a precursor to the anti-malarial drug artemisinin, can be produced in E. coli by
adding heterologous genes from yeast and Artemisia annua (Tsuruta et al., 2009).
RNAi. To our knowledge, small double stranded RNAs (dsRNAs) have not been used
as effector genes to interfere with parasite-vector interactions through RNA inhibition
although they could offer a powerful route to either kill parasites outright or block some
important interaction with the vector. RNAi has been used in mosquitoes to knock out or
repress particular genes by injecting the dsRNAs directly in to adults. Delivery of
dsRNA to the gut environment by bacteria expressing dsRNAs might target mosquito gut
tissues or parasites directly. Delivery of dsRNA via bacteria to silence genes is a
standard technique in Caenorhabditis elegans biology (Timmons & Fire, 1998). Strong
caveats to using this method should be considered, especially the fact that many
eukaryotic parasites lack a response to dsRNA because they lack the machinery to
process it. For example, Plasmodium sp. parasites and Trypanosoma cruzi lack this
machinery although Trypanosoma brucei retains it (Kolev et al., 2011). Obviously, the
potential effectiveness of RNAi would have to be evaluated on an individual
pathogen/vector basis.
The need to express more than one effector. Paratransgenic strains of bacteria that
express a single effector against a parasite or pathogen can be expected to lose
effectiveness quickly. This is because the use of the effector will provide strong selective
pressure and favor those parasite or pathogen variants that are resistant to the effector.
The scientific literature is replete with instances of the failure of a drug or resistance
strategy when single effectors or drugs are used by themselves. Bacteria, viruses,
eukaryotic pathogens, agricultural insect pests, weedy plants, and even cancer cells all
display this phenomenon as the simple and entirely predictable result of directional
natural selection. Therefore, any paratransgenic strain that will be released into nature
should express more than one effector. A simple way to do this would be to construct an
artificial operon with two or more effector genes driven by the same promoter.
Importantly, the effectors should act in different ways to minimize the chances that
resistant parasites or pathogens will evolve.
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An aside: codon optimization. Effector genes have their origin in a wide variety of
organisms, many of them eukaryotes. The native genes, therefore, reflect the codon
usage bias of the organism from which they originated. This bias can cause problems
during translation in the paratransgenic bacteria. A well-known solution to this problem
is to optimize the codon usage of the effector gene to match that of the organism where
translation will take place (Welch et al., 2009; Francis & Page, 2010). In practice, this
means resynthesizing the gene from scratch. Commercial gene synthesis services are
available that specialize in codon usage and we strongly recommend this practice. A
recent permutation on codon optimization is codon harmonization which seeks to reflect
the inherent use of both common and rare codons in a single protein coding gene, with
rare codons clustered in regions where translation naturally slows to allow the nascent
protein sufficient time to fold before translation resumes (Angov et al., 2011).
3. Effector delivery
Once effectors are discovered that kill or impair the pathogen of interest, a way to deliver
these from the paratransgenic bacterial species must be found. If the paratransgenesis
bacterium is Gram positive, efficient secretion of proteins or peptides can be achieved
using simple secretion signals added to the N-terminus of the effector constructs. This
was the method used to secrete cecropin A from Rhodococcus rhodnii in the Chagas’
disease paratransgenesis system (Durvasula et al., 1997).
Effector delivery is more complicated if the paratransgenesis species is Gram negative.
Gram negative bacteria have two cell membranes bounding a compartment known as the
periplasm that separates the cytoplasm from the exterior of the cell. Any protein or
peptide that is to be secreted has to traverse this complicated barrier. Passage through the
periplasm is beneficial in some cases, however, as it allows certain proteins to fold
properly and form disulfide bonds within a reducing environment. In nature, Gram
negative bacteria have evolved at least 6 different mechanisms to secrete proteins and
some of these have proved useful to secrete foreign proteins (Holland, 2010). Two of
these mechanisms and the structure of the Gram negative cell membranes and periplasm
are shown in figure A.2.
Heterologous secretion systems. As a first step toward achieving secretion of effectors
from a new paratransgenesis species, heterologous systems can be tried. Two effective
ones are the hemolysin A (HlyA) autotransporter secretion system from pathogenic E.
coli and the pelB leader sequence from the pectate lyase gene of Erwinia carotovora.
Hemolysin A is a toxin encoded by the hlyA gene in the hemolysin operon of particular
pathogenic strains of E. coli (Blight & Holland, 1994; Holland, 2010). This secretion
system is designated as Type I, or an autotransporter. These sorts of secretion systems
are dedicated to the secretion of a single protein and usually accomplish secretion in one
energy-dependent step across both the inner and outer membranes of the Gram negative
cell. Studies of various deletion constructs of HlyA have demonstrated that a C-terminal
46-50 amino acids are the signal that directs the protein toward the secretion apparatus
(Kenny et al., 1992). That apparatus consists of the HlyB and HlyC proteins encoded by
the hemolysin operon in addition to TolC, a native outer membrane protein. Together,
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HlyB, HlyC, and TolC form the transport mechanism that moves HlyA from the
cytoplasm to the outside of the cell. Any protein or peptide linked to the HlyA signal
sequence can also be transported using this system and it is highly efficient (Tzschaschel
et al., 1996; Fernandez et al., 2000; Bisi & Lampe, 2011). Using the HlyA system, Wang
et al. (2012) were able to secrete 7 different anti-malarial effector proteins from the Gram
negative bacterial species Pantoea agglomerans in both An. gambiae and An. stephensi
midguts.
Two caveats should be mentioned when discussing HlyA, however. The first is that,
although very efficient, proteins secreted in this way do not spend any time in the
periplasmic space (Holland, 2010). The periplasm is an important environment that
allows many proteins to fold correctly before final secretion takes place. Secondly, the
HlyA system depends on the presence of a host membrane protein, TolC. The success of
malaria paratransgenesis in P. agglomerans using HlyA was achieved in no small
measure due to the fact that P. agglomerans has a native TolC protein that can function
with the E. coli HlyA system (Bisi & Lampe, 2011; Wang et al., 2012). Not all bacterial
species are likely to have a homologue of TolC and thus HlyA-based secretion is not
likely to work in them. For example, genome sequences Gluconobacter oxydans and
Gluconacetobacter diazotrophicus, to which Asaia sp. are related (see chapter X, this
volume), have no closely-related tolC homologues (unpublished results, Lampe and
Bongio).
Another heterologous system that has proved effective at secreting foreign proteins is the
pelB secretion system. PelB encodes the pectate lysase gene which is secreted from the
plant pathogen Erwinia carotovora (Lei et al., 1987). The PelB protein is secreted via a
Type II secretory mechanism, a category that includes several different pathways grouped
together under what is termed the general secretory pathway (Sec) (see figure 2). This
pathway is universal in Gram negative bacteria and seems to be homologous to secretion
from eukaryotic cells (see reviews of the system in (Pugsley et al., 2004; Holland, 2010).
Proteins that are synthesized with short N-terminal hydrophobic leader sequences are
targeted to the inner membrane where they pass through the membrane in an energy
dependent process involving numerous proteins in the secretion apparatus. Once in the
periplasm, proteins cross the outer membrane to be inserted into the outer membrane or
to be secreted outside the cell. Protein passage out of the cell is mediated by numerous
mechanisms, many of which are poorly understood. Type II secretion using leader
sequences like pelB have been very successful in secretion of a variety of proteins,
especially scFvs and their variants (Dammeyer et al., 2011).
There are many positive features of heterologous Type II secretion. The main one is
simplicity. The addition of a pelB or other leader sequence to a gene encoding an
effector protein is trivial unlike the HlyA system which requires the presence of several
other heterologous proteins. The downside to using Type II secretion is that, while
simple, proteins cannot be targeted easily to exit past the outer membrane. Thus, proteins
secreted by Type II secretion often get “stuck” in the periplasm which can have
deleterious effects on cell fitness. We and others have noticed a strong correlation
between efficient secretion and cell fitness (Bisi & Lampe, 2011).
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Native secretion systems. If heterologous secretion systems fail to function it may be
necessary to develop native secretion systems for a given bacterial species. If a genome
sequence is available it can be mined using bioinformatic methods to identify candidate
secretion signals (Nielsen et al., 1997; Petersen et al., 2011). Bioinformatic methods are
likely to miss many secreted proteins since it is known that many secreted proteins
contain leaders that do not conform well or at all to any secretion consensus sequence
(Payne et al., 2012). Alternatively, secreted proteins can be identified directly via 2D
electrophoresis followed by MALDI-TOF which, again, requires the use of genomic data.
More than likely, the genome sequence will not be available for many candidate
paratransgenesis species. Even if a genome sequence does exist, it can be difficult to
identify secreted proteins based on computer algorithms alone, as noted above. In either
case, classical microbial genetics can be used to identify candidate secretion signals.
Identification of secreted proteins by genetic means is based on the use of a modified E.
coli phoA gene that encodes alkaline phosphatase (AP) lacking its native secretion signal.
When secreted into solid media containing 5-bromo-4-chloro-3-indolyl phosphate
(BCIP), AP hydrolyzes BCIP turning it blue. BCIP cannot penetrate the inner membrane
of Gram negative bacteria so the screen can identify proteins secreted, membrane bound,
or periplasmic.
AP can be used in two different ways to identify native secretion signals. The first
method is through the use of the transposon TnphoA (Manoil & Beckwith, 1985; Boquet
et al., 1987; Gutierrez et al., 1987; Manoil et al., 1990). This transposable element,
derived from a modified miniTn5, carries a phoA gene lacking a secretion signal
sequence placed very close to the end of the transposable element. TnphoA is introduced
into the target species (commonly by conjugation with E. coli) where it inserts randomly
into the chromosome. If it jumps into a gene that encodes a secreted protein, the phoA
gene in TnphoA may be fused with the secretion signal of the chromosomal gene. When
a library of these random insertions is plated on agar with BCIP, blue colonies indicate
the insertion of TnphoA into a gene encoding a secreted, membrane-bound, or
periplasmic protein. Because the genes are “tagged” by the transposon, it is trivial to
recover the sequence of the insertion site by anchored PCR techniques. There are,
however, important caveats to consider when using this method, the main one being that
TnphoA insertions will only recover secretion signals of genes that are active under the
conditions used for the screen (i.e., on the agar plate) so some genes may be missed. In
addition, the screen will only work if the transposon is active in the species in question
and there are reports that Tn5 is not universally active in all bacteria. In that case, a
similar transposon can be built based, for example, on Himar1, which seems to have
fewer species barriers (Choi & Kim, 2009). Finally, the paratransgenesis species may
have endogenous AP activity. This can be overcome by including Na PO4 in the medium
which dampens the endogenous signal so that the TnphoA AP signal can be seen (Bina et
al., 1997).
The second method to identify native secretion signals is to construct a plasmid library of
genomic fragments fused to a leaderless phoA gene (Bina et al., 1997). Typically,
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genomic DNA from the paratransgenesis species is incompletely digested with a 4bp
cutting restriction enzyme, size-selected to isolate 1-3 kb fragments, and then cloned
upstream of a leaderless phoA gene. Importantly, this system incorporates a constitutive
promoter so, in principle, any secreted protein can be recovered circumventing a shortfall
of TnphoA. The library is transformed into the paratransgenic species and then plated on
suitable media that includes BCIP. Blue colonies are picked and the positive clones are
sequenced to determine the signal sequence directing secretion of AP. Not surprisingly,
there are caveats to this method as well. If it is difficult to transform the paratransgenic
species, then it may be preferable to transform the library first into E. coli and perform a
screen for secretion there. Positive clones isolated in E. coli can then be transformed
later into the paratransgenesis species to confirm that they secrete. The use of E. coli to
perform the initial screen, however, means that some secreting clones may be missed.
Despite the caveats of TnphoA or the construction of a secretion library, both of these
methods allow direct identification of native secretion signals without the need for a
genome sequence and should be considered even if a genome sequence is available.
4. Fitness considerations for paratransgenic bacteria
As noted at the beginning of this chapter, the fitness of paratransgenic organisms must be
kept in mind. Ultimately, paratransgenic strains are destined for release into the
environment where they must compete with wild strains and species. Any severe fitness
disadvantage will eliminate them before they can colonize vectors and suppress parasites
or pathogens. We have already discussed several areas where fitness concerns can be
addressed, including ensuring efficient secretion, codon optimization of effector genes,
and the use of conditional promoters (see below). Ultimately, fitness levels of
paratransgenic strains will have to be measured empirically.
Transcription of effector genes. Effector genes must be transcribed in the
paratransgenesis species. Ideally, transcription would be strong, ensuring an abundance
of the effector product. The kind of transcription necessary for a particular
paratransgenesis program should be considered carefully. Does the effector need to be
produced continuously or only under the specific conditions when the pathogen or
parasite is present? Can the two conditions be distinguished? The answers to these
questions will determine what kind of promoter to use to drive effector gene
transcription.
Constitutive promoters. If a continuous supply of effector gene product is desired, the
gene should be placed under the control of a constitutive promoter. Heterologous
constitutive promoters exist that function in a wide variety of bacterial species. One such
promoter is that from the neomycin phosphotransferase II gene (nptII) (Auerswald et al.,
1981; Beck et al., 1982; Reiss et al., 1984). If a genome sequence is available, then the
native promoters for genes like the homologues of E. coli rpsL (30S ribosomal subunit
protein S12) and groEL (an E. coli chaperonin) should be considered. Of course, any
gene expressed in a constitutive manner can be considered as long as the promoter is
sufficiently active to produce the desired amount of effector gene transcript. For the
laboratory demonstration of paratransgenesis for malaria using P. agglomerans, we used
the nptII promoter (Wang et al., 2012).
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Conditional promoters. If the parasite or pathogen enters the insect vector under specific
conditions, then the use of conditional promoters should be considered. Female
mosquitoes that transmit malaria, for example, acquire the parasite in a blood meal,
which leads to a dramatically different gut environment than does sugar feeding.
Conditional promoters offer distinct advantages over constitutive ones in this context. In
particular, bacterial strains that only express the anti-pathogen effector proteins under
narrow conditions are more likely to be able to compete with wild strains since the
potential fitness cost of expressing the effectors is limited in time.
Bacterial genetic screens have been developed to detect genes that are activated under
specific conditions. The most common and successful of these screens are in vivo
expression technology (IVET) and differential fluorescence induction (DFI). Many
permutations of both of these screens as well as their relative strengths and weaknesses
have been reviewed (Rediers et al., 2005; Jackson & Giddens, 2006; Hsiao & Zhu, 2009).
Both consist of methods to fuse bacterial DNA from the species of interest to some
reporter gene to create a library, and then a screen of this library under the desired
conditions to detect promoters that drive the reporter under the desired conditions. The
hypothetical use of DFI to isolate blood meal induced promoters from a paratransgenic
strain of bacteria is described in figure 4. Briefly, a library of size-selected genomic
fragments from the paratransgenic species is cloned upstream of a promoterless
fluorescent protein gene (typically, some variant of GFP) on a plasmid. This library is
transformed into the paratransgenic bacterium and this population of bacteria is fed to
mosquitoes in a blood meal. After a suitable amount of time, the midguts of the bloodfed mosquitoes are dissected, homogenized, and the bacterial cells sorted in a
fluorescence-activated cell sorter which selects and enriches the population of bacteria
that are expressing GFP. The selected fluorescent bacteria are collected and the process
repeated however many times the user feels is necessary. Individual clones are then
transformed back into the paratransgenic bacterium, and the individual strains rescreened to ensure that no false positives were selected and that the promoter is truly
conditional.
5. Genetically stable paratransgenic strains suitable for field release
Insertion of effector constructs into the chromosome. For a paratransgenic strain to be
stable and to reduce the odds of horizontal transfer of the effectors it will be necessary to
insert the promoter-effector construct into the chromosome of the paratransgenic strain.
Insertion into the chromosome insures that all progeny will inherit the effector genes and
that no selection is necessary to retain them. Chromosomal insertion can be
accomplished in a variety of ways.
Perhaps the simplest way to insert genes into the chromosome is by transposition.
Transposons mediate DNA breakage and joining of DNA sequences through a
transposase protein that is contained within inverted terminal repeat (ITR) sequences that
are specific to the given transposon. Insertion of transposon DNA occurs at a transposonspecific target site in the genome. The target site can be at one specific site per genome
(e.g., attTn7 for Tn7) or scattered throughout the genome in a way that is essentially
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random (e.g., Tn5 or Himar1). Transposons are almost always used in microbiology in a
mini-transposon format where the transposase that mediates the movement of the DNA is
separated from the ITRs. Figure 5 shows pSC189, a typical embodiment of this kind of
system for the Himar1 transposon (Chiang & Rubin, 2002). The plasmid contains
inverted terminal repeats that bound a kanamycin-resistance (kanR) gene to select for
transposon insertions. The kanR gene is itself inserted between two FRT sites for the
FLP recombinase of yeast (see below). The transposon also carries in it the plasmid
origin of replication, in this case oriR6K which is conditional on the presence of the 
protein. Without this protein, the plasmid will not replicate so it is only stably
maintained as a plasmid in special strains of E. coli that have the  protein transduced
into the chromosome. This feature ensures that whatever kanamycin-resistant cells are
recovered after movement of the plasmid into the paratransgenesis strain are due to
transposition and not plasmid replication. An 8 bp cutting AscI site is present near the
end of the transposon for insertion of foreign DNA. Outside the transposon in the
backbone of the plasmid is a beta lactamase gene for selection of the entire plasmid, the
transposase gene driven by a lac promoter, and an origin of transfer (oriT). OriT enables
the conjugation of this plasmid from E. coli strains carrying the conjugation machinery
for oriT to essentially any other bacterial cell. This feature is crucial in transferring
plasmids to species where chemical or electrotransformation techniques work poorly and
that will undoubtedly include many species contemplated for paratransgenesis. While
transposition can efficiently create stable insertions of effector genes into paratransgenic
strains of bacteria it should be noted that the user has no control over the site of insertion
so there may be fitness costs or other unintended effects on the strain and these will need
to be measured under conditions that are likely to be encountered in the field.
The second method to introduce effectors into the chromosome is recombination. The
most common kind of recombination occurs when a single cross-over event occurs
between a plasmid carrying the effector construct and a homologous site on the
chromosome. This results in the integration of the entire plasmid into the chromosome
and such events are common enough that they are easily produced and isolated.
Ideally, only the effector gene and its promoter and terminator would be recombined into
the chromosome. This requires a double-cross over event which is much more rare.
Such events can be increased in frequency by orders of magnitude by supplying enzymes
that mediate recombination of foreign DNA into the chromosome. The most highly
developed of these is the Red recombination system derived from bacteriophage lambda
(Datta et al., 2006; Thomason et al., 2007). The use of Red recombination is developed
in E. coli to such a degree that no drug marker is necessary to recover chromosomal
recombination events (Sawitzke et al., 2007). It is likely that this technique will work in
many Gram negative bacteria and the recombination machinery for Red recombination
has been placed on broad host range plasmids for just this use (Datta et al., 2006).
Drug marker removal. If drug markers are used to help select recombinants into the
paratransgenic strain chromosome, either by transposition or recombination, they must be
removed before the strain can be released into the field. This is straightforward if the
insertion was constructed properly beforehand. For example, the kanR gene carried by
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the Himar1 transposon on pSC189 in figure 5 is flanked by two FRT sites. These sites
are the recognition sites for the FLP recombinase from yeast. When these sequences are
in the same orientation around a central DNA sequence, recombination by FLP
recombinase at the FRT sites results in the excision of the DNA between them leaving
behind a single FRT site. Many plasmids carrying FLP recombinase exist that can be
transformed into strains carrying drug markers constructed this way. Selection of cells
that are kanamycin sensitive is a simple matter of patching cells onto media with and
without the selective agent. Once sensitive cells are recovered, the FLP plasmid can be
eliminated by counter selection. An excellent review of the use of this technique in
bacteria can be found in Schweizer (2003).
Standardization of parts. As noted earlier, genetically engineering bacterial strains for
paratransgenesis can be considered as a type of synthetic biology. The synthetic biology
community in beginning an effort to standardize the parts of synthetic constructs so that
different modules can be interchanged easily. One effort in this regard is the BioBricks
Foundation (Smolke, 2009). Another is the recently-published Standard European Vector
Architecture (SEVA) (Silva-Rocha et al., 2013). Each effort seeks to create a vector
platform that is standardized and easy to use. SEVA, in particular, stresses broad host
range platforms that are most suitable to testing and creating paratransgenic bacterial
strains from non-model system bacteria. Origins of replication, drug markers, origins of
transfer, promoters, and “cargo” are all modular and easily replaced or changed. We
strongly urge workers in the area of paratransgenesis to adopt the SEVA standards which
should make paratransgenesis more straightforward and easier to adopt as this method
spreads to different species and systems.
6. Introducing and spreading bacterial strains for paratransgenesis.
A critical step in the success of a paratransgenesis program is the introduction and spread
of paratransgenic microorganisms within a vector population in nature. Bacterial species
that form an obligate association with vectors are ideal in this context since, once
obtained by the vector, they will spread naturally via the biology of the vector itself. As
noted above, our current knowledge of mosquito microbiota suggests that such obligate
associations do not exist, although some species are quite common. Many common
species of bacteria that live in adult mosquitoes, like Pantoea sp. and Asaia sp., are also
found in floral nectar, suggesting that mosquitoes acquire these members of the
microbiota from sugar meals.
The use of bacterial strains that do not have inherent drive mechanisms (like Wolbachia,
e.g.) or that do not form obligate associations with their vectors will require a careful
choice of bacterial species and clever uses of vector behavior. Asaia (reviewed in
Chapter XXX) is a genus that has very attractive microbial ecology. These species infect
mosquito midguts, salivary glands, and ovaries, multiply with the blood meal, are spread
from males to females during copulation, and are deposited on eggs by the female (Favia
et al., 2007; Damiani et al., 2008; Crotti et al., 2009). These properties suggest that
paratransgenic Asaia strains might be easily spread in the field.
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Spreading bacteria to mosquitoes in the field will also require taking advantage of
mosquito behavior. One suggestion has been to take advantage of the fact that the
females of many mosquito species require sugar meals in addition to blood while males
exclusively sugar feed. It may be possible to spread paratransgenic strains by sugar
meals supplemented with strong attractants (Muller et al., 2010; Beier et al., 2012). No
such field demonstration of the spread of paratransgenic strains exists, however, and this
remains an area where much work is needed.
Paratransgenesis of mosquitoes against malaria with genetically modified bacteria.
Using the strategies outlined above, we successfully demonstrated paratransgenesis
against malaria in the laboratory using transgenic strains of Pantoea agglomerans (Wang
et al., 2012). This species was isolated from a laboratory colony of Anopheles stephensi
and was later selected to persist in the midgut of these flies for up to 14 days (Riehle et
al., 2007). P. agglomerans is a gammaproteobacterium in the Enterobacteriaceae, the
same family to which E. coli belongs. Strains expressing various anti-malarial peptides
and proteins were able to reduce the prevalence of females carrying any oocysts from
90?% to 18% after an infectious blood meal (Wang et al., 2012). A reduction in
prevalence was measured in both An. gambiae carrying P. falciparum and in An.
stephensi carrying P. berghei, suggesting that these strains may work in any Anopheles
vector species against multiple different species of Plasmodium. This is an important
consideration and a distinct advantage of paratransgenesis against malaria since there are
five species of Plasmodium that cause malaria in humans vectored efficiently by at least
40 species of Anopheles (Sinka et al., 2012).
Paratransgenesis with naturally-occurring bacterial strains. So far we have
described strategies to genetically engineer bacteria with favorable microbial ecology into
paratransgenesis strains. Interestingly, some bacterial strains are naturally
paratransgenic. For example, Cirimotich et al. (2011) isolated 16 culturable bacterial
species from the midguts of Anopheles gambiae collected in Zambia. One of these
strains belonged to the genus Enterobacter as determined by 16S sequencing. This
strain, Esp_Z, was capable of completely inhibiting P. falciparum development in the
midgut of An. gambiae. Additional experiments showed that the factor responsible for
the inhibition was diffusible, heat insensitive, and was most likely some kind of reactive
oxygen species since the effect could be eliminated through the presence of the
antioxidant Vitamin C. One hypothesis to account for the presence of this strain in An.
gambiae is that it was selected for because it offers some kind of advantage to the
mosquitoes that carry it by reducing the load of P. falciparum in the mosquitoes. If this
hypothesis were correct, we might expect to see Esp_Z widespread in African An.
gambiae, but it is not. An alternative hypothesis is that the anti-Plasmodium properties of
Esp_Z are fortuitous and were selected for some other reason, most likely competition
with other bacteria. If this hypothesis is correct, many other naturally-occurring bacterial
strains will prove to be anti-plasmodial. Strains like these have the advantage of not
having been genetically engineered, however they may lack the appropriate microbial
ecology and their discovery requires the mass screening of culturable bacteria from wild
mosquitoes.
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Conclusion
Reducing the ability of insects to vector disease through paratransgenesis offers a
promising route to decrease the burden of many of the most important human diseases,
like malaria and Dengue fever. Although the creation of paratransgenic strains requires
many facets, the genetic tools are available to modify nearly any bacterial species. These
include broad host range plasmids, constitutive promoters, broad host range transposons,
an abundance of effectors, and simple genetic screens to isolate secretion signals and
conditional promoters. Many challenges remain, especially gaining an improved
understanding of insect microbial ecology and methods to deliver and spread
paratransgenic species in nature. The use of metagenomics in different mosquito species
will begin to clarify the nature of the mosquito microbiome and suggest bacterial species
for which specialized culture techniques can be developed so that these species can be
developed as paratransgenesis platforms. An increasing understanding of the microbial
ecology of mosquitoes will also suggest ways to deliver paratransgenic bacterial species
in the field to ensure their spread throughout a vector population. Finally, a systems
biology approach to paratransgenesis and a standardization of vector construction will aid
in the rapid development of paratransgenic strains for many mosquito species, as well as
other important insect vectors.
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Figure A.1. Derivatives of antibodies useful in paratransgenesis. Variable heavy and
light chains of monoclonal antibodies are constructed into a single gene (scFvs,
antimicrobial peptide fusion, and nanobody) or two genes that are coexpressed (diabody)
that can reconstitute the binding properties of an immunoglobulin. For details on each of
these see the text or Kontermann (2010).
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Figure A.2. Secretion of effector proteins by bacteria using one of two different
pathways. The hemolysin autotransporter system is shown in part A. The type II
general secretory pathway is shown in part B. Both are highly simplified. Effector
proteins destined for secretion carry either a ca. 50-amino acid C-terminal signal
sequence for the HlyA pathway or a short N-terminal signal sequence for the Type II
secretion pathway. The signals differ in Type II depending on whether or not they will
cross the inner membrane via either the twin-arginine pathway (Tat) or the general
secretory pathway (Sec). The hemolysin system consists of HlyB, HlyD, and a native
TolC protein that assemble to create a pore that spans the inner and outer membranes.
Proteins using this pathway are secreted directly into the extracellular space in one
energy dependent step. Effectors targeted to the Type II secretion system cross the inner
membrane and spend time in the periplasm where the signal sequence is cleaved and they
may undergo disulfide bond formation. These proteins cross the outer membrane in
many ways which are not completely understood. For a fuller discussion see Korotkov et
al. (2012).
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Figure A.3. A genetic screen to identify native secreted protein genes in bacteria
using TnphoA. The transposon Tn5 was modified to carry a kanamycin resistance gene
and E. coli phoA without the leader sequence that normally targets it for secretion.
TnphoA is introduced into the bacterial species in question where it randomly inserts into
the bacterial chromosome. A library of random insertions is then plated on medium
containing kanamycin (to select for transposition events) and BCIP, which turns blue if
TnphoA is fused to a bacterial gene that encodes a secreted protein. For more details, see
Manoil & Beckwith (1985).
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Figure A.4. A differential fluorescence genetic screen in bacteria to identify
conditional promoters activated in a blood meal. A library of random chromosomal
fragments from the bacterial species of interest is cloned upstream of a promoterless GFP
gene in a broad host range plasmid. This bacterial promoter trap library is then fed to
adult female mosquitoes, which are then subsequently given a blood meal. Promoters
active in the blood meal can be separated from inactive ones by fluorescence activated
cell sorting.
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Figure A.5. pSC189, a broad host range transposon insertion vector based on
Himar1
pSC189 is used to make random insertions into the chromosome of many bacterial
species. See text and Chiang & Rubin (2002) for details. ApR = ampicillin resistance;
KmR = kanamycin resistance; oriT = origin of transfer; Himar1 transposase=transposase
gene; FRT=recombination sites of yeast FLP recombinase; AscI=insertion site for
exogenous DNA; oriR6K=a conditional origin of replication; solid triangles indicated the
transposon inverted terminal repeat sequences.
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